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Abstract
Huntington’s disease (HD) is a neurodegenerative condition in which the 
predominant loss of neurons occurs in the striatum. At present there is no treatment for 
this condition, although neural transplantation may prove to be a viable therapeutic 
strategy if an appropriate source of donor cells can be identified. A major requirement of 
these donor cells is that they are able to differentiate into the cells lost to the disease 
process; that is, largely medium spiny projection neurons (MSNs). Currently, suitable 
donor cells (i.e. those already committed to developing into MSNs) can be extracted from 
foetal brain and early clinical trials have provided some evidence of efficacy when 
human foetal-derived striatum is transplanted into the brain of patients with HD. 
However, there is a major problem of supply and demand with respect to human foetal 
tissue and so alternative source of donor cells must be identified.
However, only a small proportion of animal studies in the literature report 
differentiation of MSNs from either animal or human stem cell sources and the 
percentage of mature MSNs is generally low, most cells becoming glia or taking on a 
‘default’ GABA-ergic neuronal phenotype. Thus it is likely that stem cells will need to be 
‘directed’ towards a MSN phenotype.
Knowledge of the molecular signals that cause striatal progenitors to differentiate 
into a MSN phenotype in vivo would help us to understand how to direct the fate of stem 
cell populations towards this phenotype in vitro.
In this thesis I have studied the genetic changes that occur during normal striatal 
development in the mouse with the aims being (i) to identify genetic markers of stages of 
differentiation for these cells and (ii) to identify genes important for striatal development 
with the ultimate aim of using this information to design protocols to direct the 
differentiation of stem cells towards a MSN phenotype.
I have studied the gene expression of the population of cells that make up the 
whole ganglionic eminence during its period of peak neurogenesis using Affymetrix 
micro array. I then validated the results of a subset of genes that were found to be 
significantly up-regulated using in situ hybridisation and then used these genes to 
characterise either primary cells that were differentiated in vitro, or cells that have been 
proliferated and then differentiated in vitro.
This study has not only provided a gene expression signature of a developing 
population of striatal precursors, enabling future experiments to compare and contrast 
expression patterns seen in different in vitro studies, but it has also highlighted Foxpl and 
Foxp2 that have been shown to have a high degree of association with this period of 
development. This has encouraged future work in this laboratory in which the 
developmental functions of these genes in relation to MSN differentiation and 
development will be studied.
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IChapter One
1 Introduction.
1.1 H u n tin g to n 's  Disease.
Huntington’s disease (HD) is one of the most prevalent monogenetic autosomally 
dominant neurodegenerative disorders in the developed world. The mutated gene that lies 
at the heart of the pathology is found on chromosome four (Hummerich et a l , 1994; 
Mangiarini et al., 1996) and codes for a protein called Huntingtin. Although this gene is 
ubiquitously expressed, the main pathological changes that take place during the course 
of the disease do so in a single cell type; the medium spiny neuron (MSN) found in one 
distinct area of the brain called the striatum. As the disease progresses there is more 
widespread loss in other brain regions although the extent to which this is a primary 
process or secondary to degeneration of the striatum is not clear. The precise roles of this 
gene and its product are not known, although studies looking at Huntingtin knockout 
mice have found that this type of mutation leads to embryonic lethality (Duyao et a l , 
1995; Zeitlin et al., 1995; Nasir et a l , 1995).
Fig.l. 1; A macroscopic comparison of an HD brain slice (left) and a normal control brain slice (right).
Note the enlarged lateral ventricle (central white arrow) dne to striatal atrophy and evidence of major neocortical atrophy in
the advanced HD brain.
Although it is not fully understood how the mutated gene product causes neuronal 
degeneration, it is thought to be by some kind of ‘gain of function’ caused by the
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abnormal poly-glutamine repeats (coded for by the codon CAG), whose numbers are 
amplified in the mutated form and somehow confers the molecule’s toxicity. The normal 
upper limit of CAG repeats for the human Huntingtin gene is said to be 36. More recently 
it has become apparent that disease onset approaches 100% with repeat numbers of 39 
and over, and that 36 to 39 repeats represents an intermediate range where risk of 
developing the disease has not been fully determined. There is also a reciprocal 
relationship between CAG repeat number and age of onset, so that the higher the number 
of CAG repeats on the mutant gene, the younger the onset (Rubinsztein, 2002), although 
this relationship is not sufficiently strong to allow a prediction of disease onset for 
individual subjects. When the repeat sequences are very long, a form of young onset HD 
results, in which the signs and symptoms are different; taking the form of bradykinesia, 
distonia and rigidity with chorea frequently being absent, and the affected children often 
developing epileptic seizures (Vonsattel and DiFiglia, 1998).
The disease affects between 3 and 7 people per 100,000 in most populations of 
western European descent (Harper and Newcombe, 1992), although in some instances 
this may be as high as 15 people per 100,000, explained by the distribution of 
predisposing alleles in the normal population of the country in question (Hayden et al., 
1981). This is in contrast to other ethnic populations, where the prevalence may be much 
less; i.e. Japanese and African populations (<1 in 10,000,000 (Rubinsztein, 2002)).
HD has an average age of onset of between 30 and 50 years with mean disease 
duration being approximately 15-20 years from onset of symptoms to death. This timing 
means the sufferer may well have parented children before being diagnosed and each 
child then stands a 50/50 chance of inheriting the dominant mutation.
1.2 Symptoms of the disease.
The course of the disease tends to be slow, particularly in the early stages. Onset 
may be recorded with the start of slight, uncontrollable muscular movements, stumbling 
and clumsiness, lack of concentration, short-term memory lapses, depression and mood 
swings (sometimes including aggressive or antisocial behaviour). The cognitive and 
behavioural symptoms may precede the motor onset by up to ten years (Lawrence et al., 
1998; Kremer et a l , 2002). Great strain is often put on personal relationships due to
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unexpected temper outbursts caused by the above symptoms and directed towards the 
partner or loved ones.
As the disease progresses sufferers begin to experience a wide range of symptoms 
which may include increased clumsiness, problems with balance, involuntary 
movements, tremor, dysarthria and dysphagia. These involuntary movements include 
chorea, dystonia and tics. The chorea (from the Latin verb meaning to dance) can be 
described as purposeless movements that affect the face, trunk and limbs that may appear 
in a series of groups that result in movements that appear to be complex. The movements 
can be made more complex by the patient’s own (possibly subconscious) attempts to 
mask them by purposeful movements.
Cognitive changes can also result in a loss of motivation, initiative and/or 
organisational skills, some or all of which may result in the person appearing to be lazy. 
There also may be difficulty in concentrating on more than one activity at a time.
Emotional changes can also occur, resulting in stubbornness, frustration, mood 
swings and depression. However, unlike the motor and cognitive symptoms, psychiatric 
symptoms do not typically follow a progressive course, and can be greatly influenced by 
psychosocial aspects (Craufurd et al., 2001).
Unfortunately, the end stage of this disease leaves a patient who is mute, 
wheelchair bound and tube fed before an inevitable death usually occurring as a result of 
a secondary complication due to the immobility of the patient; the average age of death 
being 54-55 years old (Kremer et al., 2002).
HD is not just a personal tragedy in terms of the victims and their families but 
also expensive in economic terms. This is due to the fact that HD strikes sufferers at a 
point in life when they would normally be at peak earning potential. The progression of 
the disease is also long and drawn out, the sufferer needing full nursing care towards the 
latter stages, before an inevitable death; as such the costs to the community are enormous.
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1.3 Therapeutic strategies for the treatment of HD.
At present, there is no cure for HD. Therefore, if a patient reports symptoms and 
is found to test positive for the mutation, the prognosis is bleak. Once symptoms start to 
appear, doctors can try to control the emotional problems by the means of medications 
used in standard psychiatric practice; however, many of these drugs have side effects 
such as fatigue, restlessness or hyper-excitability. There are also a number of drugs that 
may help with the choreiform symptoms, although these are of limited efficacy. 
Unfortunately at this time there are no treatments available that can alter the underlying 
course of this disease.
1.3.1 Developing novel therapeutic strategies.
A variety of approaches are being used world-wide to try to develop disease- 
modifying treatments for HD. These include strategies to target the pathogenic 
mechanisms of HD as well as more empirical approaches. In summary, general 
approaches include:
• Gene therapy
• Understanding the underlying cellular pathology of HD with the view of targeting
specific pathways.
• Screening all known drugs for activity in cellular and model animal assays of HD.
• Neuronal protection.
• Cell replacement therapies.
A detailed discussion of these strategies is beyond the scope of this thesis and can 
be found in (Bonelli and Wenning, 2006; Handley et al., 2006). However, a few 
examples are outlined below.
Gene therapy may include the introduction of either genes that code for proteins 
that will aid survival of the affected cells (Tuszynski, 2002; Bloch et al., 2004) or 
molecules such as RNAi that interfere with the expression of the mutant Huntingtin 
protein itself (Rodriguez-Lebron et al., 2005; Huang and Kochanek, 2005).
An example of a potential treatment that will utilise information on the pathogenic 
mechanisms of HD is based on recent evidence that gene transcription dysregulation may
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be a contributing factor to the cell death seen in HD; one possible mechanism for this is 
the binding of mutant Huntingtin to components of histone acetylases preventing histone 
acetylation (Hockly et al., 2003). Thus, a rational approach that is being considered is to 
administer histone deacetylase (HDAC) inhibitors (Ferrante et al., 2003). These have 
been shown to rescue lethality and degeneration in a Drosophila model of polyglutamine 
disease (Steffan et al., 2001), and dramatically improve motor impairments in the R6/2 
transgenic HD mouse model (Hockly et al., 2003).
Other groups are following up the hypothesis that HD is mediated through defects 
in mitochondrial pathways. Support for this comes from many areas including the recent 
finding that tauroursodeoxycholic acid, a bile acid normally produced by humans in very 
low levels, exhibits neuro-protective effects in the R6/2 transgenic HD model (Keene et 
al., 2002).
A number of groups have set up drug screen projects to screen candidate drugs 
using PC 12 cells in culture. These projects provide candidate drugs for further 
investigation (Aiken et al., 2004; Wang et al., 2005b). A related approach is the SET-HD 
project which provides an objective and systematic evaluation of available pre-clinical 
and clinic data so that researchers can select the most promising agents for further study 
(http://www.huntingtonproject.org/).
Another possibility is cell therapy that will be discussed further below. It should 
be emphasised that it is likely than more than one of these approaches will be utilised in 
any one patient as it is likely that no one approach will completely stop the progression of 
this disease in its tracks.
1.4 Cell replacement therapies as a possible treatment for Huntington’s 
Disease.
Cell replacement differs from most approaches outlined above in that it attempts 
to be restorative, based on the use of cell implantation to replace the striatal medium 
spiny neurons that have been lost to the disease process.
HD lends itself well to a cell replacement therapy due to the relatively focal loss 
of MSNs from the caudate nucleus and putamen. These neurons receive their major 
inputs from the cerebral cortex, thalamus and substantia nigra (pars compacta), and have
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their primary outputs via GABA-ergic projections to the globus pallidus and the 
substantia nigra pars reticulata. Studies in animal models of HD have shown that cells 
dissected from the developing striatum of a developing foetus can show functional 
integration when transplanted into the lesioned striatum of experimental animal models 
of HD (Dobrossy and Dunnett, 1998; Nakao and Itakura, 2000; Dobrossy and Dunnett, 
2005a; Dobrossy and Dunnett, 2005b).
Evidence from animal studies has demonstrated the efficacy of foetal striatal 
transplants in animal models of HD (Dunnett, 2000). Furthermore clinical studies have 
provided preliminary, but convincing evidence that human foetal striatal implants can 
produce clinical benefit (Bachoud-Levi et a l, 2006).
To date, the donor cells used in clinical neural transplantation trials have been 
derived directly from primary foetal striatum (Kopyov et a l, 1998; Bachoud-Levi et al., 
2002; Hauser et a l, 2002; Rosser et al., 2002). However, although primary foetal tissue 
transplants are crucial to demonstrate the effectiveness, or otherwise, of transplantation 
strategies in HD, due to the ethical and practical constraints involved with the harvesting 
and use of these cells for use in research and medicine, there are severe limitations of 
supply and thus the chances of mainstream therapies adopting their use is negligible. For 
cell implantation to be widely adopted, therefore, it is imperative that alternative 
renewable sources of donor cells are identified.
A number of possible sources of donor cells can be considered. Some not 
discussed further here include primary foetal xenographs, where developing striatal cells 
are obtained from other species (most commonly pig) and are used to replace those that 
degenerate. So far xenografts have been performed in animal models (Isacson et al., 
1989; Armstrong et al., 2002; Armstrong et a l, 2003) and in the clinical setting as pilot 
studies for a replacement therapy for Parkinson’s disease patients. However, although the 
animal model studies have shown promising results, the clinical results showed little 
evidence of graft survival or functioned improvement, either on Positron Emission 
Tomography (PET) scanning or on post mortem analysis, probably due to graft rejection.
Genetically modified cells lines are also a current research target. Using neurally 
committed cell lines functional benefit has been reported in animal models (Lundberg et 
al., 1996) and some cells with characteristics of MSNs were seen (Saporta et al., 2001).
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However, other studies have reported good survival but still no expression of striatal- 
specific markers and no functional improvement (Fricker-Gates et a l, 2004b).
Stem cells have received considerable attention recently as a potential renewable 
source of cells for neural implantation and indeed there are already examples of stem 
cells being applied medically in other systems (skin (Wu et a l, 2006), bone marrow 
repopulation in cancer (Wang et al., 2005a)). Stem cells are discussed in more detail 
below.
1.4.1 Stem cells
The definition of a stem cell is one that can divide by both symmetric division to 
produce two identical daughter cells and can also divide asymmetrically to give rise to 
another stem cell and a more differentiated progeny.
Depending on its developmental stage stem cells may have the potential to 
differentiate into all cells including placenta (totipotent), all cells of the developing 
organism (pluripotent) (e.g. ES cells), many (multipotent) (e.g. bone marrow stem cells), 
or even just one sub-type of specialised cell.
From this one cell the first four or so cleavages give rise to more totipotent cells 
(that may split to form twins, triplets etc), after which the generation of pluripotent stem 
cells confers the potential to form the different germinal layers of the embryo and all the 
cells in the adult organism. These latter cells are not, however, capable of forming cells 
of the extra-embryonic membranes (which are derived from the trophoblast).
There are at least three sources of pluripotent cells;
1.4.2 Pluripotential Stem cells.
1.4.2.1 Embryonic Stem (ES) Cells,
These can be isolated from the inner cell mass (ICM) of the blastocyst; at the 
stage of embryonic development when implantation occurs (Evans, 1989; Notarianni et 
al., 1991; Thomson et a l, 1998).
ES cells are pluripotential and can be tested for this by injection into immuno­
compromised nude (SCID) mice to produce teratomas that contain differentiated 
derivatives from all three germ layers (ectoderm, mesoderm and endoderm). These cells
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have a wide therapeutic potential, but need to be directed towards the cell type of interest. 
However, there is an ongoing ethical debate as to whether they should be used due to the 
fact that they are presently harvested from eggs that are collected for in vitro fertilisation 
(IVF) but are surplus to requirements.
Those who oppose the use of ES cells do so because;
1. these cells have the potential to be implanted and grown to produce viable 
embryos and thus an argument is made that to use them would be destroying a 
human life, or
2. the potential for these cells being used to clone a human baby would be vastly 
increased (Sandel, 2004).
Human ES cells (hES cells) and mouse ES cells (mES cells) are thought to differ, 
in the fact that they show several morphological and behavioural differences (Odorico et 
al., 2001). Some signalling pathways may also differ, although many of the known pluri- 
potentiality genes expressed are also common to both species (Stojkovic et al., 2004). 
These differences make observations seen in one species harder to replicate/infer in other 
species and they also emphasise the need to validate results in the human cells that are 
under consideration for clinical use.
1. Fertilised Oocyte
2. Blastocyst Stage (5-7days post coitum)
3. Removal of the Inner Cell Mass
4. Undifferentiated ES cells In Culture
5. Differentiated cells forming
a.Mesodermal cells (eg. blood)
b.Ectodermal cells (eg. neurones)
c.Endodermal cells (eg. liver)
Fig. 1.2; Derivation, culture and differentiation of ES cells. Adapted from (C Sand T Centre Museum of Science Boston M.A.,
2005).
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Despite the enormous therapeutic potential of ES cells, there are still many 
challenges in the use of these cells. For example, we currently know very little of how to 
control their expansion and differentiation to produce exclusive cells types tailored for a 
specific purpose. This said, research using ES cells is still very much in its infancy and 
these problems are recognised and may be overcome given time.
1.4.2.2 Embryonic Carcinoma (EC) Cells,
Pluripotent EC cells are derived from, and are the stem cells of, tumours known as 
teratomas (also known as teratocarcinomas). These growths arise from embryonic germ 
cells that have continued to divide and EC cells are considered to be the malignant 
counterparts to ES cells (Przyborski et al., 2004).
EC cells such as the mouse P I9 embryonic carcinoma line have been used in 
research as alternatives to, and models of ES cell development and culture (although 
caution is required as they are clearly different cells). Although the actual differentiation 
capacity of EC cells is more limited than ES cells this can be used to advantage in 
providing a simpler and more robust experimental system for studying cell 
differentiation.
1.4.2.3 Embryonic Germ (EG) Cells,
These cells are derived from Primordial Germ Cells (PGCs) and are the 
embryonic precursors of the male and female gametes. EG cells are defined as PGCs that 
continue to divide in culture beyond the time they would normally do so in vivo (Labosky 
et al., 1994). During early embryonic development these cells migrate from the posterior 
endoderm of the yolk sac and hind gut before taking up position into the gonadal ridges 
where the genitalia later develop (McLaren, 1992).
Mouse EG cells have reportedly been differentiated and contributed to a range of 
tissues in foetal chimeras including heart, lung, kidney, intestine, muscle, brain and skin 
(DurcovarHills et al., 2001; Durcova-Hills et a l, 2003). The fate of mouse EG cells 
seems to be determined by the distance they have migrated prior to their removal from 
the embryo; the earlier the removal, the more likely they are to divide for longer, while if 
removed later, their ability to proliferate prior to differentiation seems to be progressively 
more restricted (McLaren, 1992).
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Human EG (hEG) are less well understood with various studies in the literature 
reporting that human PGCs are prone to apoptosis or spontaneous differentiation when 
put into culture (Pesce et al., 1993; Felici et a l, 1999). Some reports suggest that hEG 
cells are not as easy to manipulate in culture as mouse EG cells (Turnpenny et al., 2003), 
although one group do claim to have proliferated a ‘possible’ hEG population on a mouse 
STO feeder layer for around a year (Park et a l, 2004) while still remaining 
karyotypically normal (expressing high levels of alkaline phosphotase, OCT4 and certain 
surface markers). These cells were also reported to form embryoid bodies and 
differentiate into cell types from ectodermal, endodermal and mesodermal tissues (Park et 
a l, 2004).
Currently hEG cells need to be fully characterised, but may eventually prove useful for 
therapy as well as providing a model system to elucidate the mechanisms of 
differentiation of other types of stem cell.
1.4.3 Tissue Specific Stem cells.
1.4.3.1 Foetal Neural Precursors (FNPs).
Instead of obtaining ES, EC or EG cells and having to elucidate the signals 
needed to drive differentiation firstly towards firstly a neural lineage and then a specific 
cell type in vitro, an alternative approach is to isolate proliferative stem cells that are 
already destined to give rise to the required cell type.
Foetal Neural Precursors (FNPs) are cells that have been isolated from the neuro­
epithelium of the embryonic CNS and can be defined as single cells that are clonal 
precursors of identical daughter cells as well as a defined set of differentiated progeny 
(Weissman et a l, 2001). These cells can be isolated from most parts of the foetal brain.
Striatal FNPs are derived from the Whole Ganglionic Eminence (WGE; the area 
in which striatal cells are bom). FNPs can be encouraged to proliferate in culture with 
growth factors such as FGF2 and EGF (Tropepe et a l, 1999; Kelly et al., 2003) to form 
spheres of cells also known as “neurospheres” or Embryonic Neuronal Precursors 
(ENPs). FNPs can be caused to differentiate into neurones by removal of EGF and FGF2 
and the addition of serum or other growth factors (Arsenijevic et al., 2001b; McKay, 
2004) and exposure to a substrate.
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FNPs are a potential source of cells that can be isolated from striatum for cell 
replacement therapies due to the fact that they are already restricted to a CNS lineage and 
can be more restricted to a striatal lineage. When FNPs were first explored as a potential 
donor cell source for HD it was hoped that cells derived from the developing striatum 
could be expanded in number in vitro whilst retaining their capacity to differentiate into 
MSNs.
However, the reality has proven more complex; A substantial proportion of 
neurons differentiating in vitro from FNPs appear to be MSNs, provided that the FNPs 
are derived from the developing striatum and providing that they are allowed to 
proliferate for a limited time only in vitro. The capacity to produce MSNs (identified by 
DARPP32-see below) declines rapidly with proliferation in vitro so that MSNs are seen 
after 10 days to 2 weeks of proliferation for mouse cultures and approximately 2-4 weeks 
for human. After longer periods of proliferation the cells can still differentiate into 
neurons, but have lost the capacity to differentiate into MSNs, even following 
transplantation into the CNS (Armstrong et al., 2003; Zietlow et a l , 2005). PCR analysis 
of expression of a limited battery of genes suggests that the striatal FNPs have lost 
positional information as they proliferate in culture. That is, they appear to retain 
commitment to an MSN phenotype after a few divisions under these conditions, but in 
the absence of developmental signals in vitro, this capacity is lost.
These problems suggest that there are a number of changes happening over time 
within these cultures: The cells that are produced after multiple divisions are not the same 
cell phenotype as those that are produced from the cells originally dissected from the 
donor. Characterising the changes in gene expression that occur with proliferation in vitro 
may aid understanding of the changes that are taking place and help to define the 
intracellular and extra cellular signaling cascades that control their expansion and 
differentiation in order to provide the correct environment to obtain MSNs to use in a cell 
replacement therapy.
1.4.3.2 Adult neural stem cells.
Adult neural stem cells are stem cells found in discrete regions of the brain that 
have a differentiation capacity limited to the production of neural cells. To date there
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have been reports of finding such cells in the sub granular zone (SGZ) of the dentate 
gyrus, within the hippocampus (Gage et a l, 1995; Gage et a l, 1998; Bottai et a l, 2003; 
Alvarez-Buylla and Lim, 2004; Emsley et a l, 2005; Becq et a l, 2005) and the sub 
ventricular zone (SVZ) where newly formed neurons migrate towards the olfactory bulb 
(Merkle et a l, 2004; Soares and Sotelo, 2004; Alvarez-Buylla and Lim, 2004); this has 
been reported to occur in other areas of the ventricular axis such as in the fourth ventricle 
and the spinal cord (Weiss et al., 1996).
Recent reports have also mentioned adult stem cells in other areas such as the 
cortex and amygdala (Arsenijevic et a l, 2001a) although opposing reports say these are 
actually satellite glial cells positioned near to neurons (Komack and Rakic, 2001), and in 
smaller numbers still in the substantia nigra (Zhao et al., 2003) although again other 
reports argue against this (Frielingsdorf et al., 2004).
These cells present an attractive possibility for neural repair due to the fact that 
they are endogenous and present the possibility of autologous transplants or endogenous 
repair, thus reducing the problems of immuno-rejection. However, these cells remain 
difficult to isolate and culture in vitro and little is known about the signals they require to 
proliferate and differentiate so their potential as a possible donor cell line for use in a cell 
replacement therapy remains uncertain.
1.4.4 TransdifTerentiation of other stem cell types.
Recent reports have claimed success in enabling other cell types such as 
haematopoietic and bone marrow stromal cells to transdifferentiate to become neuronal 
cell lines (Jang et a l, 2004; Saji et a l, 2004; Bossolasco et a l, 2005; Jori et a l, 2005). 
These reports have caused much heated debate in the literature due to the infrequency and 
difficulties in reproducing some of the experimental data, and the rarity of the 
transdifferentiation events (Filip et a l, 2004; Corti et a l, 2004) , (however, Cogle et al 
describe a clinical study where this is reported to have happened (Cogle et a l, 2004)
One suggestion supported by both historic (Ephrussi and Weiss, 1965) and recent 
studies (Terada et a l, 2002; Ying et a l, 2002; Vassilopoulos et a l, 2003; Wang et a l, 
2003b), is that transplanted cells may not have trans-differentiated, as previously 
supposed, but rather the host tissue cells start to express genes from the donor cells due to
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a process of cells fusion and then ‘reduction division’ (Medvinsky and Smith, 2003) to 
produce a cell that can express genes from both host and donor cells.
The general consensus is that more investigation and debate needs to occur before 
this strategy is likely to supply a possible donor cell type for transplantation therapies.
1.5 What is currently known about Striatal development: A Literature 
Review.
The striatum is a key component of the mammalian central nervous system 
(CNS), affecting motor function, cognition and behaviour in the individual. An 
understanding of the molecular and anatomical aspects of its development is key to 
developing new treatments to treat striatal diseases such as HD, and especially relevant to 
the cell replacement strategies discussed above.
However, due to its complex structure, it is only in the very recent past with the 
help of research into homologous molecules in organisms such as Drosophila 
melanogaster, Rattus norvegicus and Mus musculus that clues pertaining to the molecular 
mechanisms causing this region of the basal ganglia to grow, differentiate and develop, 
have begun to surface.
Ultimately, I would like to relate genetic changes precisely to embryological 
developmental stages. This has been attempted to some extent in Chapter Four. Previous 
studies have tended not to make this association in a direct way and so in the following 
section I have separately reviewed the anatomical development of the striatum and what 
is know about the associated gene expression changes.
1.5.1 The striatum.
The basal ganglia are comprised of a number of interconnected nuclei linking the 
basal ganglia to the cortex, the thalamus and the brainstem through several independent 
pathways. These nuclei are the striatum, the sub thalamic nuclei (STN), the internal and 
external segments of the globus pallidus (GPi/e) and the substantia nigra (SN) pars 
compacta and pars reticulata (SNc and SNr).
The human striatum consists of the caudate nucleus (from the Latin adjective 
Caudatus describing a tail-like appendage; referring to its physical shape), and the
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putamen (from the word naming the hard stone of fruits such as the peach, plum or 
cherry). Both of these areas develop from an area of the embryonic telencephalon called 
the ganglionic eminence that, as the name suggests, goes on to form the whole of the 
basal ganglia later in development
One of the principal cellular components of the striatum is the medium spiny 
neuron, which accounts for 90-95% of the striatal neuron population in the rodent and 
approx 85% in the human. These neurons have a medium-sized cell body approximately 
20-25 pm in diameter, with dendritic filaments that are covered in spines (that are 
themselves covered in synaptic boutons) that begin about 20pm from the soma of the 
MSN and continue to the end of the dendrite which extends approximately 150-250pm 
(Kemp and Powell, 1971; Wilson and Groves, 1980). The most common way of 
identifying this mature phenotype currently is by immuno-histochemical detection of the 
DARPP32 protein.
The majority of afferents that project onto MSNs come from cortical and thalamic 
inputs that provide excitatory input (Hattori et a l , 1979; Bouyer et a l , 1984) and 
dopamine-ergic fibres from the SNc (Bouyer et a l , 1984; Freund et a l, 1984; Freund et 
a l , 1985). Other afferents come from neighbouring MSNs and also striatal intemeurons 
(Wilson and Groves, 1980).
The major efferents of these GABA-ergic MSNs, (containing endogenous 
opioids, and substance P) project to the pallidum and substantia nigra in a topographically 
organised manner (Semba et al., 1987). Intemeurons whose axons do not leave the 
striatum make up around 10% of the total striatal neuronal population. These include 
large cholinergic aspiny neurons (Bolam et al., 1984), and several types of medium sized 
aspiny neurons containing somatostatin and neuropeptide Y (DiFiglia and Aronin, 1982; 
Gerfen, 1992; Marin et a l, 2000), and those that contain the calcium-binding protein 
parvalbumin (Gerfen, 1992).
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Fig. 1J ; Schematic representation of the Striato-Pallidal and Striato-Nigral pathways.
(Red denotes excitatory, Black denotes inhibitory)
1.5.2 The Embryonic Origins of the Striatum.
Development of the vertebrate nervous system begins with neural induction when 
a dorsal region of the embryonic ectoderm becomes specified as neural plate. Neurulation 
then occurs as the neural plate folds in on itself forming the neural tube. This is lined by a 
pseudostratified columnar epithelium consisting of uncommitted progenitors from which 
the future CNS will arise (Kandel et al., 2001; Jain et a l , 2001).
In the mouse the neural tube is first distinguishable at around E7 with 
regionalisation of the neural tube taking place from around E8. This leads to the rostral 
neural tube forming three primary vesicles; the forebrain (prosencephalon), midbrain 
(mesencephalon), hindbrain (rhombencephalon) and the caudal neural tube forms the 
spinal cord (Cecchi et al., 1999).
ISTRMTO-
PALUOAL
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Fig. 1.4; A Schematic diagram of the mouse brain at K8
The neural tube can be further divided up using another model proposed by 
Peulles and Rubenstein (Rubenstein et a l , 1994; Rubenstein et a l , 1998; Puelles et a l , 
2000). This model divides the prosencephalon into different prosomeres according to 
gene expression and fate mapping of the cells. It consists of three prosomeres numbered 
caudally to rostrally P1-P3 that are formed from the area situated around the notochord 
known as the epichordal region and give rise to the caudal diencephalon and the 
secondary prosencephalon which is formed from the precordal region of the neural tube 
that later gives rise to the rostral diencephalon and the telencephalon.
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Fig. 1.5; The prosomere model of forebrain dev elopment (Rubenstein et aL, 1994).
The mesencephalon later gives rise to the midbrain and the rhomobencephalon 
splitting into two distinct parts; the metencephalon (which goes on to form the 
cerebellum) and the myelencephalon (which forms the medulla).
The origins of the striatum lie in the ventral telencephalic vesicle of the 
embryonic brain, derived from an area between the medial septum, and the border of the 
dorsal telencephalon that later develops into cortex.
Fig. 1.6; Schematic diagram showing formation of the telencephalon in coronal section showing the enlargement of the ventral
telencephalon to form the striatum (MGE and LGE).
In mammalian development, the pallidum and striatum are derived from the 
transient swellings in the ventral region of the embryonic telencephalon known as the 
Medial Ganglionic Eminence (MGE), Lateral Ganglionic Eminence (LGE) and the 
caudal area where they both join, the Caudal Ganglionic Eminence (CGE). The LGE 
appears first, followed later by the MGE. These areas are collectively known as the 
Whole Ganglionic Eminence (WGE).
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1.5.Z1 Timings o f Striatal Development
In the developing mammalian telencephalon the proliferating cells are found 
mainly within two areas; the first is found within the Ventricular Zone (VZ) forms the 
pseudostratified neuroepithelium that borders the central aqueduct of the neural tube and 
the second is found predominantly in the Sub-Ventricular Zone (SVZ) that extends from 
the basal portion of the VZ to a deeper region found within the ventricular wall 
(Takahashi et al., 1995; Bhide, 1996). After their final post-mitotic division within these 
germinal areas neural precursors migrate outwards away from their place of origin and 
differentiate in their given structure of the brain.
The Ganglionic Eminence starts to form immediately after anterior neuropore 
closure (Kohtz et a l, 1998; Cecchi et a l, 2000) at around embryonic days 9.5 (LGE) to
10.5 (MGE) in the mouse (E9.5-E10.5 corresponds to Carnegie Stages 12-13 or 26-32 
days post ovulation in the human embryo (Davidson et al., 2002) with the expression of 
ganglionic transcription factors such as GSH2, DLX1/2 and NKX2.1 (Rubenstein et a l, 
1998; Corbin et a l, 2000). In humans the striatum begins to appear comparatively later, 
during the 6th week in development around Carnegie Stage 18 (O'Rahilly and Muller, 
1999). It has been reported that there are sexual differences in the timing of peak 
neurogenesis within the murine striatum, with this point occurring earlier in females (E l3 
as opposed to E l5 in males) suggesting that this process may be under the influence of 
certain sex hormones (Floerke-Nasher et al., 2000).
At E l0.5 the murine CNS is still no more than a neural tube, formed from the 
cells of the neuro-ectoderm. These are progenitor cells that multiply to form yet more 
progenitors and also daughter cells (either immature neurons or glial cells) that will 
migrate outwards toward the periphery of the neural tube to take up their final positions 
before maturing and finally sending out axons and dendrites to form connections with 
their targets. As progenitor cells within the ganglionic eminence multiply, the neural tube 
also begins to bulge inwards as the cell populations within them enlarge.
The striatum develops in the ventral telencephalon just lateral to the peri­
ventricular germinal zone of the whole ganglionic eminence. Early in CNS development, 
cells bom within the germinal zone become post mitotic and begin their migration 
outward to take up the specific positions that they are destined to occupy in the adult
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striatum. Recent evidence has shown the LGE to be the origin of most of the MSNs 
(Gerfen, 1992; Deacon e/ al., 1994; Campbell et al., 1995; Corbin et al., 2000; Toresson 
et a l , 2000b; Polleux et al., 2002), whilst MGE contributes fewer MSNs and most of the 
intemeurons.
1.5.3 Patch and matrix organisation
These two areas contain cells that are bom at different times, expressing different 
signals and transmitters, receiving innervation from different areas of the cortex and also 
projecting to different regions (Gerfen, 1992; Redies et al., 2002).
The patches receive innervation from cortical neurons, originating in the deep 
parts of layer V and layer VI (Gerfen, 1992). The first identification of a patch/matrix 
type organisation was made when it was found that cells within these patches were 
enriched for p-type opiate receptors (Pert et al., 1976). Later it was also noted that 
acetylcholine-esterase (AChE) staining in these areas (Graybiel and Ragsdale, 1978) was 
found to be weaker. MSNs within the matrix are innervated by projections from the 
superficial areas of layer V of the cortex (Gerfen, 1992). GABA-ergic striatal projection 
neurons from within the patches have also been found to have somewhat different 
projections than do the matrix neurons; e.g. they provide innervation to dopaminergic 
neurons within the substantia nigra pars compacta (SNc), whereas the matrix projects 
largely to the pars reticulata (SNr).
1.5.3.1 Patch/Matrix organisation during development
The peak of patch formation occurs earlier than that of the matrices (Garel et al.,
1999) with patch/matrix organisation starting to be evident from around E l8.5 when 
Encephalin (Enk), DARPP32 and Dopamine Receptor-2 (DRD2) markers will stain early 
bom striatal matrix neurons (Corbin et al., 2000) These neurons will later make up most 
of the striato-pallidal (indirect) pathway medium spiny projection neurons (Gerfen, 
1992), Ebf-1 (a striatal homeobox gene (Garel et al., 1999) described below, Calbindin 
(Seto-Ohshima et al., 1988) and Somatostatin will mark later bom matrix neurons 
(Corbin et al., 2000), which make up the majority of the striato-nigral (direct) pathway 
medium spiny projection neurons (Gerfen, 1992).
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1.5.3.2 Cortical interneuron migration
From around E ll, differentiated striatal neurons start to migrate outwards to 
eventually populate the striatum (Shimazaki et a l , 1999; Wichterle et a l, 2001); Peak 
striatal neurogenesis occurs at E14 in the mouse (Shimazaki et al., 1999) (although minor 
differences have been seen that are due to gender, see (Floerke-Nasher et al., 2000)) and 
around E l5-16 in the rat (Fricker-Gates et a l, 2004a).
In vitro studies have shown that neurons migrating from within the ganglionic 
eminence not only populate the developing striatum, but some also populate areas of the 
cortex and hippocampus; a dramatically reduced number of GABA-ergic intemeurons are 
found in these areas if DLX1 and DLX2 transcription factors (expressed in both the MGE 
and LGE, see below) are knocked out (Wichterle et al., 1999; Wichterle et a l, 2001; 
Polleux et a l, 2002) suggesting that MGE and LGE also contribute. Previous studies 
have also indicated that the tangentially migrating neurons from the ventral to dorsal 
telencephalon gave rise to cortical GABA-ergic intemeurons (Pamavelas et a l, 1991; 
Pamavelas, 2000). The use of 1,1 ’-dihexadecyl-3,3,3’-tetramethylindocarbocyanine 
perchlorate (Di I) tracer injected into the LGE as early as El 1.5 resulted in the presence 
of a few of these same cells in the dorsal intermediate zone and cortical pre-plate 36 
hours later. This number increased in slices taken one day later in development at E l2.5 
suggesting that El 1.5 is the very beginning of this migration.
The actual source of these migrating neurones, though once thought to be just the 
LGE, has now been shown to also be the MGE; a recent study has reported that the 
number of cells migrating out of the MGE into cortex is two to three times greater than 
those originating in the LGE, indicating that most of the ganglionic eminence cells that 
migrate into the cortex are from the MGE (Polleux et a l, 2002). Interestingly, the same 
study also shows that a number of these cells don’t stop in the neo-cortex, but go on to 
populate the hippocampus CA-1 to CA-3 areas, although they don’t invade the Dentate 
Gyrus (Polleux et a l, 2002). Further evidence of this migration of MGE neurons into the 
hippocampus comes from a study of Nkx-2.1V' mice (a gene that is not expressed in the 
LGE this early in development); in these mice the MGE is respecified to LGE and cell 
populations of the striatum (Marin et al., 2000), cortex (Sussel et al., 1999a) and 
hippocampus (Pleasure et a l, 2000) are all depleted. However, these populations are even
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more depleted in the Dlx-1/2 knockout mouse, suggesting that the LGE is still the 
birthplace for some of these migratory neurons.
Recent advances in our understanding of neuronal migration have suggested that 
there are at least three types of neuronal migration involved in the development of the 
striatum, these being;
• Radial (or outward) migration from the LGE that go on to form the projection 
neurons of the adult striatum.
• Tangential (or lateral) migration from the MGE that develop to form the 
intemeurons of the adult striatum, and
• Inward migration from the piriform pre-plate; this last group of cells are thought 
only to exist transiently during development as ‘early generated neurons’. These 
cells mature much quicker than others and are thought to “provide the tract 
direction for growing striatal axons and/or accompany them to ensure their 
proceeding to the proper destination” (Hamasaki et a l , 2003).
1.6 Molecular regulation of the development of the striatum.
There is a growing literature relating to identification of the signals involved in 
striatal differentiation. As yet, however, this information is incomplete and the 
relationship between certain genes has not been fully elucidated and not all pathways 
have been defined. However, this information is important for placing any new genetic 
information from this work in context.
The MGE and LGE are defined not only by anatomical position but also by the 
expression of the many different genes throughout development. A crucial property of 
any progenitor is its ability to integrate extra-cellular signals with its intrinsically defined 
intra-cellular state to decide, or at least partially direct, the fates of their progeny (Livesey 
et al., 2004). It has been estimated through initial transcriptional profile studies of neural 
progenitors, that although there are around 2500 (Ramalho-Santos et a l , 2002; Ivanova et 
a l, 2002) genes up-regulated in a stem cell at any one time, only a small subset was 
found to be common to different stem cell types (although there were substantial 
differences in this subset between these studies, posing the question as to whether the 
genes found were actually indicative of “sternness” at all, see (Vogel, 2003) and
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(Fortunel et al., 2003)). The expression level of genes may increase or decrease during 
the development and maturation of the cell itself and during changes in its environment. 
These changes are dependent on a host of temporal, environmental and/or spatial factors 
that may in turn give rise to other changes in the expression of “downstream” genes that 
cause other developmental processes to occur within the cell or its environment The 
elucidation of these processes, even with the masses of data available from recently 
acquired profiling techniques, will take years of painstaking analysis as each part of the 
final combination is found, explained and then fitted precisely into the final puzzle.
1.6.1 What is known to date about the signals regulating striatal 
differentiation?
The following passage attempts to give an up-to-date description of the 
development of the striatum. This is a complex process and, although the adult rodent 
striatum is 90-95% medium spiny neurons, other cell types are also developing or 
migrating through this region. However, until very recently the available technologies 
have not allowed for the analysis of single cell types.
A host of molecular changes occur throughout development in response to 
fluctuations in the cells internal and external environment. Some of these changes 
regulate the expression of genes that code for many types of small molecules, some of 
which will act on the cell to influence its development and differentiation. These 
molecules range from signalling proteins such as Delta and Notch (Grandbarbe et al.,
2003) that inhibit neuronal fate and promote glial cell fate and later promoting astrocytic 
differentiation, to the newly discovered potential of the post transcriptional control 
exerted by other elements such as gene silencing using RNA interference molecules (Fire 
et al., 1998). All of these changes are controlled through changes in the transcription of 
genes, and the way the gene products interact with each other.
1.6.2 Gene products linked with striatal development.
Transcription Factors are gene products that recognise specific target sites in the 
cis-regulatory elements of target genes and function to positively, negatively, 
competitively or differentially regulate target gene expression; either on their own, or in
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coalition/competition with other molecules. Activity of these transcription factors may 
rise, fall, or disappear during cellular processes such as development or during normal 
activity. This regulatory complexity is especially evident in areas such as the brain.
A proportion of the genes that code for these transcription factors are known as 
Homeobox genes. These code for DNA-binding proteins that interact with other gene 
regulatory proteins to exert control over the antero-posterior patterning of the organism 
(Alberts et al., 2002). Expression control is achieved by the protein product of a 
homeobox gene binding to specific areas of DNA and regulating protein expression via a 
highly conserved DNA binding domain, coded for by a 180-base-pair segment (the 
“homeobox”).
Another class of gene product that can also exert effects on development are 
morphogens. A cell’s response to these molecules is finely graded, depending on the 
signal’s concentration; high concentrations received by cells close to the source may 
direct cells onto one developmental pathway while lower concentrations received by cells 
further away from the source will have other effects. Therefore, depending on where cells 
are positioned in relation to the source, they may be driven in a variety of different ways, 
according to the concentration of morphogen they experience.
1.6.2.1 Sonic Hedgehog
Sonic hedgehog (SHH) (a homologue of the Drosophila signal protein hedgehog) 
is a prime example of a morphogen that has a variety of effects in the developing embryo 
(Fuccillo et al., 2006a).
Within the telencephalon, cell fate is determined not just by concentration of 
SHH, but also by the actual timing of cell exposure to SHH (Kohtz et a l , 1998; Fuccillo 
et al., 2004). Deletion of this gene in an shh mutant shows that it is vital for the 
generation of the globus pallidus and the striatum (Kohtz et a l , 1998; Gunhaga et al.y
2000), resulting in the telencephalon being greatly dysmorphic and reduced in size 
(Machold et al., 2003) as well as changes in many other ventral structures along the 
rostra-caudal axis of the CNS. These changes lead to a dorsalisation (Kohtz et al., 1998; 
Gunhaga et a l , 2000; Machold et a l , 2003) of the telencephalon, with the only part 
expressing ventral markers being a small region in the ventral midline. Further work
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carried out on sonic hedgehog (Fuccillo et a l , 2006a) mutants with deletions of the 
dorsalising Pax6 (Shh v' Pax6'') do show a partial rescuing, resulting in the dorsal LGE 
reappearing (Fuccillo et a l , 2006b). Further analysis of ventral markers suggest that 
oligodendrocytes are also entirely absent from the shh mutant (Rallu et a l, 2002; 
Machold et a l , 2003). SHH is first expressed in the mesodermal notochord tissue and 
later within ventral regions of the neural tube known as the floor plate (Alberts et al., 
2002). It induces ventral identity in a concentration-dependant manner (Shimamura and 
Rubenstein, 1997) and has been shown to induce the expression of NKX2.1 (also known 
as Thyroid Transcription Factor-1 or TITF1) a ventral forebrain marker in the MGE 
(Gulacsi and Anderson, 2006). Although NKX2.1 and SHH are both expressed in the 
MGE, neither has been detected in the LGE, begging the question as to whether SHH 
actually has a role in LGE induction.
LGI LGE
E10
Fig. 1.7; At E10 SHH influences the expression of transcription factors that 
leads to ventralisation of the neural tube.
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E 11
Fig. 1.8; At El 1 SHH influence causes the expression of more transcription factors in the LGE that lead to ventral fate in both
the MGE and LGE.
However, after targeted mutagenesis of Shh, the LGE marker DLX5 (a member of 
the Distal-less gene family) is lost, the neocortical marker Empty Spiracles Homologue 1 
(EMX1) expands ventrally to take its place and the LGE fails to form (Kohtz et al., 
1998). At a later stage of development (around E8.5 to E9.5 in the mouse), SHH 
expression has been shown to induce the expression of LGE specific proteins (Kohtz et 
al., 1998) and it seems that it is the ability of these cells to respond to SHH at this stage in 
development that determines the sequence of MGE development followed by that of the 
LGE (Kohtz et al., 1998).
Shh has also been shown to induce the other ventral forebrain markers DLX2 
(possibly through the actions of Genomic Screened Homeobox-2 (Gsh-2)) and the LIM 
homeodomain protein Isletl (ISL1) (Kohtz et al., 1998; Corbin et a l, 2000), whilst if 
SHH is expressed ectopically in the cerebral cortex at this time it results in the expression 
of NKX2.1, DLX2 (both normally ventral markers) and the LGE-specific marker CRBP 
(Cellular Retinoic Acid Binding Protein) (Shimamura and Rubenstein, 1997; Kohtz et al, 
1998; Gaiano et a l, 1999; Corbin et a l, 2000; Rallu et a l, 2002).
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Loss of GSH2 expression causes a reduction in the size of the LGE and a 
subsequent loss of DLX1 and DLX2 expression from the LGE (but not from the MGE) 
(Toresson et a l9 2000b; Toresson and Campbell, 2001; Yun et al.9 2003).
1.6.2.2 Bone Morphogenic Proteins (BMPs).
Other molecules that play a role in dorsalisation of the dorsal telencephalon are 
the Bone Morphogenic Proteins (BMPs) (Gulacsi and Lillien, 2003; Lillien and Gulacsi, 
2006). Studies in Xenopus levis show dorso-ventral patterning in the telencephalon 
involves firstly the induction of an anterior neural fate by BMP inhibitors followed by the 
ventral neural fate being induced by FGF8 (Fibroblast Growth Factor 8) (Lupo et al., 
2002).
Evidence from studies in Gallus gallus (chicken) indicate that BMP7 causes 
ventralisation when chordin, a BMP antagonist, is down regulated (Dale et al., 1999).
1.6.2.3 The Distal-less gene fam ily
There are six murine DLX homologues (related to the Drosophila Distal-less 
homeobox gene family (Panganban and Rubenstein, 2002)) that are expressed in several 
tissues including the craniofacial primordia, limbs and central nervous system (Eisenstat 
et a l, 1999; Panganban and Rubenstein, 2002). Four of the Dlx genes (Dlx 1/2/5 and 6 
(Anderson et a l , 1997b; Eisenstat et a l , 1999)) are expressed in the developing LGE and 
have been described as being critical for striatal development.
The expression of DLX1 and DLX2 was originally thought to be 
indistinguishable, although work has indicated that DLX2 expression proceeds that of 
DLX1, which itself proceeds expression of DLX5, although early bom striatal cells still 
express DLX5 and DLX6, indicating that these earlier bom cells express DLX5/6 
independently of DLX 1/2 (Eisenstat et al., 1999). Single mutants for DLX1, DLX2 and 
DLX5 have been made, and have shown no discemable forebrain defects, suggesting 
there is some degree of genetic redundancy; i.e. the only defect shown to date in the 
DLX2 mutant is a lack of tyrosine-hydroxylase expressing olfactory bulb intemeurons 
(Qiu et a ly 1995; Eisenstat et al., 1999). In SHH mutants (Shhy') it has also been found 
that DLX2 is lost, while in the Shh'/VPax6'/' a broad domain of this gene is seen (Fuccillo 
et al., 2006b).
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However, the DLX 1/2 double mutant shows an absence of the later-born (after 
E l2.5 (Eisenstat et al., 1999)) GABA-ergic intemeurons containing somatostatin, 
neuropeptide-Y and nitric oxide (Jain et al., 2001). These later bom striatal matrix 
neurons are believed to be derived from the sub ventricular zone (SVZ) of the developing 
striatum and are thought to remain in the SVZ apparently due to an arrest in their 
migration (Anderson et al., 1997b; Eisenstat et a l, 1999). Tangential migration from the 
MGE to the cortex and pallidum of cells that are due to become the majority of 
neocortical intemeurons in the neonate, is also decreased or absent (Anderson et al., 
1997a; Anderson et al., 1997b). It seems that Dlx genes in general have a role to play in 
the development of GABA-ergic neurons, as the expression of the Dlx genes coincides 
with the location of virtually all neurons that use GABA as their transmitter. Further 
proof of this is shown by studies in which ectopic expression of Dlx genes has induced a 
GABA-ergic phenotype (Panganiban and Rubenstein, 2002).
1.6.2.4 Gsh-2
Gsh2 (the mammalian homologue of the Drosophila Intermediate neuroblasts 
defective (Ind) gene), also leads to the expression of Mash-1 (Mammalian achaete-scute- 
like homologue-1, (also known as AScl-1) a gene that is closely related to the Drosophila 
Achaete-Scute gene and expressed in similar regions to Dlx2 and implicated in striatal 
early-born cholinergic intemeuron development (Jain et al., 2001) ) in the MGE; a loss of 
Gsh-2 will cause a subsequent loss o f MASH1, affecting the generation of neural 
precursors in the MGE by E12.5 (Casarosa et a l, 1999; Kriks et a l, 2005) and altering 
the timing of production of SVZ precursors in the LGE. This leads to a perturbed 
generation of neuronal populations in the basal ganglia (Yun et al., 2003) and cortex (as a 
proportion of cells bom in the ganglionic eminence are destined to migrate tangentially 
towards dorsal regions to become cortex later in development (Casarosa et a l, 1999; 
Nery et al., 2002)). As with the Achaete-Scute gene in Drosophila, MASH1 is confined 
to a subpopulation of neural precursor cells. Expression also precedes and ends upon 
neural differentiation in a similar fashion to its Drosophila homologue (Lo et a l, 1991).
Pax-6 (the murine P a x - 6 mutant is known as small eye or sey and the 
mammalian homologue of the Drosophila intermediate neuroblasts defective, (ind) gene)
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is a homeobox gene expressed in the dorsal telencephalon, a region that later develops 
into cortex, but not in the ventral telencephalon which later forms the striatum (Mastick 
et a l, 1997; Toresson et al., 2000b). Conversely, GSH2, is expressed in the MGE (this is 
thought to be a result of the presence of Shh along the ventral antero-posterior axis) 
firstly at around E l0.5 (Corbin et al., 2000), then spreading to the whole WGE later on, 
but not in the dorsal telencephalon as it is repressed by PAX6 (Quinn et al., 2006). 
However, see (Yun et a l , 2001a; Yun et a l , 2003) who propose there is a small 
population of cells that double label for both GSH2 and PAX6 along the dorso-ventral 
border that may give rise to Tyrosine Hydroxylase+ (TH*) cells that populate the 
telencephalon (Yun et a l, 2003). These two DNA regulating genes seem to cross repress 
one another and thereby regulate the expression of a further subset of genes that will 
cause the areas in question to develop certain fates, i.e. of cortex or striatum (Toresson et 
al., 2000b). The repressive interaction between these two genes appears to mark out this 
pallidal (dorsal) and sub-pallial boundary. As in the spinal cord, they have overlapping 
expression domains (Rallu et al., 2002). However, the repressive actions of GSH2 are not 
limited to the telencephalon; in the spinal cord class A progenitors GSH2 and subsequent 
MASH1 expression lead to the repression of -expressing type dI2 neural progenitors 
cells in favour of dI3 neuronal progenitors (Kriks et al., 2005). It has been shown in vitro 
that the loss of GSH2 in cultured LGE neurospheres may be the reason why these cells are 
increasingly restricted in their differentiation potential, the longer they are cultured, as the 
cells can no longer respond to contact-mediated region-specific developmental cues from 
primary cells that would otherwise cause them to differentiate into LGE neurons (Jensen 
et a l, 2004).
Loss of the ventralising Gsh-2 gene (as in the Gsh-27" mutant) also allows the 
expression of Pax-6 to spread into ventral areas (Chapouton et a l , 1999; Chapouton et 
a l, 2002; Suslov et a l, 2002) causing the expression of dorsal markers such as NGN1 
and NGN2 (Corbin et a l, 2000; Fode et al., 2000) (both basic-Helix-Loop-Helix (HLH) 
transcription factors) that are required for the production of cranial sensory neurons in the 
cortex (Casarosa et a l, 1999; Corbin et a l, 2000; Fode et a l, 2000) in areas that would 
otherwise have been ventral. However, later on in development it seems the molecular 
identity of these areas recovers; this is reported to be due to another member of this gene
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family; Gsh-1, compensating for the loss of Gsh-2 (Jain et al., 2001). Furthermore, a loss 
of GSH2 at around E l5.5 causes major path finding defects in corticofugal, 
corticothalamic, and thalamocortical fibres that would otherwise path through the 
striatum at this time before heading for their destinations (Yun et al., 2003). It can be 
seen, therefore, that both Pax-6, Gsh-2 and a number of other genes that they control are 
implicated in dorsal/ventral identity (Mastick et al., 1997; Corbin et al., 2000; Toresson 
et al., 2000b; Yun et al., 2001b). It seems they take a part in laying a ‘molecular border 
line’ down between the ventral ganglionic eminence and the dorsal cortex, as well as 
many other roles that they may play in cellular differentiation, development and normal 
activity.
1.6.2.5 Nkx-2.1
rr lAnother gene that is expressed in the foetus as early in development as the 3 and 
4th somite stages and in the MGE at around E9-E9.5 (Yun et al., 2003) is Nkx-2.1. As 
stated above, this gene is thought to be induced by the presence of Shh (Rubenstein et al., 
1998) along the rostro-ventral axis of the neural tube at around E8.5 and is maintained in 
the presence of Shh (Gulacsi and Anderson, 2006); Nkx-2.1 is expressed in cells that 
originate in the MGE but later migrate dorsally into the LGE (although not as far as the 
cortex (Chapouton et al., 1999)). At E14.5 and later stages, Nkx2.1 expression is 
prominent in the developing globus pallidus and as development continues its expression 
can be detected in several other ventral telencephalic structures including the Bed 
Nucleus of the Stria Terminalis (BNST), parts of the septum, the ventral pallidum and 
parts of the amygdala (Sussel et al., 1999a).
Mice lacking the Nkx-2.1 gene have a deficiency in striatal cholinergic, calretinin, 
somatostatin, neuropeptide-Y and nitric oxide containing intemeurons, indicating that 
this gene is implicated in striatal intemeuron development (Jain et al., 2001). Nkx-2.1 
deficient mice have also been found to not form pallidal structures; they lack basal 
forebrain Trk-A positive cells (probably the cholinergic neurons mentioned above (Jain et 
al., 2001)) and also have reduced numbers of cortical cells expressing GAB A, DLX2 and 
Calbindin; cells that would normally have been bom in the MGE and migrated through
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the LGE into the cortex (Sussel et al., 1999b). Hippocampal cell numbers are also 
reduced (Pleasure et a l, 2000).
1.6.2.6 Foxg-1
Foxg-1, a gene formerly known as Bf-1 {Brain factor-1, related to the Drosophila 
Sloppy paired and a member of the large forked head gene family) is a winged helix 
transcriptional factor first expressed at around E8.5-9 (Xuan et al., 1995; Jain et a l,
2001), that acts as a negative regulator in the telencephalon and is expressed downstream 
of FGF8 (Storm et al., 2006). A lack of expression of Foxg-1, as seen in the mutant 
Foxg-1v‘, results in cortical hypoplasia and still birth (these mutants are only viable up to 
the age of E l8.5 (Hanashima et al., 2004; Martynoga et al., 2005; Storm et a l, 2006)). 
This is thought to be due to progenitors differentiating early leading to reduction of the 
progenitor population and therefore a reduction in the final numbers of cells within the 
telencephalon (Xuan et al., 1995). FOXG1 interacts with transcriptional co-repressors 
from the GROUCHO/TLE (transducin-like enhancer o f Split) family and also associates 
with histone deacetylase to repress transcription of certain genes (Yao et al., 2001) that 
would otherwise enhance neuronal differentiation.
In a recent study FOXG1 was found to suppress the earliest bom cortical neurons 
(the Cajal-Retzius neurons of layer 1 of the cortex) in normal development, while in the 
Foxg-1v' mouse there is an excess of these cells within the cortex (Hanashima et al., 
2004).
1.6.2.7 Ebf-1
Differentiation of striatal cells may also be associated with the expression of the 
transcription factor EBF1 (Early B-cell factor-1 also known as Olf-1, or Coe) which is 
expressed in both the LGE and MGE between E ll and E17.5 (Garel et al., 1997). This 
gene has been found to be highly up-regulated in striato-nigral projection neurons, a 
subset of MSNs (Lobo et al., 2006). In the normal brain, antibodies raised against EBF1 
will highlight later bom matrix neurons (Corbin et al., 2000). The protein product of this 
gene contains a zinc-finger domain and a non-basic Helix-Loop-Helix dimerisation 
domain. Although the knockout model shows no defects within the striatum until E l7.5, 
inactivation of this protein does affect cells within the SVZ/mantle transition in the LGE,
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affecting the differentiation processes coincident with the migration of cells to the mantle 
zone, therefore leading to abnormal gene expression within the mantle later in 
development. Due to this, cell death later on in embryological development is increased 
(Garel et a l9 1999).
1.6.2.8 Meis-1/2
The Meis {Myeloid Ecotropic Viral Integration Site) family of homeobox genes 
belong to a super-group of transcription factors that have a Three-Amino acid Loop 
Extension (TALE). Meis genes are related to the Homo-thorax gene found in Drosophila 
and the Knotted (Kn) family of genes found in plant embryogenesis (Cecconi et a l , 
1997). Three Meis genes have been found in vertebrates; Meis-1/2/3. However, only 
MEIS1 and MEIS2 have been detected in significant levels within the telencephalon; at 
around E l0.5 MEIS1 is detected in low levels in the ventricular zone (VZ) of the ventro­
lateral telencephalon while MEIS2 is present in high levels in the areas destined to 
become the LGE. Twenty four hours later at around El 1.5, when the MGE and LGE 
become morphologically distinct MEIS1 is highly expressed in the CGE and developing 
amygdala and at lower levels in the LGE and MGE. This protein continues to be 
expressed in ventro-lateral regions of the striatum, cortex, ventral pallidum and medial 
septum (Toresson et al., 2000a). LGE precursors that have been passaged six times and 
then differentiated in vitro have also been seen to express Meis2, PBX and Dlx, all 
characteristics of LGE derived neurons (Parmar et a l , 2002). In drosophila, the homo­
thorax protein is known to co-locate with another protein known as extra-denticle while 
in vertebrates MEIS1 and 2 are also known to act as co-factors with the extra-denticle 
TALE protein homologues PBX3 (Toresson et al., 2000a) and PBX1 (Knoepfler et a l , 
1997; Swift et a l , 1998). Toresson and colleagues have also shown that DLX expression 
overlaps that of MEIS and PBX proteins within the telencephalon. MEIS2 has also been 
shown to interact with other TALE proteins to regulate gene transcription, for example, 
by competing with TGIF (Transforming Growth Interacting Factor) to differentially 
regulate (Meis-2 activates, TGIF represses) transcription of the Dia dopamine receptor in 
striatal cells (Yang et al., 2000).
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1.6.2.9 RetinoicAcid
The active metabolite of vitamin A, Retinoic Acid, is another morphogenic 
molecule that has been implicated in the differentiation of striatal neurons. This molecule 
works as another gene regulator, via ligand activated transcription factors known as 
retinoic acid a  receptors (RARs) and retinoid acid % receptors (RXRs), which are both 
nuclear receptors belonging to the steroid and thyroid hormone receptor family 
(Zetterstrom et a l , 1999).
In the spinal cord, Retinoic acid acts in opposition to FGF8, as a requirement for 
neuronal differentiation (Diez del Corral et al., 2003) and to specify neuronal 
development in the early neural tube.
Retinoic acid begins to appear in the developing CNS around E7, and Cellular 
Retinoic Acid Binding Protein (CRABP) assays have been detected in high amounts in 
the striatum in newborn rats (when compared to cerebellum, hippocampus and control 
samples). This expression can also be related to the areas of dopamine D2 receptor 
innervation within the striatum suggesting a functional relationship between these two 
molecules. Expression falls back to just above background levels by the time the rat pup 
reaches 5 weeks old (Zetterstrom et al., 1999).
The appearance of retinoic acid is further confirmed by the presence of 
retinaldehyde dehydrogenase-3 (RALDH3) (an enzyme that oxidises retinol (vitamin A) 
to retinoic acid) within the LGE (Li et al., 2000) and RALHD2, (also known as 
retinaldehyde dehydrogenase-1) which has been found within dopaminergic nerve fibre 
terminals within the striatum, suggesting that retinoic acid may be involved in gene 
regulation within this area (Zetterstrom et al., 1999). However, the expression of this 
gene is reduced in the LGE of Gsh2 mutants concomitant with a reduction of DARPP-32 
(a phosphoprotein that marks striatal projection neurons but not striatal intemeurons 
(Anderson and Reiner, 1991)). This deficit can be partially rescued by ectopic exposure 
to retinoic acid (Waclaw et al., 2004). MSNs that express GABA, dynorphin, substance 
P and enkephalin have also been shown to express RARs and RXRs (Ferre et al., 1997). 
More support for this has been shown in a study in chick embryos by (Marklund et al.,
2004) which shows that retinoic acid acts to specify the intermediate zone neurons that 
later become the striatum early on in the formation of the neural tube. Marklund
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describes this early influence of retinoic acid as coming from the ectoderm adjacent to the 
ventral and intermediate areas of the neural tube, and it is this that influences the 
intermediate cells to express markers such as MEIS2 and PAX6 (in the dorsal-most areas 
of the intermediate zone). Retinoic acid has limited or no effect on more ventral cells due 
to the opposing action of FGF, hence ventral cells remain under the influence of ventral 
transcription factors such as NKX2.1 (Marklund et cd.9 2004).
During embryonic development of the striatum, glial cells (possibly radial glia) 
within the LGE are a localised source of retinoids, allowing cells that are migrating 
through the LGE into the developing striatum to come under the morphogenic influence 
of retinoids that could affect their differentiation. Findings that treatment of LGE cells 
with either RAR or RXR agonists also enhances the striatal neuronal characteristics of 
these cells further support this hypothesis (Toresson et al., 1999).
From the information provided by these earlier studies it can be seen that the 
differentiation, growth and maturation of the striatum involves a complex spatial and 
temporal interchange of many different molecular signals (the above list is by no means 
exhaustive). These signals act over the whole time period of striatal development from its 
initiation and neurogenesis at around E9.5 (Corbin et al., 2000), throughout its cellular 
proliferation until its final maturation. Some of these signals even change in their actions 
depending on the stage of development.
1.7 Aims of this project
Small clinical trials of foetal striatal tissue implantation in HD have demonstrated 
the validity of a restorative approach. However, in order to become more widely 
available therapy a renewable supply of MSN precursors is required. Any stem cells 
grown in culture will require some direction towards an MSN phenotype. Thus, 
understanding the signals important for the development of this specific phenotype is 
important irrespective of the proposed cell source.
In this project the aim was to identify genes likely to be important in striatal 
development. This was done by characterising gene expression in striatal neural 
progenitors that later give rise to the MSNs of the adult striatum, over the peak time
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period for MSN specification in this group of the neural progenitors, i.e. between the ages 
of E12 and E l6.
Identification of such genes is important for a number of reasons;
• Identifying gene expression changes that are functionally relevant for striatal 
development will be important in the process of producing protocols to direct the 
differentiation of stem cells towards a functional MSN phenotype for 
transplantation. However, although primary associations may be made in this 
thesis, validation of a functional association would most likely take longer than 
could be accommodated in the time frame of this project and will not form a part 
of my work, but will be carried out by other researchers.
• To identify genes that are associated with striatal differentiation for use as 
markers of stages of striatal development Genes used for this purpose do not 
necessarily have to be proven to be part of the differentiation machinery so long 
as they can be demonstrated to be strongly associated with the process. As 
described above, very few markers of striatal differentiation have been defined to 
date.
A panel of striatal markers is required for the following reasons;
• As part of the process of learning to direct the differentiation of cells toward a 
striatal phenotype a panel of markers is required to identify potentially useful 
protocols. To date reliable identification of striatal cells has relied on DARPP-32 
labelling of transplanted cells (DARPP-32 staining of cells differentiated in 
culture is unreliable). A panel of markers to identify developing cells that have the 
potential to become MSNs would be extremely valuable for this work.
• Primary foetal tissue studies have demonstrated that the developmental stage at 
which cells are transplanted is crucial for their survival, integration and function. 
Defining and recognising the optimal stage at which to transplant directed stem 
cell populations would be greatly aided by a panel of developmentally associated 
striatal genetic markers.
• FNPs are a potential source of transplantable cells for HD but, as described above, 
they lose the capacity to differentiate into MSNs possibly due to loss of position
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information. A panel of developmentally associated striatal genetic markers 
would be important in understanding this process and developing method of 
manipulating it.
35
Chapter Two
2 Methods
2.1 Dissection
All animals were treated within the constraints of the Animals (Scientific 
Procedures) Act 1986, the laboratory project licence and the author’s own personal 
licence.
2.1.1 Manual dissection under microscope
This technique is described by Dunnett and Bjorkland (Dunnett and Bjorkland, 
1992) for foetal rat dissection but a similar technique is suitable for foetal mice between 
E l2 and E l6. However, due to the differences in gestation length, (that of the rat being 
21-22 days and that of the mouse being 19-20 days), the foetal mouse is bigger and more 
developmentally advanced than the foetal rat at a specific gestational stage, therefore the 
following chart shows the Crown-Rump length (CRL) for foetal mice during the age 
range dissected. The Carnegie Staging system, (devised by Franklin Mall of the Carnegie 
Institute in Washington, USA in the early 1900s), is an internationally recognised 
protocol for staging human embiyos, based on the morphological characteristics of the 
embryo. Accurate staging in this case is important as the aim is to define genetic 
expression at discrete points in the development of the foetus.
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Relationship between murine foetal age 
and Crown Rump Length (CRL)
20
18 Average CRL o f fresh murine foetus 
Comparative Carnegie Stage -  22
16
-  20
14
- 18
12
- 16
10
8
E15 E16E12 E13 E14
Gestation Age (days) S'
Table 2.1; Relationship between gestational age, CRL and Carnegie Stage of murine foetuses.
2.1.1.1 CRL measurement
The procedure adopted was simply to measure the foetuses straight after removal 
from the uterine horn and amniotic sac. A millimetre ruler was viewed alongside each 
foetus under low magnification and the CRL for each foetus recorded. This was used to 
produce a range of CRLs for the whole batch that was then taken and recorded before 
each dissection.
The CRL was used as a more accurate indication of age of the batch than 
estimating gestation from the time of mating (usually recorded using the day of vaginal 
plug as day 0): depending on environmental conditions murine females may also delay 
implantation (diapause) by a number of days (Lanman, 1970; Nieder and Weitlauf, 1984) 
which is particularly relevant when using mice for this study. Furthermore, animals could 
have mated any time during a 12 hour period, which is the standard period of pairing of a 
male and female for the purpose of mating.
Conditions were standardised to minimise variability between foetal tissue 
collections. In particular, pregnant mothers were food deprived from the afternoon of the
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day before sacrifice to reduce the likelihood of insulin-related gene expression changes, 
and all maternal donors were sacrificed within 2 hours of “lights on” in their 12:12 
light/dark cycle to control for the changes associated with circadian rhythms.
2.1.1.2 Removal offoetuses from the pregnant mother
Instruments; Large blunt ended scissors (Dumont FST-14012-17), fine pointed 
scissors (Dumont FST14060-10), 2 haemostatic clamps (Dumont FST-), large tissue 
forceps (Dumont FST-11002-16), ruler with mm graduations.
Equipment; Category II tissue culture/dissection hood, dissection microscope.
Plastic ware; Sterile Petri dishes (10cm diameter), 50ml sterile tubes (Sarstedt).
Solutions; Ice cold Hanks Medium buffered Saline Solution (HBSS-Gibco).
Pregnant mothers were sacrificed by cervical dislocation, out of sight, sound and 
smell range of other animals; thus controlling for any gene expression changes that would 
otherwise occur due to stress of anaesthesia or sensing danger. All animals were 
decapitated straight after sacrifice.
Dead animals were then laid ventral side upwards and a midline incision made 
first through the skin and then through the abdominal fascia from just above the genitalia 
to just below the xiphous sternum with blunt ended scissors. The severed abdominal 
layers were then retracted with forceps or clamps. The uterine horns were then removed 
and placed in a sterile 50ml tube containing 15-30ml ice cold HBSS.
Once both uterine horns from all animals had been dissected, they were 
transferred to a Category II dissection hood and placed into a 10cm sterile Petri dish 
containing ice cold HBSS. The amniotic sacs were removed with small pointed scissors 
from each uterine horn and then each foetus was cut from its amniotic sac and placenta 
and placed into a separate 10cm Petri dish containing ice cold HBSS for measurement of 
CRL.
2.1.1.3 Removal o f the brain from  the foetus.
Once the foetuses had been removed from the mother, their brains were removed; 
In addition to above the following equipment was used;
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1Instruments; Fine forceps (Dumont FST-number 5), Micro dissection/iridectomy scissors 
(Dumont FST-15000-08), Fine scalpel (Dumont FST-100035-00) with fine blade 
(Dumont FST-10035-15).
The foetuses were sacrificed by cervical severance or decapitation before further 
dissection was carried out.
The cranial bones do not start to calcify in the murine foetus until around E l6.5 
(unpublished observations), therefore any dissections before this time could be carried 
out using the lateral approach (Dunnett and Bjorkland, 1992) as shown below;
With the foetus illuminated from below, the outline of the brain could be made 
out within the developing cranium. A single cut was made with a fine scalpel blade, 
below the base of the brain and just above the eye, extending from the front of the head 
back to just in front of the mesencephalic flexure of the brain. Care was taken not to 
damage either the ventral mesencephalon of the ventral forebrain. The tips of fine forceps 
or the blunt side of the scalpel blade were then inserted under the skin at the apex of the 
cut and the overlying skin and meninges of the brain pulled away in a single motion, 
leaving the brain naked. Figures 1-4 show this carried out on an E14 murine embryo, 
however, much the same method was adapted for all ages between E l2 and E l6. A cut 
was then made across the mesencephalic flexure, or as low as possible on the brain and 
the brain removed and placed in a fresh Petri dish containing ice cold HBSS.
Fig. 2.1; After cervical severance or decapitation, a cut was made, 
beginning in the area of the muzzle, below the eye, and cutting towards the mesencephalic flexure.
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2.1.1.4 Removal o f the Whole Ganglionic Eminence.
The whole ganglionic eminences develop as ‘heart shaped’ structures on the 
rostro-ventral floors of the two lateral ventricles and can be made out in embryos of E12 
and above, although by E l6 and beyond the ‘heart shape’ is lost as the striatum grows to 
fill the lower part of the lateral ventricle. Dissection was carried out by laying the 
dissected brain ventral side facing down in a 10cm Petri dish containing ice cold HBBS. 
A longitudinal incision was made using iridectomy scissors along the upper surface of 
each of the cortical hemispheres, and the hemispheres then retracted outwards to reveal 
the inside of the lateral ventricle with the whole ganglionic eminence lying along the 
floor. Approaching the brain caudally with the iridectomy scissors lying parallel to the 
bottom of the Petri dish, a superficial incision was made under the ‘heart shaped’ bulge to 
separate it from the floor of the ventricle. This was repeated for the other hemisphere.
Fig. 2.2; The brain in ice cold HBBS after severance at the mesencephalic flexure.
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Fig. 2.3; The cortical hemispheres were retracted and the WGE removed using Dumont iridectomy scissors.
Fig. 2.4; The brain after removal of both whole ganglionic eminences (placed above the brain for illustration purposes).
The tissue was then placed in a suitable solution for fixing and either immuno- 
histochemistry or in situ hybridisation (4% Paraformaldehyde (PFA) for 1-2 hours then 
25% Sucrose overnight then storage in -80oC) or for RNA extraction; (placed in to a 
Matrix D® lysing tube (Q Biogene) and ‘snap frozen’ in liquid nitrogen and stored at - 
80°C).
2.1.2 Im m uno-cytochem istry and in situ  Hybridisation
Whole foetal brains at E l2, E l4, and E16 were placed inside 1.5ml microfuge 
tubes filled with “Tissue-Tek” OCT compound (Miles Inc.) Care was taken to orient the 
brain rostro-caudally and the tube ‘snap-frozen’ and placed at -80°C until needed.
Brains were cut into 16pm sections on a Bright cryostat and mounted onto 
Superfrost Plus slides. These were stored at -80°C until further processing for either in
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situ hybridisation or immuno. Sections were quenched (solution 1 below) for 5 minutes 
then washed in TBS (solution 2 below) three times for ten minutes each time. They were 
then blocked using 3% ‘normal’ serum (see antibody list) in TXTBS (solution 3 below) 
for 1 hour.
After blocking, sections were transferred (without washing) straight into primary 
antibody for varying amounts of time (see antibody list) in TXTBS with 1% ‘normal’ 
serum for at 4°C, after which they were washed three times in TBS, for ten minutes each 
time. Next, the sections were immersed in the secondary antibody (see antibody list for 
timings and conditions for each antibody) in TBS with 1% ‘normal’ serum.
2.1.2.1 Solution 1 Quench:
10ml Methanol 250ml TBS
10ml Hydrogen peroxide 30% 500pl Triton X-100
80ml Distilled water Adjust pH to 7.4 with Cone. HC1
2.1.2.2 Solution 2 TBS:
12g Tris-Base
9g Sodium Chloride
1000ml Distilled water
Adjust pH to 7.4 with Cone. HC1
2.1.3 RNA Extraction
This extraction method was advised by Dr Angela Hodges of the Dept of Medical 
Genetics at the Heath Hospital Cardiff, and has been shown to substantially increase final 
yields of labelled cRNA (personal communication).
10ml tubes were labelled for each sample of RNA and 2ml of ice-cold TRIzol for 
every sample of RNA being extracted was pipetted into a waiting 50ml tube. 1ml of ice- 
cold TRIzol was added to each sample whilst it was still in the matrix D Lysing tube and 
these were placed into a Fast prep agitator (Q Biogene) and homogenised on speed 4.0 
for 30 seconds. The TRIzol and sample were then transferred into a 10ml polypropylene 
tube and another 1 ml of ice-cold TRIzol was used to wash the Lysing Matrix D tube by 
and pipetting up and down a few times to ensure all the sample had been removed to the
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10 ml tube. For small samples, spinning the Lysing Matrix D tube for a few seconds in a 
microfuge before pipetting with a yellow tip to obtain the last few pi’s of TRIzol.
Samples were then incubated at room temperature for 5 minutes. 400pl of 
chloroform (reserved for RNA use only) was then added to each sample, before shaking 
vigorously for 15 seconds and incubating at room temperature for 5 minutes from 
finishing the last sample. Samples were then centrifuged at 12,000g for 15 minutes at 
4°C. While samples were spinning, lm l of isopropanol was added to the second set of 
10ml tubes and an Eppendorf rack with one RNeasy (Qiagen) column, two 2ml collection 
tubes, one 1.5ml Eppendorf and 1 small eppendorf for (Genequant) sample, per sample of 
RNA was made ready; all tubes were labelled.
After centrifugation, the upper aqueous phase was transferred to a fresh 10ml 
tube. If extracting from small samples a 200pl yellow tip was used for the last few pi’s to 
get in to the meniscus at the side of the tube, in order to take off all the aqueous phase, 
lm l of isopropanol (reserved for RNA use only) was then added to each 10ml tube; this 
was mixed gently and incubated at room temperature for 10 minutes from finishing the 
last sample to allow precipitation.
Samples were then centrifuged 12,000g for 10 minutes at 4°C. After 
centrifugation, the supernatant was removed and the pellet washed carefully in 2ml of 
RNase-free 75% ethanol. Samples were then centrifuged again at 7,500g for 5 minutes at 
4°C.
While samples were in the centrifuge the required amount of RLT buffer (RNeasy 
lysis buffer) with B-Mercapto-ethanol (BME) was made up (350pl of RLT buffer with 
1% BME) in a separate 50ml tube. After centrifugation the supernatant was removed and 
the pellet washed again in 2 ml of 75% RNase-free ethanol.
Samples were centrifuged at 7,500g for 5 minutes at 4°C before the supernatant 
was removed and the tube spun again to force the last of the ethanol to the bottom.
The pellet was dried for 5 minutes in a 45°C incubator/oven then resuspended in 
lOOpl RNase-free water by vortexing followed by incubation at 65°C for 5 minutes and 
further vortexing.
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2.1.3.1 RNeasy column cleanup
The RNA was purified further using the Qiagen RNeasy Mini kit as per the 
manufacturer’s instructions:
Samples were mixed in the holding tube before adding 350pl of Buffer RLT (with 
1% p-mercapto-ethanol) and mixing thoroughly. 250pl of RNase-free ethanol (96-100%) 
was then added to the diluted RNA and again mixed thoroughly (by pipetting, not 
vortexing). The sample (700pl) was then immediately added to an RNeasy mini column 
that had been placed in a 2ml collection tube. This was then centrifuged for 1 minute at 
10,000g. (The eluate was then reapplied back on to the column and re-centrifuge for 1 
minute at 10,000g).
The RNeasy column was then transferred into a new 2ml collection tube and 
500pl of Buffer RPE (a phosphate washing buffer) pipetted onto the RNeasy column. 
This was centrifuged for 1 minute at 10,000g. The samples were then incubated with 
Qiagen RNase-free DNase for 15 minutes (to rid the sample of genomic DNA 
contamination) before another 500pl Buffer RPE pipetted onto the RNeasy column. This 
was again centrifuged for 1 minute at 10,000g before discarding the flow-through and 
centrifuging for another 2 minutes at 10,000g. The RNeasy columns and tube were then 
turned 180° in the centrifuge and spun again for a further 1 minute at 10,000g.
The RNeasy columns were then eluted in to freshly labelled 1.5ml 
eppendorfrcollection tubes. 30pl of RNase-free water was pipetted directly onto the 
RNeasy silica-gel membrane before waiting 5 minutes and centrifuging again for 1 
minute at 10,000g.
The sample left in the collection tube was then passed through the column again 
to Re-elute, or, if there was more than 150pg of RNA expected from the sample, a further 
30pi of RNase-free water was pipetted directly onto the RNeasy silica-gel membrane and 
turning the column and collection tube in the centrifuge 180° and centrifuging for another 
1 minute at 10,000g.
RNA was then quantified on a Genequant spectrophotometer to calculate the total 
yield of RNA, concentration, and 260/280nm ratio to check the quality of the RNA.
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An aliquot (<=500ng/pl) was also sent for analysis on an Agilent chip to check 
quality, both from the visual ‘gel picture’ and the ribosomal RNA ratio. Total RNA was 
stored at -80°C.
2.2 Micro array methodology
The Asymetrix micro array process was carried out by the staff of the Micro 
array facility, The Department of Pathology, University of Wales College of Medicine 
(UWCM). Therefore the following is a summary of the protocol used by this facility; I 
observed this process in its entirety on one occasion.
2.2.1 Micro array protocol
Synthesis of double-stranded cDNA was performed using separate components 
from the standard Superscript Choice II cDNA synthesis kit. First-strand cDNA synthesis 
a T7-(dT)24 primer containing a T7 promoter site was used. After second-strand 
synthesis (using DNA polymerase 1 and T4 DNA polymerase) the double-stranded 
cDNA was “cleaned-up” sing an ethanol precipitation.
The IVT (In Vitro Transcription) was carried out using a BioArray HighYield 
RNA Transcript Labelling Kit from Enzo Life Sciences to make biotinylated cRNA, 
which was purified using RNeasy columns (Qiagen). Following quantification on a 
spectrometer at A260nm, the labelled cRNA is fragmented to 35-200 base fragments. 
Fifteen pg of fragmented cRNA are hybridized for sixteen hours at 45°C with the 
Mouse430A GeneChip Array using the GeneChip Hybridization Oven. Spiked 
hybridization controls include labelled transcripts from E. coli bioB, bioC and bioD, and 
ere from bacteriophage PI.
Following hybridization, the arrays are washed and stained in an Aflymetrix 
GeneChip Fluidics Station 400. Staining was done in a three-step procedure starting with 
a streptavidin-phycoerythrin staining solution, followed by incubation with biotinylated 
anti-streptavidin and finally a second staining with streptavidin-phycoerythrin. Stained 
arrays were scanned with an Agilent GeneArray Scanner. Analysis of data was performed 
using the Afrymetrix software Micro array Suite 5.0 (MAS 5.0) and Robust Multi
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Averaging (RMA), GeneSpring from Silicon Genetics and the NIA (National institute of 
Ageing) Array Analysis ANOVA Tool.
.3 Post Array Analysis
2.3.1 Primer design
Once a gene of interest had been identified the accession number was obtained via 
a search using the NCBI cross database search website (Geer et al., 2004) at 
http://www.ncbi.nlm.nih.gov/gquery/gquery.fcgi
The above website gave access to the gene accession number which could then be 
used to search for the sequence. Once the sequence was found this could be cut and 
pasted into primer analysis design software such as Primer 3 (Rozen and Skaletsky, 2000) 
or Oligo.
Factors taken into account when designing primers;
• Primer length was designed to be long enough for the sequence to be both unique, 
and not to be found at non-target sites. This length was usually between 18 and 30 
bases; lengths of more than 24 base pairs do not confer greater specificity as they 
can hybridise with mismatching base pairs and decrease specificity.
• Primers were designed to have near 40-60% GC content.
• Complimentary areas of the sequence at the 3’ end of primer pairs were also 
avoided where possible; this prevented amplification of the primers themselves to 
form primer-dimers. Thymidines should be avoided at the 3’ end, as this base is 
more prone to mispairing than other nucleotides.
• Mismatches at the 3’ end were also avoided as the last three nucleotides have to 
anneal to the template for the polymerase to catalyse extension.
• Sequences with the potential to form a secondary structure (such as hairpins) were 
avoided as this would destabilise primer annealing.
• Primers were designed to have a PCR product of between 300-400 base pairs if 
possible; if shorter than this they were likely to be less specific, longer and they 
were likely to diffuse slowly into the tissue to the target and would need to be 
hydrolysed before RNA probe hybridisation.
• If designing primers for genes that were known to be closely related (i.e. 
haemoglobin genes or Foxpl/Foxp2/Foxgl etc), the primers were designed for 
areas of these specific gene sequences that were not common with close 
homologues.
• If there was a risk of genomic DNA contamination in the cDNA sample that was 
able to bind either the primer or a product of the primer such as an RNA probe, 
then primers were designed to include an intron (a piece of DNA that is not 
transcribed into mRNA). If these types of primer bind to genomic DNA, the 
product would be shown to be longer (therefore above) the mRNA product on a 
gel, so both could easily be differentiated from each other.
• Where primers were used that did not contain introns, an RT- (without the reverse 
transcriptase) stage was used during PCR to check for DNA contamination 
causing spurious results.
2.3.1.1 Primer melting temperature (T^
This is found by taking the base content of the primer; a primer with a high GC 
content will have a higher melting temperature due to the primer duplex having a higher 
number of hydrogen bonds holding it together than a primer with more AT base pairs.
23,1,2 Primer annealing temperature (TJ
This is the temperature when 50% of the primer and its complementary sequence 
are present in a duplex state. Knowing this is necessary to establish the annealing 
temperature for PCR. Ideally the annealing temperature was designed to be low enough 
to guarantee efficient annealing of primer to target, but also high enough to minimise 
non-specific binding. Reasonable temperatures range from 55-70°C, and are generally set 
to around 5°C below the Tm of the primers (which were, where possible, designed to 
have a similar Tm). Higher annealing temperatures can reduce the formation of primer- 
dimers and non-specific products. Too low an annealing temperature will lead to non­
specific annealing and therefore amplification.
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2.3.1.3 PCR Buffer effects on amplification
In PCR, annealing occurs between the primers and their complimentary target 
sequences on the cDNA, this leads to amplification of the PCR product. However, due to 
the high concentration of primers needed to get efficient hybridisation during the short 
annealing time, primers may also anneal to non-complimentary sequences resulting in the 
non specific amplification of products in competition with, and reducing the yield of the 
specific PCR product.
2.3.1.4 Primer concentrations
For the optimisation steps this was set at 0.4 pM (see PCR Reaction Mix, below). 
Lower concentrations may result in a reduced yield while higher concentrations may 
result in the amplification of non-specific products.
2.3.1.5 Optimisation o f Primers
PCR success depends upon the high ratio of specific to non-specific annealing of 
primer molecules which is influenced by a number of factors; including the PCR buffer 
and the concentration of the cations within the buffer which neutralises the negatively 
charged phosphate groups on the DNA backbone weakening the electro-repulsive forces 
between the DNA strands, facilitating the annealing between primer and template. In the 
absence of adequate free magnesium, Taq DNA polymerase (Promega) is inactive. 
Conversely, excess free magnesium reduces enzyme fidelity and may increase the level 
of non-specific amplification. Thus, it was important to empirically determine the optimal 
MgCL concentration for each reaction. Primers were optimised using 1.0, 1.5, 2.0 or 
3.0fiM MgCb concentration (see Buffer Mix, below).
The number of cycles through which each primer was hybridised was dependent 
upon the primer, and its ability to hybridise with its target. This can also be changed by 
changing the abundance of target cDNA; for the majority of primers used the cycle 
number was between 25 and 30.
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Theoretical field
Actual Yield
0 20 30 40
Cycle Number
Fig. 2.5; Each PCR has a yield limit dependent on starting concentration of target cDNA.
2.3.1.6 Buffer Mix
End
Concentration l.O^M 1.5nM 1.5*iM 1.5^M 2.0jaM 2.5 i^M 3.0nM
10 x  PCR Buffer 
(pi) 1 X 29 29 58 116 29 29 29
MgCI2 [25nM] 
(pi) Variable 11.6 17.4 35 70 23.2 29 35
DMSO (nl) 5% 14.5 14.5 29 58 14.5 14.5 14.5
dNTP [IOOjiM] 
(pi) 0 .8 mM 2.3 2.3 4.6 9.2 2.3 2.3 2.3
dH20 (*il) Variable 192.6 186.8 374 747 181 175.2 169.2
End Volume (|al) 250 250 500 1000 250 250 250
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I2.3.2 Polym erase Chain Reaction (PCR)
PCR was carried out using the reaction mix shown above in a PTC-100 
Programmable Thermal Cycler (M .J. Research, Inc.).
Step Temperature/°C Time/M in/sec. Reason
#1 94 2.00 Primary De-nature
#2 94 0.15 De-nature
#3 Tm( Annealing) 0.20 Annealing
#4 72 1.00 Elongation
#5 Go to Step 2 x amount of times # of cycles
2.3.2.1 Reaction M ix
PCR Reaction Volume: 20pl End Concentration
Buffer Mix 17.2
cDNA lpl
Primer 1 [lOpM] 0.8pl 0.4pM
Primer 2 [lOpM] 0.8pl 0.4pM
Taq Polymerase (Promega) [5 Units/pl] 0.2pl 1 Unit per reaction
Total (pi) 20pl
2.3.2.2 Reverse transcription o f RNA to obtain cDNA
This was done using Thermo-script Reverse Transcriptase (Invitrogen) and RNase 
H (Invitrogen).
2.3.2.3 For a 20 p i Reaction volume
Before starting a bucket of ice was filled (for all enzymes) and the thermal cycler 
set to 65°C hold. The following constituents were then added in order, to a thin 
walled/flat topped 0.2 ml PCR tube;
1 Pg RNA (total RNA)
1 pi of 50 pM Random hexamers
0.5 pi dNTP (Amersham) [lOOmM]
ad 13 pi dH20
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This was Incubated at 65°C for 5 min and then immediately placed on ice. It was 
then briefly centrifuged and the remaining constituents added;
4 pi 5x cDNA Synthesis Buffer
RNasin
n a 0.1 MDTT
lp l ThermoScript RT (Invitrogen)[15 U/pl]
The following program was then entered into the thermal cycler;
Step Temperature/°C Time/Min. Reason
#1 25 10.00 Mixing/Equalisation
#2 50 50.00 Annealing
#3 65 15.00 Extension
#4 85 5.00 Denaturing of RNA/cDNA
Any remaining RNA was digested by adding lpl of RNase H [2 U/pl] and 
incubating at 37°C for 20 min.
A control reaction containing all constituents except the Thermoscript RT was 
also run to indicate if there were any genomic DNA ‘carry over’ that may interfere with 
upstream reactions. Gels were then run to check the amounts of cDNA in each sample 
before running an RT+ (and RT-) G3PDH PCR reaction to equimolarise (and check for 
genomic DNA carry over). The amounts of cDNA used in subsequent PCR reactions 
altered accordingly.
2.3.3 Cloning, transform ation of prim er products and subsequent
purification of plasm ids
Using the TOPO TA Cloning Kit (Invitrogen®) as per manufacturer’s 
instructions:
2.3.3.1 Overview
Once the primers had been optimised and primer product made these were then 
cloned into the pCR®II-TOPO® plasmid vectors and then transformed into competent 
E.coli.
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23.5.2 Cloning
The following ingredients were added to a 0.2ml PCR tube;
0.5 - 4.0pl Fresh PCR product
lpl j Salt Solution (from kit)
Ad 5 pi RNase-free Water
lpl TOPO® vector
6pl Final Volume
The above ingredients were mixed gently and incubated at room temperature for 5 
minutes before being placed on ice.
2.3.3.3 Transforming E.coli
The following were needed for each cloning reaction;
• 1 vial of competent E.coli cells thawed on ice.
• S.O.C. medium (included with kit) warmed to room temperature.
• 2 LB plates containing 50pg/ml ampicillin pre-warmed to 37°C for 30 minutes.
• Water bath equilibrated to 42°C.
2pl of the TOPO cloning reaction was pipetted into a vial of TOP 10 E.coli and mixed 
gently by stirring with the tip of the pipette (not pipetted up and down).
This reaction mix was incubated for 10 minutes on ice.
The cells were then “heat shocked” for 30 seconds at 42°C then immediately 
transferred back to ice for 2 min.
250pl of room temperature S.O.C. was then added to the vial and allowed to mix with the 
cloning reaction.
The whole reaction mix was then transferred immediately to a 15ml Falcon® shaking 
tube (with the lid tight) and shaken at 37°C for 1 hour.
lOOpl was then taken and spread on a plate of agar (150pg/ml ampicillin), the remaining 
centrifuged at 1000 rpm for 3 minutes then after taking off a further ~750pl, a further 
lOOpl was spread over another plate of agar (150pg/ml ampicillin) in case the 
transformation had not been efficient.
Plates were left upside down at 37°C overnight.
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2.3.3.4 Plasmid Mini-prep.
Once the plasmids had been transferred into E.coli and grown into colonies on 
agar plates the plasmids containing the insert of the gene of interest and an SP6 and T7 
promoter (one on either side) then had to be purified using a plasmid DNA mini-prep 
protocol which used an alkaline lysis to remove the bacterial DNA by utilising the fact 
that the E.coli genome is much longer than the plasmid DNA and therefore takes longer 
to re-nature.
The following equipment was needed for each plasmid mini-prep sample;
4 inoculation loops
4 separate 15ml Falcon® shaking tubes with ~15ml of LB (150pg/ml ampicillin)
1 agar plate (150pg/ml ampicillin)
GET solution (to make 200 ml) (Store at 4 °C)
Quantity End concentration Reagent Stock So In.
5ml 25mM Tris-Cl pH 8.0 1M
1.8g 50mM Glucose
4ml lOmM EDTA 0.5M
20mg lOOjig/ml Rnase A
Alkaline-SDS (to make 200 ml) (Stable at RT)
1.6g 0.2M NaOH Mw=40.0
2g 1% SDS
KAc [K+ 3 M, Ac- 5 M] (to make 200 ml) (Store at 4 °C)
58.8g KAc Mw = 98.14
23ml Acetic acid-glacial
Ad 200ml Distilled H20
4 separate colonies of transformed E.coli were taken from the original agar selection plate 
for each sample.
Each was used to inoculate one 15ml Falcon® shaker tube.
Tubes were shaken at max speed (250rpm) overnight at 37°C.
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The following morning a fresh agar (150pg/ml ampicillin) plate was taken and a 
grid drawn on the underside of i t  A sample of each Falcon tube was then smeared into 
each square on the grid. These E.coli were used at a later stage to grow new colonies if 
they were proven to be good samples. This plate was put at 37°C overnight to grow and 
then stored in the fridge until needed.
Each Falcon tube was then centrifuged for 10 min at 300rpm, before the 
supernatant was tipped off and discarded and the lip of the tube wiped with a tissue.
The pellet was then resuspended in lOOpl of GET by vortexing on maximum speed.
200pl of alkaline SDS was then added and mixed by gentle shaking until the solution 
became clearer (no more than 3 min.).
150pl of KAc solution was then added, and the reaction mixture shaken and transferred 
to 4°C for 20 min.
The reaction mixture was then centrifuged at 13500 rpm for 10 min.
A further purification step (an ethanol precipitation) was then carried out:
2,3.3,5 Chloroform purification of DNA
The supernatant was transferred into a 1.5ml eppendorf tube and 500pl of 
CHCL3 :IAA added. The reaction mixture was then vortexed for 3 min.
The reaction mixture was then centrifuged for 7 min. at 13500 rpm.
The supernatant was then transferred into a new eppendorf tube containing lml of ice 
cold EtOH before incubating at -20°C for 20 min.
The reaction mixture was then centrifuged at 13,500 rpm for 7 min and the supernatant 
poured off; the pellet was allowed to air dry.
Once totally dry (any EtOH would interfere with downstream reactions) the pellet was 
dissolved in 60pl of TE.
A 1% agarose gel was run using 2pl of the above to check for presence of the plasmid 
DNA (length of PCRII-TOPO was 4Kb plus the gene of interest PCR product).
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2.3.3.6 EcoRI Restriction o f Plasmids.
/acZaATG
M 1 3  R e v e r s e  P rim e r
CA G GAA A C A G C T ATG AC
G TC C T T T O T CG A TAC TC
So6 Promoter
A T G  A T T  A C S  C C A  AG C T  I T  T T A  G O T G A C  A C T  A T A I ?
Nsil Hina III Kpn  I S a c  I Band  I S p a  Ii i  T  i i  i
T A C  T C A  A G C  T A T  GCA T C A  AGC T T G  O T A  C C G  A G C  T C G  G A T C C A  C T A  O TA  A C G  G C C  
A T G  A G T  T C G  A T A  C O T A G T  T C G  A A C  C A T  GG C T C G  A G C  C T A  GOT G A T  C A T  T G C  C G G
BstX  I E c o R II
GCC A G T  O T G  C T G  GAA T T C  G C C  
CGG T C A  C A C  GAC C T T  A A G  C G G
E c o R I  E c o R VI I
G G C  GAA T T C  T G C  A G A  T A T  
T T C  C C G  C T T  A A G  A C G  T C T  A T A
SsfXI N od  X h o l  N sil X b a l
T G G  CGG C C G  J t C  G A G  C A T  G c J  I T T  AGA GGG S 'C C A  T C A  C f l t  C T CA' T C  C C C  A A T  T C G  C C C  T A T  
G O T  A G T  G T G  A C C  G C C  G G C  GAG C T C  C T A  C O T  AGA T C T  C C C  GGG T T A  AGC GGG A T A
T 7  P ro m o te r M 1 3  (-2 0 )  F o rw a rd  P r r o a r
A G T  GAG T C G  T A T  TA C A A T  T C A  C T G  G C C  G T C  C T T  T T A  
T C A  C T C  A G C  A T A  AT 3 T T A  AGT C.AC CG G  CA G  CAA AAT
C O T C G T  GAC T G G  GAA AAC 
GCA G C A  C T G  A C C  C T T  T T G
Fig. 2.6; PCRII-TOPO (Invitrogen®) map, showing the PCR product insertion site and the ECO-RI restriction sites either 
side of the PCR product insertion site. (Invitrogen life technologies, 2003)
Once the DNA had been visualised using a 1% agarose gel, it was restricted using the 
Eco-RI restriction enzyme, that cut the PCR product out of the plasmid in order for it to 
be sequenced;
The following constituents were made up per sample;
2|il Plasmid
0.3pi (3 units per restriction) Eco-RI
1.5 pi Eco-RI buffer
0.15pl BSA
11.06 dH20
isja Total volume
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This reaction mixture was incubated overnight at 37°C and a 1% agarose gel run the 
next morning.
The gels showed which of the samples had the right size PCR product, and how much 
was available in the sample. Those samples with the right size product and a large 
amount of DNA were chosen for sequencing.
Sequencing was then carried out by MWG-Biotech AG.
The plasmid/PCR product were then sequenced against BLAST (Altschul et al., 1997) for 
an exact match with the gene of interest.
2.3.3.7 Restriction digestion o f Plasmid/insert
Once the sequencing had shown the correct PCR product had been inserted into the 
plasmid a number of restriction enzymes were tried on each plasmid, in order to check 
whether the restriction site would be in the PCR product insert as well as on one side of 
it; if this was found to be the case, then another restriction enzyme was chosen.
2.3.3.8 In situ probe preparation
All plasmids were test restricted using the following enzymes (New England Biolabs):
• BAMH1
• H1NDIII
• XHOI
• XBAI 
Using the following;
2pl Plasmid
0.3pi (3 units per restriction) Restriction Enzyme
1.5pl Enzyme buffer
0.15pl BSA
11.06 dH20
15pl Total volume
These were incubated for 3 hours and a 1% agarose gel run of the resulting DNA 
alongside an unrestricted sample of each was completed. If the resulting restricted 
plasmid only showed one band indicating one length of DNA (only one restriction site for
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that particular enzyme in the plasmid) then the plasmid was midi-prepped to amplify 
plasmid number.
2.3.3.9 Midi-prep:
Plasmids numbers were amplified using the HiSpeed plasmid Midi Kit from 
Qiagen as per the manufacturer’s instructions:
Colonies were picked from the refrigerated agar plates containing samples of 
colonies selected for test restriction. These colonies were seeded into 100ml of LB 
(containing ampicillin at 150pg/ml) and incubated overnight at 37°C.
The next morning the Elution buffer QF was pre-warmed to 50-60°C and buffer 
P3 pre-chilled to 4°C prior to starting.
The LB/bacteria were split into 50 ml aliquots and centrifuged at 5000rpm for 15 
minutes before being resuspended in 6ml of buffer PI lysis buffer and vortexed to get rid 
of clumps of cells. 6ml of buffer P2 was then added and the solution mixed gently by 
inverting then left to incubate for 5 minutes.
After incubation 6ml of chilled buffer P3 was added and the solution gently 
mixed shaking. The solution was then gently poured into a QIAfilter cartridge and 
incubated for 10 minutes before removing the cap using the plunger to push the solution 
into a pre-equilibrated HiSpeed Midi tip. The tip was allowed to clear by gravity as the 
DNA bound to the resin filter before being washed with buffer QC. The tip was finally 
eluted with 5ml of pre-warmed buffer QF. The DNA was precipitated by adding 3.5ml of 
isopropanol and incubated for 5 minutes before being centrifuged at 10,000rpm for 5 
minutes and resuspended in 70% ethanol. This was transferred to an eppendorf microfuge 
tube and the ethanol removed and the pellet dried before resuspending in 300pl of H2O.
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2.3.3.10 Plasmid linearisation
This was done using the selected restriction enzymes (as above) using the
following amounts:
7.5pl Plasmid
1 .Opl (20 units per restriction) Restriction Enzyme
15pl Enzyme buffer
1.5pl BSA
125pl dH20
150pl Total volume
2.3.3.11 Ribo-probe generation by purification and IVT
The plasmid linearisation was verified as complete by running a 1% agarose gel. 
The DNA was further purified using a chloroform purification step (outlined under Mini- 
prep subheading) and precipitated with 2.5 volumes of 100 % ethanol. The pellet was 
then washed with 70 % ethanol, dried and dissolved in DEPC-treated Water.
lpl Linearised Plasmid DNA
2pl DIG RNA Labelling met lOx (Roche)
2pl Transcription buffer lOx (Roche)
2pl Polymerase (Roche) for T7 and SP6 sites
2pl RNasin (Promega) 30 units/pl
20pl Add dH20  to total volume (11 pi)
This solution was incubated at 37°C for 2 hours before adding 2pi of RNase-free 
DNase (Invitrogen) and being further incubated at room temperature for 15 minutes. 
Concentration and hybridisation conditions of each probe were then tested for each 
individual probe.
2.3.4 In situ hybridisation
All solutions that could be were treated with 0.5% DEPC (diethyl-pyrocarbonate) and 
then autoclaved to inactivate the DEPC. Glass boxes were baked, and hybridisation 
chambers washed in active DEPC water overnight. Powder free gloves were worn at all 
times.
58
2.3.4.1 Solutions fo r in situ:
DEPC = diethyl pyrocarbonate 
X-phosphate = BCIP
BCIP = 5-bromo-4-chloro-3-indolyl-phosphate [Mr = 
NBT = nitro blue tetrazolium chloride [Mr = 817.7]
2.3.5 C oncentrated stock solutions
2.3.5.1 20x PBS pH  7.4 (1 litre)
160g/l NaCl
4g/l KC1
28.84g/l Na2P04 x 2H20
4.14g/l k h 2po 4 x H20
+ 1 ml DEPC (diethyl pyrocarbonate); 
over night on stirrer; autoclave for 45 min 
at 120 °C
2.3.5.2 20x SSC  (1 litre)
175g/l NaCl
88.3g/l Tri-sodium citrate dihydarate
pH 7.0
+ 1 ml DEPC; over night on stirrer at RT; 
autoclave for 45 min at 120 °C
2.3.5.3 50x Denhardt solution (100 m l in 
DEPC treated H20)
lg Ficoll
lg BSA (bovine serum albumin, non- 
acetylated)
1% PVP (polyvinylpyrrolidone)
Heated to 50° on stirrer, filtered through 
0,45 pm filter, aliquots 10ml stored at 
-20 °C. Dissolve on stirrer at 60°
326.44; 4-toluidine salt = 433.6]
2.3.5.4 TBS-TlO x (Detection buffer)
0.1M Tris-HCl (1M in 100 ml)
87.7g NaCl (1.5M)
10ml Tween 20 (1%)
2.3.5.5 lOx AP buffer (without MgCh and 
Triton X-100)
121.lg Tris-Base
58.4g NaCl (1M)
Dissolved in 800ml water, pH adjusted to 
9.5 with a few drops of conc. HC1,
Volume adjusted with water to 1 litre, autoclave
2.3.S.6 1M MgCh (1 litre)
203.3g MgCl2 x 6H20
2.3.5.7 lOx TE (1 litre)
12.lg Tris-Base (lOOmM)
3.72g EDTA (pH8-10mM)
2.3.5.8 10% PFA (200ml)
20g PFA
375pl IMNaOH
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2.3.6 lx  solutions:
2.3.6.1 4% Paraformaldehyde (PFA) (fixative)
Diluted from 10% stock solution in PBS
2.3.6.2 Probe washing buffer
50% formamide (FA), 0.2 x SSC (To
increase stringency you can change the SSC into 0.1 x or increase the FA concentration).
2.3.6.3 lx  PBS (1 litre)
Diluted from 20 x stock solution.
0.1% DEPC treated.
2.3.6.4 TBS-Ty pH  7.5 (Detection buffer + Triton X-100)
Diluted from lOx stock solution
10mM Tris-HCl
150mM NaCl
0.1% Tween 20
2.3.6.5 1 x  AP  buffery pH  9.5 (1 litre) 
Diluted from lOx stock solution and 1M
MgCl2
lOOmM Tris-Base
lOOmM NaCl
50mM MgCl2(lM in 50ml)
2.3.6.6 NTMT: (300 ml) = 1 x  AP buffer + Triton X-100
lOOmM Tris-HCl (pH 9.5-1 M in 30ml)
50mM MgCl2(lM in 15ml)
lOOmM NaCl (5M in 6ml)
30 pi Triton-X-100 (0.1%)
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2.3.7 Staining solutions:
2.3.7.1 Pre-hybridisation/hybridisation buffer (10 ml)
5 ml (100%) Formamide (50% in 10ml)
2.5ml (20x) SSC (5x in 10ml)
lml (50x) Denhardts (5x in 10ml)
lOOmg 250pg/ml yeast total RNA (lOmg/ml)
lOOmg 500pg/ml herring sperm DNA 
(lOmg/ml)
2.3.7.2 Ab blocking buffer:
For section staining:
3% Milk powder (Marvel) in lx detection buffer = 30g/l detection buffer
2.3.7.3 Antibody working solution
Alkaline phosphatase antibody (1:2000 in 1 x blocking buffer (in 3% milk powder)) (Prepare 
immediately before use)
2.3.7.4 Development solution (10 ml)
45pl 75 mg/m I NBT (337.5pg/ml)
35^ x1 50mg/ml X-Phosphate
(175gg/ml)
Adjusted to 10 ml with NTMT buffer or lx AP buffer (prepare before use).
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2.3.7.5 Enhanced development solution (50 ml)
5g Poly Vinyl Alcohol (PVA) 
(10%)
37.5ml H20
5ml 10 x AP buffer (1 x in 50ml)
2.5mM 1 M MgCl2 (50mM in 50 ml)
Mix levamisole, BCIP and NBT with NTMT or lx AP buffer containing PVA.
[PVA to be dissolved in lx AP buffer without Mg2+ at 90°C (do not allow to boil), then 
add MgCh and other components]
2.3.7.6 NB T solution
Either bought in (Melford) or make up (below). Store at -20°C 
75 mg/ml Nitroblue tetrazolium salt in 70% dimethylformamide
2.3.7.7 X-Phosphate solution (BCIP, (Melford))
Buy in (Melford) or make up. Store at -20°C
50 mg/ml 5-bromo-4-chloro-3-indolylphoshate (= BCIP) in 100% dimethylformamide
2.3.7.8 Levamisole stock solution 
Store at -20°
24 mg/ml levamisole hydrochloride salt in lx AP buffer
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2.3.8 Hybridisation Protocol
2.3.8.1 Day 1
Sections were post fixed with 4% PFA in DEPC-treated 1 x PBS for 7 min. then 
washed twice for 5 min in PBS then once for 10 min in 0.1% DEPC/1 x PBS.
Sections were then equilibrated in DEPC-treated 5xSSC for 15 min before 2 further 5 
min washes in 1 x PBS followed by a 5 min wash in 2 x SSC.
Each slide was then pre-hybridised in 50% formamide, 5x SSC containing 40 jxg/ml 
ssDNA (denatured for 10 min at 100°C) for 3 hrs or more at 58°C.
They were hybridised in the hybridisation buffer with 0.4-0.8 pg/ml DIG labelled probe 
overnight at 58°C.
Z3.8.2 Day 2
Slides were hybridised by putting 250 pi of the hybridisation buffer onto each 
slide and covering them with parafilm in a sealed hybridisation chamber to prevent them 
drying out before being placed in a hybridisation oven.
Post hybridisation slides were washed in 5 x SSC for 2 min at 56°C in a water 
bath, then washed in 5 x SSC for 5 min followed by 2 x SSC for 5 min at 56°C and then 
in 0.2 x SSC for 5 min at 56°C before being washed in 50% formamide/0.2 x SSC for 20 
min at 56°C in a water bath. This was followed by a further wash in 0.2 x SSC for 5 min 
at RT, and 2 x 5  min washes in 1 x TBS-T at RT for 5 min each.
Slides were then blocked using 3% milk powder in TBT-T at RT for 60 min 
Following block, the slides were transferred into hybridisation chambers and each was 
covered in 250pl of antibody solution (anti-DIG-AP in 3% milk powder/blocking 
solution) before being covered in parafilm and left at RT for 60 min.
After antibody binding slides were washed three times in 1 x TBS-T (for 2, 15 
and 15 min periods) before being equilibrated in 1 x AP bufFer/MgCl2 for 5 min at RT.
The slides were then developed over-night in a hybridisation chamber, using 
500pl of development solution, overlaid with a glass cover slip to prevent dehydration.
2.3.8.3 Day 3
Finally the reaction was stopped in TE buffer or water for 15 min, and slides were 
rinsed in ddf^O and dehydrated and mounted in PVA/glycerol.
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2.3.9 Cell Culture
2.3.9.1 Cell derivation and preparation
Batches of embryos (E12, E14 and E16) were collected from separate dams and 
placed into ice cold HBSS. Foetuses were dissected and the dissected WGE and cortical 
tissue was collected using a Pasteur pipette and left to settle in a 15ml tube containing 
HBSS solution on ice.
The medium was removed and 200pl of trypsin/DNAse was added to the tissue 
and incubated for 20 minutes at 37°C. Trypsin inhibitor and DNAse were then added, 
mixed and incubated for a further 5 minutes at 37°C. The tissue was then washed twice 
with Dulbecco’s Modified Eagle’s Medium (DMEM F-12) supplemented with 1%PSF, 
and then collected by centrifugation at lOOOrpm for 3 minutes. The medium was poured 
off and the tissue was re-suspended in proliferation medium (DMEM F-12 + FGF2, 
20ng/ml and EGF, 20ng/ml). The tissue was resuspended in 200pl normal medium and 
then triturated using a fire-polished pipette or no more than 10 strokes of a 200pl Gilson 
pipette to produce a single cell suspension.
Cells were counted under a haemocytometer using trypan blue exclusion to assess 
the viability of the cells:
To do this lOpl of the cell suspension was diluted in 40pl of differentiation 
medium (DMEM/F12-1%PSF, 2%B27 and 1% Foetal Calf Serum (FCS)), lOpl of this 
was mixed with an equal volume of trypan blue and then lOpl was transferred to the 
haemocytometer for counting. Cell viability was calculated according to the formula:
cells/square x dilution factor x 10 = cells/p 1 cell suspension
2.3.9.2 Differentiation ofprimary foetal cells in vitro
100,000 cells, in 30pl of the cell suspension was also plated onto poly-lysine 
coated cover slips and allowed to differentiate. Cells usually began to adhere within a few 
hours, but in general cells were allowed to adhere over night, after which the wells were 
flooded with 500pi of differentiation medium per well. Cultures were maintained in the 
same conditions as described above for 7 days. These were then stained using immuno- 
cytochemistry.
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2.3.9.3 Derivation and passaging o f FNPs
The cells were seeded at a concentration of 2,000,000 cells/well in 6 well plates 
with 5mls of proliferation medium (DMEM F-12 + FGF2, 20ng/ml and EGF, 20ng/ml). 
Cultures were maintained at 37°C in humidified 5% C02, 95% atmospheric air.
When proliferating in culture FNPs form free-floating spheres of cells (termed 
‘neurospheres’) which continue to grow in size.
Passaging was performed by mechanical dissociation using a fire-polished pipette 
using 10 strokes or less to provide a single cell suspension. An aliquot of these cells 
(1/10) was trypsinised and a trypan blue count carried out in order to assess cell numbers 
for re-seeding at the correct density.
Dissociated cells were re-suspended at the same concentration as mentioned 
above in proliferation medium, except that B27 was replaced with 1%N2 after the first 
passage. Passaging was repeated every 7 days. Cells were fed every 2-3 days by 
replacing half the medium with fresh medium that was made up of twice the 
concentration of growth factors, thus maintaining the growth factor concentrations 
throughout.
2.3.9.4 Differentiation o f FNPs
When cells were abundant an aliquot from each condition was removed for 
differentiation as per primary cells.
65
Chapter Three
3 Dissection Accuracy Study
3.1 Introduction
3.1.1 Why it was necessary to show that accurate dissection had been 
achieved?
This thesis aimed to record gene expression patterns within the developing whole 
ganglionic eminence, (WGE - the area known to contain the progenitor populations that 
gives rise to the cells of the adult striatum) over the time when the major part of its 
development takes place. Thus, it was important to restrict the dissection to this region 
and as far as possible to exclude non-striatal brain regions such as neighbouring cortical 
and septal regions. This required learning, practicing and perfecting a suitable dissection 
method.
However, it should also be emphasised, as noted elsewhere (Parmar et a l , 2002) 
the WGE is in developmental flux during the period of striatal development, so however 
anatomically accurate the dissection it will contain a small proportion of cells migrating 
to other brain regions; specifically cortex (see Chapter One, Introduction), although as far 
as can be estimated to date, these should be present in relatively small numbers at any 
particular gestational age.
Other sources of error include production of mRNAs that are not usually 
expressed in this area due to non-translated RNAs that are reported to function at the 
RNA level as regulators of gene expression (Fischer et al., 2002). There may also be 
underreporting of genes expressed in small discrete areas with the ganglionic eminences 
where the cellular content would be too small to allow any rare mRNA species to be 
recorded above background noise.
3.1.2 Consideration of alternative dissection methods.
Dissection is usually carried out using anatomical landmarks under a dissection 
microscope. However, consideration was also given to using more accurate ways of 
dissecting tissue.
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Laser Capture Micro Dissection was evaluated for this purpose. This technique is 
capable of dissecting single cells, or larger regions containing hundreds of cells, and 
‘catapulting’ these from a tissue slice mounted on a microscope slide into a microfuge 
tube, ready for RNA extraction to take place. However, the small amounts of cells 
collected mean that the resulting RNA would have to be amplified in order to achieve the 
amounts needed to run micro array analysis. Amplification itself would introduce another 
source of inaccuracy into the experiment, due to the differences in efficacy of available 
polymerases to recognise some mRNAs with shorter length poly A tails, and therefore 
introducing variability in amplification instead of amplifying all mRNAs in a linear 
fashion.
The need to amplify could be avoided by dissecting larger amounts of tissue. 
However, because the process of laser capture is slow, the amount of tissue that can be 
dissected from a given foetal brain is limited by the instability of the RNA prior to it 
being placed in a medium that inhibits the action of RNases. Thus, it was decided that the 
technique of hand-microscope dissection without the need for post-amplification of RNA, 
would be used.
3.1.3 Study rationale
Anatomical identification of WGE is straight forward and was confirmed on 
several occasions by a second dissector. The main source of error would be inclusion of 
substantial amounts of adjacent developing cortex. Thus, the presence of large amounts 
of a known dorsally expressed gene (Pax-6), which is known not to be expressed in the 
WGE at this time in development (Corbin et al., 2000), apart from in a small number of 
cells on the pallidal/sub-pallial border (Yun et a l , 2001a), was used as a marker. As a 
control, areas of the cortex dissected under the same conditions should show high 
expression of Pax-6. The ventral marker (Gsh-2) was used to indicate the presence of 
WGE, while cortical dissections should show little or no expression of this gene (Corbin 
et a l , 2000).
Thus, an accurate dissection would be conferred by a presence of the WGE/ventral 
marker Gsh2 and low levels of expression of the cortical/dorsal telencephalon marker 
Pax6.
67
3.2 M ethods
Foetal WGE and adjacent cortex were collected at E l2, E14 and E l6 using a 
dissecting microscope as outlined in Chapter Two. Tissue was snap frozen in liquid 
nitrogen to preserve the RNA and restrict the action of RNAses. Tissue was then stored at 
-80°C until analysis. RNA extraction was effected using the methods outlined in Chapter 
Two. The WGE samples were the same samples that were analysed by Micro Array.
3.2.1 Prim er Design
Primers used by Corbin et al (Corbin et a l , 2000) were reproduced and used for 
this experiment. Pax-6, (forward primer; ctgtaccaacgataacatacc, reverse primer; 
cccttcgattagaaaacc; product size 454bp) and Gsh-2, (forward primer; 
gaggaacaatcacacaagc, reverse primer; ttcagaaaacaagacatacg, product size 580bp).
3.2.2 PCR
PCRs were carried out using the methods outlined in Chapter Two.
3.2.3 Equim olarisation calculations;
Each cDNA sample was used in a PCR to amplify a control gene 
(G3PDH)(Thellin et a l , 1999) primer product (forward primer; tccaccaccctgttgctgta, 
reverse primer; accacagtccatgccatcac; product size; 451 bp) to ascertain its concentration.
Fig. 3.1; 1% Agarose Gel showing the amplified PCR products for the G3PDH control gene primer, using lpl of each sample.
(LeffclOObpDNA ladder)
From the above gel the following Integrated Density Values (IDV) for each 
lane/cDNA primer product sample were calculated by AlphaEase FC;
WGE E12 E14 E16
65736 36864 35340
Ctx E12 E14 E16
36704 47025 34485
Table 3.1; Saturation/IDV figures given by AlphaEaseFC® 
for Ipl of each of the cDNA samples.
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The IDV value of 36500 was in the midrange of these figures and so was deemed 
to be the right amount of cDNA to use in all cases so each figure in Table 3.1 was divided 
against this figure to produce the amount to be loaded into PCR reactions in the future. 
Therefore the following amounts of each cDNA sample were used in all PCRs following:
WGE E12 E14 E16
0.56nl 0.99pl 1.03^1
Ctx E12 E14 E16
l.Oljil 0.78jil 1.06^1
Table 3.2; Adjusted cDNA amounts after Equimolarisation.
Following equimolarisation the following PCR was ran to check the amounts of 
cDNA were correct.
Fig. 3.2; 1% Agarose Gel showing the amplified PCR products for G3PDH 
control gene primer, using the equimolarised/adjusted amount o f each cDNA sample.
3.2.4 Data analysis
The gel was photographed in an ultra violet hood and the image of the PCR 
product amplification was carried out using AlphalmagerFC software. The spot density 
was then measured and the following calculation made to account for background 
intensity.
The Integrated Density Value (IDV) =£ (each pixel value - background)
Because eqimolarisation cannot be totally accurate, the ID Vs obtained in the 
experiment were then compared to the ID Vs of the relevant G3PDH sample so that a 
comparable figure, between samples was obtained. This figure was then used for 
statistical analysis.
The IDV of each WGE PCR product was compared to the Ctx PCR product of the 
same age condition using a one-tailed, paired t-test (Microsoft Excel) to find whether the 
differences were significant.
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3.3 R esults
The equimolarised cDNA samples showed the following saturations when 
analysed using AlphaEaseFC;
WGE E12 E14 E16
#1 40920 39936 41292
#2 30660 34560 30225
#3 60390 60900 56544
Ctx E12 E14 E16
#1 44928 48825 43680
#2 28644 26640 26412
#3 55488 53312 48015
Table 33; Integrated Density Values (IDV) given by AlphaEaseFC 
for each of the cDNA PCR products samples after equimolarisation.
Equimolarised quantities of cDNA were then used in further experiments to 
amplify the two primer products Pax6 and Gsh2.
E12W GE E12 Ctx E H  WGE E U C l i  E16W G E E16C1*
E12W GE E t 2 C h  E 1 4 WGE E14Ct* E 1 6 WGE E1 6 Ctx
Fig. 33; 1% Agarose Gels showing the amplified PCR products of the Pax-6 
primer on all cDNA samples
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E12WGE E l 2 C b  E14WGE E H C b  E16VMGE E 1 6 C U
E12WGE E 12C U  E H  WGE E H  Cf>: E 1 6W 3E  E 16C U
E12 WGE E12Ct* E14W GE E 14C U  E16WGE E16C!*
Fig. 3.4; 1% Agarose Cels showing the amplified PCR products o f the Gsh-2 
primer on all cDNA samples
3.3.1 Statistics; t test
Gsh-2
E12
E12 Ctx
WGE
E14 WGE E14 Ctx E16 WGE E16 Ctx
#1 42966 2904 35088 5390 36960 7098
#2 23430 0 16500 2376 23040 3072
#3 26180 4080 15180 1750 23584 0
P= 0.019329 0.034735 0.006833
t Stat= 4.93744
Pax-6
3.59345 8.46640
E12
E12 Ctx
WGE
E14 WGE E14 Ctx E16 WGE E16 Ctx
#1 363 4290 726 5456 1320 4433
#2 9207 20460 8096 13299 1116 14322
#3 10846 26845 9000 17578 2940 13440
P= 0.048852 0.018229 0.048739
t Stat= -2.95985 -5.09292 -2.96384
Table 3.4; Integrated Density Values for cDNA PCR primer products when 
amplified using Pax-6 (cortical marker) and Gsh-2 (ventral marker) primers.
3.3.2 Description of results
These results show that there was significantly more Gsh2 expressed in the WGE
samples of tissue, than there was Pax6. They also show the reverse; that is, that there was
significantly more pax6 expressed in the cortical samples than there was Gsh2.
The amounts of Pax6 within the WGE samples was less, the more developed the
foetuses were at the time of dissection, showing that as foetal age increased, so did the
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accuracy of dissection and the less cortical and pallidal/sub-pallial border tissue was 
present within the WGE samples.
3.4 Discussion
These results indicate that the WGE dissections did contain the telencephalic 
marker Gsh-2, which was virtually absent in cortex, thus confirming that they included 
tissue from the Ganglionic Eminences.
These results also show that the WGE dissections contain significantly less of the 
dorsal marker Pax6 than did the cortical samples.
However, Pax6 was present in the WGE samples, and that this declined 
proportionally with increase in age. This may be explained by two factors;
* It may indicate that some surrounding or pallidal/sub-pallial border tissue 
was included in the dissection. The fact that Pax6 levels in the dissections 
decline as the embryonic age increases, illustrates the greater degree of 
difficulty in accurately dissecting the WGE from the rest of the brain in 
these early periods of development. At E12 the WGE is very small and it 
was easy to cut too deep, therefore taking pieces of the underlying cortex 
and from areas dorsal to the WGE. However, as the age increases, the 
likelihood of this happening decreases as the WGE becomes a more 
distinct structure in its own right.
• Cortical precursors may express Pax6 as they migrate through this region 
during development to populate the cortex and one would expect this at 
this early stage. Immuno-fluorescence has shown a small amount of cells 
that are double labelled for Pax6 and Gsh2 along the ventro-dorsal border 
(Yun et al., 2003), although this contradicts the results found by Corbin et 
al (Corbin et a l, 2000).
Having obtained this result, ideally I would want to characterise the anatomical 
distribution of Pax6 particularly at the early developmental ages to distinguish between 
the two possibilities above. Indeed, this was attempted using immuno-histochemistry on 
histological slices of dissected WGE, using Pax6 antibodies but failed for technical 
reasons.
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Chanter Four
4 Affymetrix Micro Array Analysis
4.1 Introduction
Although there is a literature on gene expression within the developing striatum 
(see Chapter One; Introduction), to date no laboratory has published a systematic search 
for gene expression changes over the period of maximum proliferation and development 
of this brain region. To achieve the aims of this study (which are outlined at the end of 
Chapter One) a method by which all of the significant gene expression changes within a 
defined period, was required.
4.1.1 Choice of method.
A number of techniques were considered for this purpose, including;
4.1.1.1 Subtractive hybridisation
This method uses subtraction cloning to select genes that are switched on or up- 
regulated in the experimental condition when compared with the control condition. Two 
samples, the normal “test” (control) mRNA sample and a “driver” (experimental) cDNA 
sample are mixed, denatured and re-annealed so that matching mRNA and cDNA 
samples are allowed to bind to each other. The resulting double stranded cDNA/mRNA 
hybrids are then isolated and discarded, as they are the genes that are found in both 
samples. The remaining, unpaired single stranded cDNA molecules (“subtracted” cDNA, 
derived from the genes expressed either more, or only in the “driver/experimental” 
sample) are then isolated and cloned for further analysis.
The main advantage of SH is that it can be used in a laboratory equipped to carry 
out basic recombinant DNA techniques. No large items of equipment are required since 
the method is based on PCR and microfuge tube reactions. Another advantage is that it 
allows the detection of low-abundance differentially expressed transcripts, such as those 
likely to be involved in signalling and signal transduction, and thus, may identify 
essential regulatory components in a number of biological processes. However, this 
technique only works for genes that are controlled at the transcriptional (DNA to RNA)
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level. The expression of some gene products (proteins) are controlled at the translational 
(RNA to protein) level and hence would not be picked up by this method.
Control Experimental
Isolate mRNA
cDNA 
^  ' ' ’(labelled)
'7»
cDNA/RNA Hybrids 
discarded
/ v sscD NA
I d s DNA 
I Synthesis
Molecular Cloning 
and Analysis
Fig. 4.1; Subtractive hybridisation can pick out genes that are either up-regulated, or 
expressed only in the experimental sample.
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1.1.2 Proteomics.
Although all somatic (nucleated) cells within an organism contain the same 
chromosomes and therefore genes, only a certain number of those genes are expressed, 
depending on the type of cell and its responses to its environment. Proteomics is the 
science of studying the expressed proteins, or “functional proteome”, of a cell.
Proteins can be more difficult to work with than DNA and RNA because they 
cannot be amplified; therefore less abundant sequences become more difficult to detect. 
They also have secondary and tertiary structure that must often be maintained during 
analysis and they can also be denatured by the action of enzymes, heat or light. Some 
proteins are also difficult to analyse due to their poor solubility.
However, nucleic acid quantitation does not always accurately reflect protein 
levels, due to gene splicing or post transcriptional modification. Therefore, new methods 
have recently been devised, such as protein micro array (that can accurately reveal what 
proteins are being made within a cell-see below for information on cDNA micro arrays), 
x-ray crystallography and nuclear magnetic resonance (NMR), which can define a 
protein’s secondary and tertiary structure, in order to enhance our understanding of how it 
works. Proteomics is in its infancy, however, and the techniques involved are expensive 
and specialised.
*
*
Fig. 4.2; A single gene can yield a number of splice variants, each of which produces a different protein which can undergo
post-translational modification.
4.1.1.3 Nucleic acid Micro Arrays.
Micro array is a method of assaying large amounts of genetic information quickly and 
automatically. This is done by using a robot to make up a glass slide (commonly referred 
to as a chip), onto which thousands of separate microdots of genetic material in the form 
of DNA clones are printed. Each microdot contains one or more probes for an individual 
gene found in the organism being studied, i.e. yeast, fruit fly, mouse or human.
Samples are then taken from two tissues, a reference and a query (or experimental 
sample) or a series of query samples that can be compared against one another. The total 
RNA is extracted and transformed into cDNA with the aid of reverse transcriptases. This 
cDNA has been transcribed from mRNA extracted from the tissues in question and 
therefore contains information as to which genes are being expressed in the cell at the 
time of the RNA extraction.
In cDNA micro arrays the cDNA is then labelled with radioactive isotopes (macro arrays) 
or more commonly one of two fluorescent colours, cy5 (red) or cy3 (green); one for the 
query cDNA and one for the reference/control cDNA. This is commonly done in one of 
two ways, either with the ‘first strand’/direct method, which links the marker molecule 
directly to the ribose molecule of the bases, or using the indirect method, attaching the 
marker via a bridging molecule. The latter method will label more efficiently, due to 
there being less steric hindrance that would otherwise be caused by the size of the 
fluorescent molecule (cy5 being larger than cy3) and the make up of the RNA itself.
Once the cDNA has been labelled, the two samples are mixed. Then the resulting solution 
is hybridised to the DNA cloned probes on the microscope slide over a period of between 
16 and 48 hours. If the cDNA is complimentary for any of the probes on the slide, it will 
hybridise and cause that area of the slide to fluoresce at a certain frequency; depending on 
whether it is from the query or reference/control. If it fluoresces in both colours, then 
both tissue samples express the gene in question. The slide is analysed by a computer 
imaging system, which uses a number of methods to discount background labelling and 
mismatches in fluorescence (by normalising). However, the whole process relies on the 
quality of RNA extracted from the tissue sample. Without good quality RNA, cDNA 
cannot be made and labelled.
Because micro array technology is still evolving there are still problems with some of the 
methods; i.e. cDNA micro array has been quoted as being as low as 11% reproducible 
between experiments, (i.e. a coefficient of variation of 89%) (Hinman et al., 2002)
76
although other studies show coefficients of variation to be as low as 12% (Yue et a l, 
2001; Shi etal., 2006; Frueh, 2006). The differences between each hybridisation are due 
to a host of factors including spatial heterogeneity, non-linear array-to-array variation and 
problems arising when correcting for background (Geschwind and Gregg, 2003). These 
are problems that can only be dealt with by using increasing numbers of replicates, 
thereby increasing the overall cost.
4.1.1.4 Affymetrix Micro array.
Affymetrix micro array differs mainly from normal two colour cDNA micro array 
in that it uses one-colour technology. The RNA is extracted from the cells, and 
transcribed into cDNA as usual. However, this cDNA is then labelled in an in vitro 
transcription reaction (IVT) with biotin, before being fractionated into small cDNA 
fragments and then hybridised to a micro array chip or Genechip (Affymetrix use these 
instead of glass microscope slides on which to print their arrays). The chip is then 
scanned, resulting in an image that is processed to give a numerical representation of each 
of the features (of which there are millions on each chip). This data can then be 
normalised and analysed in a number of computer programs. (For a more comprehensive 
insight into the RNA extraction and labelling please refer to Appendix A, for an overview 
refer to Chapter Two; Methods. The normalisation and data analysis will be described 
below). The Affymetrix technique is highly reproducible (Woo et a l, 2004) and can be 
used in a wide range of applications on a whole-genome scale, including gene and exon 
level expression analysis, novel transcript discovery, genotyping, and resequencing.
Although each Affymetrix chip was substantially more expensive than its cDNA 
counterpart, the fact that they were highly reproducible meant fewer chips would be 
needed to run an experiment For these reasons it was Affymetrix micro arrays that were 
used as the primary method of investigation in this study above other possible methods.
However, it must be remembered that although micro arrays are a powerful tool in 
assaying gene expression in tissue, the data that is collected from such an experiment is 
only as good as the analysis that is done on it, and validation using other 'tried and tested" 
methods, of the most significant findings, must then be completed in order to justify any 
results they infer.
4.1.1.5 The Affymetrix Mouse 430A 2.0 GeneChip.
The most recent Affymetrix Genechip to be designed for Mus musculus at the start of this
project was the Mouse 430A 2.0 array which contained 22,626 probe sets of 21 base pair
77
oligonucleotides, each interrogating one or more of 14,484 known genes, and over 8,000 
ESTs (Extended Sequence Tags).
The MOE430A array chip has been compared to other techniques including 
cDNA and has consistently detected the largest number of significant genes and had the 
lowest false discovery rate. At the critical /7-value of 0.01, 3% of the significant genes 
were expected to be false-positives, which was less than a half compared with other 
arrays (Woo et al., 2004).
The probes were designed using sequences from GenBank (the NIH genetic 
sequence database, which is an annotated collection of all publicly available DNA 
sequences) (Benson et al., 2004), dbEST, a division of GenBank; containing sequence 
data and other information on "single-pass" cDNA sequences or Expressed Sequence 
Tags (Boguski et al., 1993), and the RefSeq collection (which includes a comprehensive, 
integrated and non-redundant set of sequences, including genomic DNA, transcript 
(RNA), and protein products).
The sequence clusters were created from the above databases in June 2002 and 
then refined by analysis and comparison with the publicly available draft assembly of the 
mouse genome from the Whitehead Institute for Genome Research in the same year.
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4.2 Aims;
As discussed fully at the end of Chapter One, the aim of this chapter is a systematic 
search for gene expression changes during the period of peak striatal neurogenesis in the 
mouse.
The specific aims of this set of experiments were;
• To characterise the gene expression within the area of the developing mammalian 
brain that gives rise to the mature striatum.
• To identify a subset of expressed candidate marker genes that have the potential to be 
used as markers of striatal commitment in human embryonic striatal precursors.
• To identify a subset of candidate marker genes for future analysis, with the long term 
goal being to direct the differentiation of human FNPs towards a striatal phenotype.
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4.3 Methods
Tissue was dissected and stored as stated in Chapter Two. RNA extraction was 
also carried out as per Chapter Two.
4.3.1 RNA Quantitation and quality checks
Before allowing the expensive and time consuming use and analysis of micro 
arrays all RNA samples were checked using the following methods that were commonly 
used by the majority of the micro array community in UK;
4.3.1.1 UVSpectrometry and Agilent 2100 Bioanalyser analysis.
These methods were used together to as each method had its strengths in defining 
different areas where RNA contamination or unreliable probe generation may have 
arisen.
4.3.1.2 Genequant Pro Spectrometry
Spectrometry is regarded generally as an accurate and reliable way to quantitate 
RNA at this time, however it does not distinguish between certain contaminants, as 
outlined below:
Genequant Pro (Amersham Biosciences) spectrometer readings were taken 
straight after RNA extraction (outlined in Chapter Two; Methods: RNA Extraction). The 
reading at 260nm allows the calculation of the concentration of nucleic acids (either DNA 
or RNA) in the sample. The Beer-Lambert law (Sambrook and Russell, 2000) was then 
used to compute the Optical Density (OD) of the sample and compare it to an OD of 1, 
which corresponds to 44.19pg/ml (Farrell, 1993) for single stranded RNA.
4.3.1.3 Agilent 2100 Bioanalyser readings
This equipment was used alongside the spectrometry results to gauge RNA 
quality before use on the Affymetrix genechip. One of the downfalls of spectrometry is 
that both DNA and RNA absorb UV light at 260nm; therefore it is hard to distinguish the 
difference between samples with high RNA content and those with low/high molecular 
weight genomic DNA (gDNA) or phenol contamination. By visualising the RNA using 
an electropherogram any contamination could be easily seen as peaks either side of the 18 
and 28S ribosomal peaks normally seen in a clean sample.
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4.3.1.4 RNA Degradation Plot (using R-Bioconductor (Bates et aL, 2004))
This simple (shifted and scaled) plot enables the user to see the condition of the 
mRNA rather than presuming its condition by looking at either the total RNA or the 
ribosomal RNA. The plot considers the comparison between probes located at the 5’ end 
of the genes/ESTs in question and the 3’ end. This measured both the amount of 
degradation (mostly due to RNases) that occurred during the extraction of the RNA and 
the ability of the DNA Polymerase I to complete second strand synthesis during the 
preparation of the samples (see Chapter Two and Appendix A for protocols). A 
significant slope that did not follow the ‘trend’ of slopes of the majority of samples gave 
a hindsight indication as to a samples quality. However, this test was only used as 
confirmation of which Genechips to use in analysis as it was only possible to complete 
after the samples had been hybridised to a GeneChip.
4.3.1.5 Comparison Analysis and Normalisation using MAS (Micro Array Suite) 5.0®, 
and RMA (Robust Multi-array Averaging).
Normalisation was carried out utilising two well known and used methods. The 
separate results were then compared in parallel throughout later analysis and the final 
significant gene lists of the two methods then merged and the common genes from both 
accepted as being significant. This was done to reduce the false discovery of expression 
changes through relying on one method of normalisation.
4.3.1.6 MAS 5.0 Analysis.
Adapted from (Affymetrix, 2001a; Affymetrix, 2001b; Affymetrix, 2002).
After hybridisation of RNA from the three conditions (each condition having 
three repetitions) the resulting Mouse430A Genechips were scanned using an Affymetrix 
2500 GeneArray scanner. Once the Genechip had been scanned, a .CEL file was 
generated by the Affymetrix MAS 5.0 software; this contained an image of the scanned 
Genechip and also calculations of the raw intensities for the probe sets on it
The resulting image files were then normalised and analysed in MAS 5.0 (see 
“comparison analysis” below) to ascertain the intensity of each of the probes in order to 
calculate whether any of these transcripts could be assigned a call of Absent, Present or 
Marginal.
The Affymetrix system uses oligonucleotides with a length of 25 base pairs that 
are designed to probe selected known genes and EST’s. Typically, each of these is
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represented by between 16 and 20 pairs of oligonucleotides (each interrogating a different 
part of the gene or EST in question) referred to as probe sets. The first component of 
these probe pairs are referred to as perfect match (PM) probes. Each one of these is paired 
with a mismatch (MM) that is created by changing the 13th (middle) base with the 
intention of measuring non-specific binding. The PM and MM are referred to as a probe 
pair.
PM 
MM
Pi ol>*
Paii s:
Fig. 4.3; In the probe set above, each probe pair is numbered from 1 to 10. All the PM intensities are 80 while the MM
intensities increase from 10 to 100.
4.3.1.7 Detection p-value.
The detection p-value was determined using two steps;
• Calculation of the discrimination Score (R).
• Test of the Discrimination Scores against a used definable threshold (Tau).
The signal intensity of each probe cell within each pair was considered when 
determining whether the transcript was either detected (Present), or not (Absent), e.g. if 
there are a total of 10 probe pairs for a given gene, and in seven probe pairs the PM is of 
much higher intensity than the MM cell, then those probe pairs would each have an R 
score closer to 1.0, while the three probe pairs with the same or higher MM intensities 
would have R scores closer to 0.0 (see below). If all the PM cells within a probe set are 
fully saturated, the probe set would be given a Present call. Conversely, if a MM probe 
cell was saturated then that probe pair was rejected from further analysis.
Therefore;
R = (PM-MM)/(PM+MM)
80  8 0  8 0  8 0  8 0  8 0  8 0  8 0  8 0  8 0
1 0  2 0  3 0  4 0  5 0  6 0  7 0  8 0  9 0  1 0 0  
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Fig. 4.4; As the MM probe cell intensity increases (x-axis) and becomes equal to PM intensity, the Discrimination (R) score
decreases (y-axis) (adapter from (Affymetrix, 2002).
4.3.1.8 M AS 5.0 Normalisation and Scaling;
The MAS 5.0 software used Global scaling (i.e. all intensities scaled so that each 
array has the same average value; set at 100). A robust normalisation, (which was non­
user modifiable), was then used to take account of unique probe set characteristics that 
were due to sequence dependant factors, such as the affinity for targets to their probes 
and the linearity of hybridisation of each probe pair in the probe set. If these factors were 
not taken into account, false positives in expression level changes could have resulted.
4.3.1.9 RMA Normalisation and scaling.
Although MAS 5.0 has been the benchmark method of normalising and scaling 
Affymetrix arrays since its introduction in 2001, it has been postulated that this method 
does not deal well with cases where there are non-linear relationships between arrays, as 
a baseline has to be chosen and the other chips normalised to this.
Therefore, to validate the normalisation/scaling processes used in MAS 5.0, 
another method known as RMA (Robust Multi-array Averaging (Irizarry et al., 2003; 
Bolstad et al., 2003)) was carried out with the kind help of Gareth Hughes, formerly of 
the Dept of Patholgy, UWCM).
RMA does not use a baseline array instead normalising both the PM and MM 
values instead of just the results of the votes of the probe pairs. The output from RMA 
was then transformed from Log2 to decimal and treated in parallel with the MAS 5.0 data 
(see below).
RMA analysis uses a quantile normalisation (dividing all of the values in each 
condition into equal groups, each containing the same fraction of the total population).
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This has been shown to provide a greater detection of differential expression, allowing a 
standard error to be formulated using a linear model which removed probe-specific 
affinities when normalising data (Irizarry et a l 2003).
4.3.1.10 GeneSpring Analysis.
Data from all the arrays were then exported into GeneSpring® (Silicon Genetics 
inc.) and further normalisation was carried out;
Per chip Normalisation; this divided all signal intensities by the median value (the 
50th percentile) for each chip; thus correcting for obscuring/technical variation due to 
scanner/hybridisation differences between chips and centering all values around the value 
of one.
Chip Chip Chip
Signal Inf nittySignal I n f  ntity
Fig. 4.5; Per Gene and Per Chip normalisations normalised each probe to the 50th percentile of that chip and then adjusted
each chip until all the chips had similar medians.
Per Gene Normalisation; this calculated the median value of all genes in the array 
and divided them by the median value. Thus highlighting genes with large fold-changes 
in expression even when they are at low signal intensities; This meant that even at low 
signal intensity levels a large fold-change that would be otherwise be overlooked due to 
the size of the transcripts signal intensity were be recognised in the same light as 
significant changes at higher signal intensities that would be easier to find but were not as 
high a fold-change.
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Fig. 4.6; The graph on the left shows the actual signal intensities (y-axis on the left graph) of two example genes which appear 
to have the same increase in expression. However, once the fold-change is measured (y-axis on the right graph) it can be seen 
the gene denoted by the red trace has a much higher fold-change.
4.3.1.11 Experimental interpretation.
In this experiment each condition (different embryological ages) were grouped 
together. Each had three replicates. These were the only parameters.
4.3.1.12 Further analysis in GeneSpring.
Once the information from both MAS5.0 and RMA had been normalised it was 
then filtered by expression levels in order to clear all genes that were expressed in only 
very low levels or not at all in all of the samples. The MAS5.0 data ranged from signal 
intensities of 0.0333 to 4,606 so all probe sets which exhibited all chip values below the 
cut off of 50 were withdrawn from further analysis (this is the number recommended by 
Genespring). The RMA data ranged from 19.87 to 25,785 after transformation from Log2 
to decimal so any probe sets with all chip values below that of 265 were withdrawn (I 
used this number as it discounted exactly the same number of genes as using the number 
50 in the MAS5.0 data).
To ensure good separation of data and remove non-changing genes both data sets 
were then filtered on expression level changes. All expression changes over a 1.8-fold 
change were deemed, for the purposes of this study, to be of interest.
4.3.1.13 Statistical Analysis o f Genes o f Interest.
Because sample replicates representing small signal changes (low gene expression 
levels) usually have smaller variances than sample replicates showing much higher signal 
intensities (expression levels) micro array data is much harder to statistically analyse 
using the standard error of the mean of the replicates. The high cost of increasing the 
amount of replicates would also restrict this. Therefore micro array software uses the
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geometric mean of the replicates. This is a measure of central tendency but is different in
that it uses multiplication rather than addition to summarize data values.
i.e.
G„=3Va*b*c
Where Gm = the geometric mean and a, b and c are the three replicates.
To counteract this and the fact that micro array data invariably has many data 
points, meaning that even a normally stringent p  value of 0.05 may give a high number of 
false positives (5% of the resulting genes that pass the test) the ANOVA test used the 
Benjamini and Hochberg multiple testing correction (Hochberg and Benjamini, 1990; 
Benjamini and Bitterman, 1990; Reiner et al., 2002). This ranked the genes found to be 
significant (p=0.05) in the ANOVA in order of p  values, giving the least significant gene 
a value of 1 and the most significant gene the highest value. The p  value (0.05) was then 
multiplied by the number of genes entering the test divided by each genes rank position 
and if the resulting number was less than the p  value (p=0.05) then that gene passed the 
test. Instead of 5% of the original gene list being false positives this test reduced this to 
5% of those genes passing the multiple testing correction being possible false positives.
A post hoc test was not done as expression between only two ages was tested 
(E12 and E16) for this experiment.
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4.4 Results:
The following results show firstly, the quality assessment of the RNA samples 
according to the methods described above.
4.4.1 Genequant Pro Spectrometry results
RNA samples were initially checked immediately after extraction using a 
Genequant Pro (Amersham Biosciences) spectrometer;
Sample / 
rep
Mass
(mg)
Dilution.
factor
230 260 280 260/230 260/280
[cone]
(ng/ml)
Yield
(Pg)
Yield
(pg/mg)
E12a -70 1:40 1.82 2.81 1.60 1.54 1.75 4498 134.9 1.97
E12b 59 1:40 1.39 2.27 1.26 1.63 1.8 3629 108.9 1.84
E12c 110 1:80 1.14 2.5 1.38 2.2 1.81 8012 240 2.18
E14a 152 1:40 1.882 2.865 1.520 1.522 1.885 4584 137.5 0.9
E14b 131 1:40 2.086 2.977 1.779 1.427 1.673 4763 142.9 1.1
E14c 118 1:80 1.024 1.932 1.032 1.887 1.872 6182 185 1.57
E16a 93 1:40 1.620 2.953 1.645 1.823 1.795 4725 141.7 1.5
E16b 138 1:40 2.476 2.939 1.557 1.187 1.888 4702 141 1
E16c 99 1:40 1.303 2.205 1.152 1.698 1.914 3528 105.8 1
Table 4.1; RNA samples were checked by spectrometry immediately after extractioa.
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4.4.2 Agilent 2100 Bioanalyser readings
The following results were obtained by the staff of UWCM Dept of Pathology at the 
micro array facility in the heath Hospital.
4.4.2.1 E12aRNA sample
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Fig. 4.7; Electropherogram graph and gel trace for sample E12a showing clear 18S and 28S rRNA bands and a flat base line
Sample
Factor
Fragment
1
2
Dilution 1:21
Name Start 
(secs) 
18S 41.45
28S 46.45
time End Time Area % of total 
(secs) Area
43.45 225.62 27.96
49.25 351.35 43.54
RNA Area 806.90
RNA Concentration (pg/pl) 6,527.41 
rRNA Ratio [28S/18S] 1.56
8 8
4.4.2.2 E12b RNA
Fig. 4.8; Electropherogram graph and gel trace for sample E12b showing clear 18S and 28S rRNA bands and a flat base line
Sample Dilution 1:17 
Factor
Fragment Name Start time End Time Area % of total
(secs) (secs) Area
1 18S 41.00 42.70 143.96 27.23
2 28S 46.65 49.35 224.59 42.49
RNA Area 528.61
RNA Concentration (pg/pl) 4,276.19 
rRNA Ratio [28S/18S] 1.56
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4.4.2.3 E12c RNA sample
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Fig. 4.9; Electropherogram graph and gel trace for sample E12c showing clear 18S and 28S rRNA bands and a reasonably flat
base line
Sample Dilution 1:16 
Factor
Fragment Name Start time End Time Area % of total
(secs) (secs) Area
1 18S 43.45 45.50 24.49 26.38
2 28S 452.15 52.15 41.43 44.64
RNA Area 92.82
RNA Concentration (pg/jil) 95.76 
rRNA Ratio [28S/18S] 1.69
4.4.2.4 E14a RNA sample
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Fig. 4.10; Electropherogram graph and gel trace for sample E14a showing clear I8S and 28S rRNA bands and a flat base line
Sample Dilution 1:22 
Factor
Fragment Name Start time End Time Area % of total
(secs) (secs) Area
1 18S 40.90 43.50 165.04 22.09
2 28S 46.65 52.05 215.34 28.82
RNA Area 747.18
RNA Concentration (pg/pl) 6,044.351 
rRNA Ratio [28S/18S] 1.30
91
4.4.2.5 E14b RNA sample
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Fig. 4.11; Electropherogram graph and gel trace for sample E14b showing clear 18S and 28S rRNA bands and a flat base line.
Sample Dilution 1:22 
Factor
Fragment Name Start time End Time Area % of total
(secs) (secs) Area
1 18S 41.45 42.75 33.84 23.25
2 28S 46.85 49.15 53.49 36.74
RNA Area 145.56
RNA Concentration (pg/pl) 1,177.52 
rRNA Ratio [28S/18S] 1.58
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4.4.2.6 E14c RNA sample
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Fig. 4.12; Electropherogram graph and gel trace for sample E14c showing clear I8S and 28S rRNA bands and a reasonably
fiat base line.
Sample Dilution 1:13 
Factor
Fragment Name Start time End Time Area % of total
(secs) (secs) Area
1 18S 43.60 45.45 12.64 25.67
2 28S 449.25 52.25 20.51 41.65
RNA Area 49.24
RNA Concentration (pg/|il) 50.80 
rRNA Ratio [28S/18S] 1.62
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4.4.2,.7 E16a RNA sample
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Fig. 4.13; Electropherogram graph and gel trace for sample E16a showing clear 18S and 28S rRNA bands and a flat base line.
Sample
Factor
Fragment
1
2
Dilution 1:22
Name Start 
(secs) 
18S 41.05
28S 46.65
time End Time Area % of total 
(secs) Area
42.55 110.43 21.86
49.25 179.12 35.45
RNA Area 505.45
RNA Concentration (pg/pl) 4,087.12 
rRNA Ratio [28S/18S] 1.62
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4.4.Z8 E16b RNA sample
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Fig. 4.14; Electropherogram graph and gel trace for sample E16b showing clear 18S and 28S rRNA bands and a flat base line.
Sample Dilution 1:22 
Factor
Fragment Name Start time End Time Area % of total
(secs) (secs) Area
1 18S 40.80 42.55 213.13 23.68
2 28S 46.50 49.30 316.81 35.20
RNA Area 899.91
RNA Concentration (pg/pl) 7,279.81 
rRNA Ratio [28S/18S] 1.49
4.4.2.9 E16c RNA sample
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Fig. 4.15; Electropherogram graph and gel trace for sample E16b showing clear 18S and 28S rRNA bands and a flat base line.
Sample
Factor
Fragment
1
2
Dilution 1:16
Name Start 
(secs) 
18S 41.45
28S 46.60
time End Time Area % of total 
(secs) Area
43.45 150.82 25.72
49.25 253.81 43.28
RNA Area 586.38
RNA Concentration (pg/jj.1) 4,743.55 
rRNA Ratio [28S/18S] 1.68
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4.4.2.10 RMA Degradation Plot
These results are used as quality control of the amount of hybridisation on each 
gene chip. Individual probes in a probe set are ordered by location relative to the 5’ end 
of the targeted RNA molecule. Since RNA degradation typically starts from the 5’ end of 
the molecule, we would expect probe intensities to be systematically lowered at that end 
of a probe set when compared to the 3’ end. On each chip, probe intensities are averaged 
by location in probe set, with the average taken over probe sets. The RNA degradation 
plot produces plot of these means, making it easy to notice any 5’ to 3’ trend and any 
abnormalities in one or more gene chips.
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Fig. 4.16; RNA Degradation Plot showing all samples followed a common trend. This indicated, when viewed alongside the IJV 
spectrometry and Agilent data that the RNA samples were of good quality (produced by RMA express (Irizarry et aL, 2003;
Bolstad et aL, 2003)).
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4.4.2.11 M AS 5.0 and RMA Normalisation
After normalisation using two methods (the Affymetrix MAS 5.0(Affymetrix, 
2001a) and the RMA (Irizarry et al., 2003; Bolstad et al., 2003)) of normalisation, to 
reduce the chance of false positives from occurring, only the genes that passed both 
normalisations and a further ANOVA in Genespring with a significance value (p<=0.05) 
were carried through to follow up analysis/candidate marker gene analysis.
MAS5.0 ANOVA RMA ANOVA
All G en es
Fig. 4.17 After scanning the Genechips, data was normalised by both MAS 5.0 and RMA before both data sets were run using 
an ANOVA in Genespring. The 175 genes shown to be significant by both methods (shown in the white area) were selected as
candidates for follow up analysis.
4.4.2.12 Genes found  to be significantly up-regulated during striatal differentiation
The Following tables show the genes that passed normalisation using both MAS 
5.0 and RMA and then achieved a significance of p<=0.05. The genes marked in red are 
those that were deemed interesting enough to carry forward to the next stage of follow up 
analysis.
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Table 4.1; 175 Genes were found to be significantly up and down regulated between the ages of E12 and E16 (p<0.05) after 
RMA and MAS5.0 normalisation and ANOVA, ranked by order of significance for up and down regulated genes (Red genes 
denote those chosen for follow up investigation, Blue denotes the one unknown gene to be chosen, that was later discarded for
technical reasons).
Affymetrix annotation Common Name G enbank ID up/down regulated RMA p  value
MAS 5 p 
value
1435222_at Foxpl BM220880 up 0.000654 0.00767
1435221_at Foxpl BM220880 up 0.000837 0.00392
1451191_at Crabp2 BC018397 up 0.000837 0.00392
1421142_s_at Foxpl BG962849 up 0.00113 0.00392
1451506_at Mef2c BB280300 up 0.00173 0.0306
1456283_at Netol AV346211 up 0.00197 0.00672
1421141_a_at Foxpl BG962849 up 0.00197 0.00677
1423343_at Slco1c1 BB667135 up 0.00197 0.00677
1424718_at Mapt M18775 up 0.00197 0.00677
1436363_a_at Nfix AW 049660 up 0.00197 0.00677
1420534_at Gucy1a3 AK004815 up 0.00197 0.00909
1449563_at Cntnl NM _007727 up 0.00197 0.0112
1423802_at BC017634 BC017634 up 0.00197 0.0151
1448978_at Ngef NM_019867 up 0.00197 0.0152
1448154_at Ndrg2 NM _013864 up 0.00208 0.00677
1450339_a_at Bcl11b NM _021399 up 0.00208 0.0119
1448194_a_at H19 NM _023123 up 0.00208 0.013
1432466_a_at Apoe AK019319 up 0.00208 0.0177
1422052_at Cdh8 NM _007667 up 0.00208 0.0306
1448330_at G stm l NM _010358 up 0.00208 0.0405
1418782_at Rxrg NM_009107 up 0.00223 0.00863
1420533_at Gucy1a3 AK004815 up 0.00234 0.0112
1452141_a_at Seppl BC001991 up 0.00234 0.0128
1426106_a_at Syt6 AB026810 up 0.00234 0.0189
1454906_at Rarb BB266455 up 0.00241 0.00909
1417466_at Rgs5 NM_133736 up 0.00241 0.0228
1460214_at Pcp4 NM_008791 up 0.00241 0.0229
1424400_a_at Fthfd AK007822 up 0.00249 0.0112
1421140_a_at Foxpl BG962849 up 0.00265 0.00466
1422014_at Foxp2 AY079003 up 0.00265 0.0112
1416114_at Sparcll NM_010097 up 0.00265 0.0128
1416149_at Oligl AB038696 up 0.00271 0.0175
1418594_a_at Ncoal NM_010881 up 0.00277 0.00533
1425846_a_at Calnl AF282251 up 0.00277 0.0191
1455242_at Foxpl BM220880 up 0.00284 0.00338
1416342_at Tnc NM _011607 up 0.00284 0.0041
1416562_at Gad1 AF326547 up 0.00284 0.0119
1448326_a_at C rabpl NM_013496 up 0.00284 0.0148
1416666_at Serpine2 NM _009255 up 0.00299 0.0256
1436364_x_at Nfix AW 049660 up 0.00311 0.0041
1420911_a_at Mfge8 NM _008594 up 0.00329 0.0197
1421840_at A bcal BB144704 up 0.0035 0.0278
1416286_at Rgs4 NM _009062 up 0.00367 0.00677
1434515_at N coal BE996469 up 0.00386 0.0101
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Tabic 4.1 (continued); 175 Genes were found to be significantly up and down regulated between the ages of E12 and E16 
(p<0.05) after RMA and MAS5.0 normalisation and ANOVA, ranked by order of significance for up and down regulated 
genes (Red genes denote those chosen for follow up investigation, Blue denotes the one unknown gene to be chosen, that was
later discarded for technical reasons)
Affymetrix annotation Common Name G enbank ID up/down regulated RMA p  value
MAS 5 p  
value
1422541_at Ptprm NM_008984 up 0.00402 0.0113
1451516_at RhebM BC016521 up 0.00402 0.0241
1426517_at Gnaz AI326356 up 0.00406 0.0311
1428197_at 9430079M16Rik AK020159 up 0.0042 0.0214
1417839_at Cldn5 NM_013805 up 0.00444 0.02
1423551 _at Cdh13 BB776961 up 0.00448 0.0116
1421101_a_at Ldb2 NM_010698 up 0.00452 0.0105
1451461_a_at Aldo3 BC008184 up 0.0049 0.0153
1423186_at Tiam2 BM228957 up 0.00522 0.0107
1434005_at Rbm sl AW 541585 up 0.00522 0.0128
1418062_at Eef1a2 NM 007906 up 0.00522 0.0137
1423493_a_at Nfix BB315728 up 0.00542 0.00908
1419225_at Cacna2d3 NM_009785 up 0.00542 0.0101
1448972_at Grial NM_008165 up 0.00595 0.0137
1420871_at Gucy1b3 BF472806 up 0.00694 0.00677
1417848_at Gig1 AW413620 up 0.00694 0.00747
1451264_at 4930488L10Rik BC019939 up 0.00694 0.00923
1450055_at Vsnll NM_012038 up 0.00694 0.0112
1428443_a_at Rap1ga1 AK005063 up 0.00694 0.0189
1449158_at Kcnk2 NM_010607 up 0.00701 0.0197
1451021_a_at Klf5 BI465857 up 0.00718 0.0112
1438802_at Foxpl BB021390 up 0.00774 0.0179
1454849_x_at Clu BB433678 up 0.00774 0.0307
1415812_at Gsn NM_010354 up 0.00783 0.0256
1416302_at Ebf1 BB125261 up 0.00794 0.0151
1449468_at Siat7e NM_012028 up 0.00794 0.0175
1435239_at Grial BQ175316 up 0.00794 0.0287
1448673_at Pvr13 NM_021495 up 0.00807 0.0151
1451475_at Plxndl BC019530 up 0.00835 0.0474
1451804_a_at Lrrc16 BC012229 up 0.00837 0.00579
1416718_at Bean NM_007529 up 0.00839 0.0236
1419420_at Siat7e NM_012028 up 0.00862 0.01
1420872_at Gucy1b3 BF472806 up 0.00864 0.0128
1416069_at Pfkp NM_019703 up 0.0092 0.0112
1451450_at 2010011l20Rik AK008190 up 0.00971 0.0312
1427005_at Plk2 BM234765 up 0.0102 0.0189
1416301_a_at Ebf1 BB125261 up 0.0109 0.0351
1452981_at Cntnl AK004399 up 0.0109 0.0415
1415845_at Syt4 AV336547 up 0.0111 0.0231
1435026_at Spock2 BM117672 up 0.0112 0.00726
1424248_at 0710001 E13Rik BB159263 up 0.0118 0.00338
1422835_at Kcnd2 BB051684 up 0.012 0.0342
1418950_at Drd2 NM_010077 up 0.0126 0.0311
1428074_at 2310037P21Rik BE981853 up 0.0126 0.0371
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Table 4.1 (continued); 175 Genes were found to be significantly up and down regulated between the ages of E12 and E16 
(p<0.05) after RMA and MAS5.0 normalisation and ANOVA, ranked by order of significance for up and down regulated 
genes (Red genes denote those chosen for follow up investigation, Blue denotes the one unknown gene to be chosen, that was
later discarded for technical reasons).
Affymetrix annotation Common Name G enbank ID up/down regulated RMA p  value
MAS 5 p  
value
1450930_at Hpca AK002992 up 0.0133 0.0189
1424852_at 5430401D19Rik BB280300 up 0.0138 0.0163
1422064_a_at Zbtb20 AY028963 up 0.0138 0.0228
1418453_a_at Atp1b1 NM_009721 up 0.0158 0.0119
1417600_at Slc15a2 NM_021301 up 0.0159 0.0311
1416783_at Tac1 NM _009311 up 0.0166 0.028
1424341_s_at Pcdha4 AW146252 up 0.017 0.035
1421027_a_at Mef2c AI595932 up 0.0174 0.026
1420981_a_at Lmo4 NM_010723 up 0.0197 0.0361
1425452_s_at AW125753 B COO 2154 up 0.0209 0.0202
1422474_at Pde4b BM246564 up 0.0214 0.0276
1420718_at Odz2 NM_011856 up 0.0228 0.0114
1448710_at Cxcr4 D87747 up 0.0228 0.0243
1416983_s_at Foxol AI462296 up 0.026 0.0125
1433888_at Atp2b2 AV343478 up 0.0288 0.0369
1439036_a_at Atp1b1 AV152334 up 0.03 0.0311
1423836_at Zfp503 BB447914 up 0.0304 0.0205
1424719_a_at Mapt M18775 up 0.0366 0.0398
1437689_x_at Clu AV152288 up 0.0368 0.0147
1425132_at Netol AF448840 up 0.0432 0.0121
1415844_at Syt4 AV336547 up 0.0454 0.0308
1450227_at Ankrd6 BM199504 up 0.0461 0.0221
1434325_x_at Prkarl b BB274009 up 0.0468 0.0276
1437458_x_at Clu AV075715 up 0.0468 0.028
1437874_s_at Hexb AV225808 up 0.0468 0.0311
1418835_at Phldal NM_009344 up 0.0468 0.0351
1437810_a_at Hbb-bh1 AV311770 down 0.000654 0.015
1450736_a_at Hbb-bh1 NM_008219 down 0.000837 0.00338
1437990_x_at Hbb-bh1 AV147727 down 0.000837 0.00747
1422851_at Hmga2 X58380 down 0.000837 0.00782
1448716_at Hba-x M26898 down 0.00173 0.00646
1450621_a_at Hbb-bh1 NM_008221 down 0.00197 0.00677
1450781_at Hmga2 X58380 down 0.00197 0.00765
1418026_at Exo1 BE986864 down 0.00197 0.0342
1423348_at Fzd8 AV345166 down 0.00208 0.00466
1450780_s_at Hmga2 X58380 down 0.00208 0.00677
1448698_at C cndl NM 007631 down 0.00208 0.00767
1449939_s_at Dlk1 NM_010052 down 0.00208 0.00767
1417419_at C cndl NM_007631 down 0.00208 0.0149
1436823_x_at Hbb-y AV148191 down 0.00223 0.00579
1418401_a_at Dusp16 NM_130447 down 0.00241 0.0143
1430542_a_at Slc25a5 AA823938 down 0.00265 0.0112
1422520_at Nef3 NM_008691 down 0.00265 0.018
1416159_at Nr2f2 AI463873 down 0.00277 0.00726
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Table 4.1 (coitiued); 175 Genes were found to be significantly np and down regulated between the ages of E12 and E16 
(p<0.05) after RMA and MAS5.0 normalisation and ANOVA, ranked by order of significance for up and down regulated 
genes (Red genes denote those chosen for follow np investigation, Bine denotes the one unknown gene to be chosen, Oat was
later discarded for technical reasons).
Affymetrix annotation Common Name Gen bank ID up/down regulated RMA p value
MAS 5 p 
value
1421841_at Fgff3 NM_008010 down 0.00277 0.0152
1421180_at Lix1 NM_025681 down 0.00277 0.0161
1418317_at Lhx2 NM_010710 down 0.00288 0.00677
1452114_s_at Igfbp5 BF225802 down 0.00289 0.0112
1437103_at C330012H03Rik AV293532 down 0.00311 0.0256
1418478jat Lmo1 NM_057173 down 0.00356 0.00726
1418761_at Igf2bp1 BB499476 down 0.00371 0.00767
1436717_x_at Hbb-y AV156860 down 0.00495 0.00747
1448363_at Yap1 NM.009534 down 0.00637 0.0105
1427633_a_at Pappa AF439513 down 0.00694 0.0112
1417649_at Cdknlc NM.009876 down 0.00694 0.0217
1417420_at Ccndl NM_007631 down 0.00781 0.01
1417457_at Cks2 NM_025415 down 0.00791 0.00747
1416802_a_at Cdca5 NM_026410 down 0.00794 0.0112
1422670_at Rohn NM_009708 down 0.00794 0.0156
1428402_at 2810406K24Rik AV140894 down 0.009 0.0471
1419700_a_at Proml NM_008935 down 0.0114 0.0325
1425458_a_at Grt>10 AF022072 down 0.0126 0.0147
1420028_s_at Mcm3 C80350 down 0.0128 0.02
1423146_at Hes5 AV337579 down 0.0131 0.00909
1424882_a_at 2510015F01RR BC011230 down 0.0145 0.0168
1456010_x_at Hes5 BB561515 down 0.0149 0.013
1423500_a_at Sox5 AI528773 down 0.0168 0.0175
1428379_at Sic17a6 BQ180367 down 0.017 0.013
1451346_at Mtap BG075139 down 0.0183 0.0278
1452654_at Zdhhc2 BB224658 down 0.0186 0.00392
1419271_at Pax6 BC011272 down 0.0187 0.0175
1439483_at AI506816 BI438039 down 0.0221 0.011
1433924_at Peg3 BM200248 down 0.0221 0.0431
1427300_at Lhx8 D49658 down 0.0226 0.0247
1422839_at Neurog2 NM_009718 down 0.0229 0.0221
1455972_x_at Hadhsc AV018774 down 0.0229 0.0402
1416558_at Me Ik NM_010790 down 0.0229 0.0466
1437807_x_at Catnal BB066232 down 0.0243 0.0191
1419380_at Zfp423 NM_033327 down 0.0261 0.0189
1437033_a_at Skp2 BB784099 down 0.0275 0.0362
1416076_at Ccnbl NM_007629 down 0.0288 0.0293
1448519_at Tead2 D50563 down 0.0319 0.0197
1448777_at Mcm2 NM.008564 down 0.0355 0.0181
1417541_at Hells NM.008234 down 0.0374 0.0147
1425457_a_at Grb10 AF022072 down 0.0401 0.0272
1426001_at Eomes AB031037 down 0.0421 0.0471
1452241_at Topbpl BC007170 down 0.0495 0.0402
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4.4.3 Reasons for selecting candidate genes to follow up;
Once the initial RMA and MAS5.0 normalisation and analysis had been 
completed and the results of both then compared it was found that there were still a very 
high number of genes that showed significant changes in expression levels over the time 
period assayed. Thus, additional criteria were set for significantly changing genes to 
select those deemed suitable for validation and further analysis. It was also decided to 
look at genes that only went up in expression between the ages of E12 and E16 for this 
project, as this reduced the number of genes and the functions and effects of these genes 
would be easier to study in future experiments that could be carried out using the 
facilities that were readily available to this laboratory group. Down regulation of genes 
was recognised as being equally important, but for reasons of time and cost this set of 
genes will be part of a separate study
The criteria were;
Genes significantly up regulated between the age of E12 and E16 that were also;
• Genes coding for transcription factors (as these are likely to important in
differentiation and knowledge of these may lead directly to methods for directing 
differentiation of stem cell populations) or
• Genes previously known to be implicated in development/migration/axonal path
finding or
• Genes coding for cell signalling proteins/receptors (as these genes are likely to be
implicated in the signals that progenitor cells need in an in vivo environment to 
proliferate and/or differentiate normally) or
• Genes for which a function has not yet been identified (for obvious reasons novel
genes that change in amounts during this period could be implicated in the
development, proliferation or differentiation of striatal neurons, and as such are of 
interest).
Genes that were known to be involved in normal cell cycle and normal cell processes 
(housekeeping genes) were discounted at this point in the analysis.
A much smaller number of genes satisfied the above criteria, and are discussed
below:
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4.4.3.1 Foxpl and Fo^p2
The up regulation of these genes between the ages of E12 and E16 is in 
accordance with a small number of papers (Ferland et a l, 2003) and this lends confidence 
to the results reported here and also validate findings seen by other laboratories using 
other methods. However, new information from this screen is the high degree to which 
this gene is up-regulated during striatal development {Foxpl being the most significantly 
up-regulated in this particular screen).
The Fox gene family all contain a domain homologous to the drosophila ‘forked 
head’ domains and are transcription factors that promote terminal, rather than segmental 
development. The forked head motif (also known as ‘winged helix’) is a 110-amino acid 
DNA binding domain which has a common involvement in early developmental 
decisions of cell fates during embryogenesis and may function as a co-regulator of 
nuclear receptors, and in particular the oestrogen receptor. The Foxp sub family is a 
distant relation of the main Fox family; the only homology being an 80-amino acid region 
within the DNA binding domain. The Foxp genes also contain domains unique to this 
subfamily, such as a leucine zipper resembling the N-myc zip dimerisation domain, a zinc 
finger and a polyglutamine tract
4.4.3.2 Foxpl
This gene was first described in neurons projecting from the striatum (Tamura et 
a l, 2000; Tamura et a l, 2003) having also been found to be expressed in lung and gut 
tissue (Shu et al., 2001) .The FOXP1 protein has four known isoforms; FOXP1A, B, C 
and D which have been implicated in the development of a range of tissues including the 
CNS, heart lungs and liver and spleen, all of the isoforms apart from the B isoform have 
been found in the brain. All of the isoforms other than the C isoform repress gene 
transcription when bound to a protein binding site occurring within the SV40 and 
Interleukin-2 (IL-2) promoters (Wang et a l, 2003a).
Foxpl is also thought to have tumour suppressing activity as it has been found to 
be varying in expression levels in a number of different types of tumours (Banham et al., 
2001; Banham et al., 2005). The subfamily also has an HNF3 binding domain that 
indicates these transcription factors bind to DNA as monomers. However, recent work 
has suggested that the leucine zipper in combination with the zinc finger domain 
promotes self association amongst different isoforms and sub family members of the 
Foxp transcription factors (Wang e ta l,  2003a). The 37-40 residue polyglutamine stretch
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(seen in FOXP 1A and B isoforms) may also infer some sort of modulatory effect on 
repression as these domains are known to mediate protein to protein interactions by either 
forming multimers (Perutz et al., 2002) or interacting with polar amino acid-rich 
sequences (Imafuku et al., 1998).
Foxpl has been observed within the developing striatum, hippocampal CA1 fields 
and cortex (mostly within layers 3-5 but also in scattered amounts in layers 2-6) from 
E12.5 (Tamura et al., 2000; Tamura et al., 2003; Ferland et al., 2003). The Striatal 
expression was not observed within the progenitor cells that reside near the ventricular 
zone, but in differentiating cells migrating away from this area and taking up positions in 
the newly formed striatum itself (Tamura et al., 2000; Tamura et a l, 2003). This suggests 
FOXP1 may have a role in post migratory neuronal development. Later in development 
and throughout adult life expression of Foxpl remains high in the striatum although after 
development its expression in the cortex is more restricted from layers 3-5 to just layer 6 
neurons within the cortex.
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MAS5.0 Normalised data for Foxpl probes
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Fig. 4.18; MAS5.0 and RMA Normalised data for Foxpl probes.
4.4.3.3 Foxp2
Foxp2 expression has also been previously reported in the developing striatum 
(Ferland et al., 2003) from around E l2.5 as well as other areas including the lung and gut 
epithelia (Shu et a l , 2001). In the brain, as with Foxpl, expression is seen within 
differentiated neurons. However, it seems that these two genes may be expressed in
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different neuronal sub-types as although they are both expressed in high amount in post 
migratory, differentiating and post differentiating neurons within the striatum and 
thalamus; Foxp2 is not expressed in any other cortical layers apart from layer 6 (even 
during development), is not expressed in the hippocampus and has also been found in the 
Purkinje cells of the cerebellum (Benitez-Burraco, 2005a; Benitez-Burraco, 2005b) 
(whereas Foxpl has not been detected in this region). The role of FOXP2 in the lungs 
seems to be to inhibit the expression of genes associated with the differentiation of 
pulmonary epithelial cells hence it might play an important role in the specification and 
differentiation of lung epithelial tissue. Whether it performs a similar role within the 
striatum has yet to be elucidated.
Recent work has shown that both FOXP1 and FOXP2 may have similar roles 
within the brain as they both may repress the transcription of the same genes (judging by 
the similarity of binding domains), are expressed in interlocking domains and also have 
the ability to dimerise with one another other (Shu et a l , 2001; Wang et al., 2003a; Li et 
a l , 2004b). It may be that these genes have similar or parallel roles in the cells within the 
development of basal ganglia circuits. There is some evidence that FOXP2 may be 
involved in the development of basal ganglia circuitry in that a point mutation of this 
gene produces a verbal apraxia and has been reported to be associated with caudate (a 
part of the striatum) atrophy (Teramitsu et al., 2004).
Several candidate target genes have been proposed for this subfamily, but little is 
known about how these genes participate in signalling and gene regulation (Wang et a l, 
2003a). However, when cells from the developing lateral ganglionic eminence (the 
birthplace of striatal projection neurones and olfactory bulb inter-neurones) are dissected 
out, expanded for long periods and then differentiated in vitro, they form cells that adopt 
a GABA-ergic phenotype (Ahmed et a l, 1995; Carpenter et a l, 1999). This 
differentiation may be a default pathway that comes about due to a lack of certain 
repressive genes such as Foxpl and Foxp2 that would otherwise enable the cells to adopt 
a separate differentiation pathway and possibly become striatal projection neurons. 
Therefore the expression of either one or both of these Foxp genes that are found to be up 
regulated genes during the development o f the striatum, may be crucial to the continued 
differentiation and development of projection neurons within the developing striatum.
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Fig. 4.19; MAS5.0 and RMA Normalised data for Foxp2 probe.
4.4.3.4 Guanylate Cyclase lp3
Guanylate Cyclase 103 (human homologue GUCYlpl) is a subunit of soluble 
guanylate cyclase (sGC). This is a hetero-dymeric enzyme composed of a and P subunits 
that also contains a haem unit that enables Nitric Oxide (-NO) to bind to and activate the 
enzyme (Arnold et al., 1977). sGC is the main and only conclusively proven receptor for 
the signaling agent -NO and is also one of only two enzymes (the other being a 
membrane-bound form) that catalyses the conversion of guanosine 5’-triphosphate (GTP) 
to cyclic guanosine 3’,5 '-monophosphate (cGMP). Therefore this peptide is probably 
involved in many signal-transduction pathways including angiogenesis (Saino et al., 
2004), vascular and non-vascular smooth muscle relaxation, peripheral and central neural 
transmission, platelet reactivity (Hobbs, 1997), photo transduction (Semple-Rowland et 
al., 1998) and possibly long term potentiation and depression (Jafffey and Snyder, 1995). 
The activation of sGC and the resulting increase of cGMP allows sGC to transmit an NO 
signal to the numerous downstream elements of the cGMP signaling cascade which 
include cGMP-dependant protein kinases, cGMP-gated cation channels and cGMP- 
regulated phospho-diesterase.
sGC is a member of larger group of evolutionary related enzymes known as the 
nucleotide cyclases. These enzymes convert guanosine tri-phosphate (GTP) and 
adenosine tri-phosphate (ATP) into cyclic nucleotide monophosphates (cGMP and
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cAMP). Other members of the group include adenylate cyclase (AC) and particulate 
guanylate cyclase (pGC) and together they are responsible for a broad range of signal 
transduction pathways.
It could be argued that the presence of this molecule would be obvious due to its 
role in angiogenesis (Saino et al., 2004). The developing striatum is a region of the neural 
tube that is proliferating at a faster rate than cortical regions between E12 and E16. 
Therefore these differentiating/developing cells that would have a comparatively high 
metabolic rate would be in need of a vascular supply rather than relying on diffusion as is 
the case for earlier stages in neural tube development. However, this protein, or the nitric 
oxide signalling pathway that it is involved in, given the diversity of its roles throughout 
other physiological processes, may play other crucial roles at this point in development 
within the developing neural progenitors and differentiating ceils that make up the 
developing striatum making it a valid candidate for further research.
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MAS5.0 normalised data for Gucy1B3 probes
350
■ E12
300 ■ E14
□ E16
c  250
•5 200
*  150
100
1420871_at 1420872_at
Affymetrix p ro b e  annotation
12 n
1 0  -J
o?
'55
73 6
E
o 4 
z
<
5 « 2
RMA normalised data for Gucy1B3 probes
■ E12
■ E14 
□ E16
1420871_at 1420872_at
Affymetrix p ro b e  annotation
Fig. 4.20; MAS5.0 and RMA Normalised data for GucylB3 probes.
4.4.3.5 Spock 2 (Testican 2)
SPOCK2 is a putative extracellular heparin/chondroitin sulphate proteoglycan 
(Kohfeldt et al., 1997; Vannahme et al., 1999). The protein was first identified from a 
human cDNA library as being a protein of 424 amino acids that contain a signal peptide, 
a follistatin-like domain, a calcium binding domain, a thyroglobulin-like domain and a C-
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terminal region with two putative glycoaminoglycan attachment sites (Vannahme et al.,
1999). The Spock/Testican group of genes form a subgroup within the BM- 
40/Sparc/osteonectin family (Hartmann and Maurer, 2001) and expression of Spock2 in 
humans occurs in a wide variety of tissues. However, it is most pronounced in the 
thalamus, hippocampus, occipital lobe, nucleus accumbens, temporal lobe, and caudate 
nucleus with somewhat lower levels in the cerebral cortex, medulla oblongata, frontal 
lobe, amygdala, putamen, spinal cord, substantia nigra, and cerebellum (Marr et al.,
2000).
In the embryonic mouse, SPOCK2 (also know as TESTICAN2), is a 401 amino 
acid protein with a mass o f44678 dalton (Schnepp et a l , 2005) that has been found in the 
embryonic brain, spinal cord and dorsal root ganglions of the peripheral nervous system 
so it seems this molecule may have an important role in the nervous system. In the adult 
this expression extends to most parts of the brain as well as lungs and testis. In a recent 
study the protein was shown by immuno-histochemistry to be associated with the cell 
bodies, axons and sometimes even the dendrites of large neurons such as the mitral cells 
of the olfactory bulb, pyramidal cells of the cortex and hippocampus and Purkinje cells of 
the cerebellum. Blood vessels were stained in all brain regions as well as a diffuse 
staining that was absent in other tissues. Antibodies also showed expression in a number 
of endocrine glands throughout the body including the pituitary, (Schnepp et a l , 2005).
The protein contains domains that are closely related to a number of other 
molecules that have been implicated in neurogenesis such as cell adhesion molecules, 
growth factor binding proteins and protease inhibitors and this supports evidence of a 
correlation between its expression and areas of active cell proliferation and migration, 
axonal outgrowth and synaptogenesis (Charbonnier et a l , 2000).
Testicanl (,Spockl), also found in mouse, is also expressed predominately in the 
nervous system during embryonic development; its expression correlating with periods of 
neuronal migration and axonal growth and path finding (Charbonnier et a l , 2000). In the 
adult mouse its expression is restricted to the brain where it is located in posts synaptic 
densities (Bonnet et a l, 1996). In the cerebellum transcripts of Spock2 have been 
observed as early as E l0.5 in the germinal trigone of the cerebellum (formed when 
granular layer precursors reach the surface of the cerebellar cortex and start to make 
connections) (Bonnet et a l, 1996; Charbonnier et a l, 2000). In the olfactory apparatus 
transcripts are again detected at E l0.5 when the neuroepithelium begins to differentiate 
(Saito et al., 1998) and expression increases through E l2.5 as olfactory nerve axons
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migrate up towards the olfactory cortex (Cuschieri and Bannister, 1975). At E l4 in the 
mouse, Spock (this study was completed when only one gene of the Spock group had 
been found) was also detected in the olfactory cortex when synaptogenesis begins 
between the axons of the incoming olfactory axons and dendrites of the mitral cells of the 
olfactory bulb (Hinds and Hinds, 1976). In the spinal cord Spock is expressed by E10 
around the time when neurogenesis begins and continues until E12 as migration of cells 
within the mantle layer increases. At E14 transcripts and protein are at their highest levels 
in the grey matter during the peak time of neuronal connection and then between El 6 and 
E l8 transcription is restricted to the dorsal and ventral horns, where synaptogenesis is 
most active at this time (Charbonnier et al., 2000).
The expression of Spock in the peripheral nervous system also seems to suggest 
its role in the migration and differentiation of neurons (Lawson and Waddell, 1991; 
Ozaki and Snider, 1997).
In general, Spock expression correlates with the development of the mouse 
nervous system at times when cell adhesion, axon path finding and synaptogenesis are 
taking place. This supports its presumed involvement in neural development and gives a 
good reason to study its expression and functions within the developing striatum.
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Fig. 4.21; MAS5.0 and RMA Normalised data for Spock2 probe.
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4.4.3.6 321000372P1 Riken (Brain Specific Binding protein)
This Riken clone had unknown function when found to be significantly up regulated 
between E12 and E16 in the WGE. However, due to the size of the known transcript of 
this clone, technical problems and the lack of information on it at the time, a suitable set 
of primers could not be made for follow on analysis (see Chapters Five onwards). 
Therefore this gene was dropped from the set of candidate marker genes.
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Fig. 4.22; 1MAS5.0 and RMA Normalised data for Riken 3210037PI probe.
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4.4.3.7 Mef2c
The mammalian myocyte enhancer binding factor genes are members of the 
MADS family of transcription factors which share a 56 amino acid N-terminal region 
known as the MADS-box (named after the first four proteins in which it was identified: 
MCM1 [yeast mating-specific gene regulator], agamous and deficiens [homeotic genes 
regulating flower development] and serum response factor [a muscle-specific and growth 
factor inducible regulator] ) (Leifer et al., 1993; Leifer et al., 1994; Leifer et a l , 1997; 
Janson et al., 2001).
The MEF2 protein was originally studied in myogenic cells and differs from other 
MADS-box proteins by the addition of a ‘MEF2-box’ of 29 well conserved amino acids 
immediately after the MADS-box. These two domains are sufficient for DNA binding 
and dimerisation while the remainder of the protein is involved in transcriptional 
activation (Shore and Sharrocks, 1995). Mef2C is unique within the Mef2 gene family in 
that it is only expressed in muscle, spleen and brain.
Within the brain Mef2c expression is found in a laminar distribution within the 
cerebral cortex as well as other areas. In human foetus at 14 weeks gestation it is present 
in cell nuclei throughout the cortical plate. Subsequently, MEF2C immunoreactivity 
develops a bilaminate, and then a trilaminate distribution and ultimately is expressed 
preferentially in layers 2, 4 and 6 of mature human neocortex (Leifer et a l, 1994). In the 
foetal mouse brain M eflC  has not been found in proliferative zones in the brain but 
instead in cells that have migrated to the subplate and cortical plate. Mef2C is also found 
in the olfactoiy bulb at high levels and at lower levels in hippocampus, basal forebrain, 
striatum, cerebellum, inferior colliculus, and in some nuclei of the hypothalamus, 
thalamus and brainstem. The pattern of expression suggests that M eflC  is expressed in a 
subset of post mitotic neurons in the brain and that it may therefore function to promote 
terminal differentiation of the cells that express it (Leifer et al., 1994). However, this 
cannot be the proteins only task, as expression carries on into adulthood.
In the adult M eflc is found in the adult olfactory bulb in large amounts, with 
reduced amounts in the hippocampus and further still reduced amounts in the striatum 
and trace expression in the thalamus (Lin et al., 1996). Recent studies of Ngnl and Ngn2 
mutants suggest that Mef2c is a downstream transcription factor of NGN2 (Mattar et al., 
2004) and that although it seems that Mashl is actually down regulated in dorsal domains 
where Ngnl and/or Ngn2 are expressed (Mattar et al., 2004), when both Mef2c and 
Mashl are expressed in P19 cells the result is that the two transcription factors act
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together to promote the expression of neuro-specific genes (Skeijanc and Wilton, 2000). 
This suggests that MEF2C, although expressed in both the cortex and more dorsal areas, 
is regulated by different genes in different areas and will act as a transcriptional regulator 
of different neuronal-specific genes depending on where it is expressed and what other 
transcription factors are available, hence it may play a pro-neuronal role in the 
developing striatum as well. Recent evidence has shown that MEF2C is regulated by Islet 
1 (also a ventral forebrain marker) (Caubit et al., 2005), within the anterior heart field 
during embryonic cardiac development (Dodou et al., 2004), so it is possible that this 
gene is regulating Mef2C within the ventral telencephalon.
Human Mef2C has at least three different splice sites and at least 5 known splice 
variants. One of which includes the ‘b’ exon is found only in brain and not other tissues 
(while other variants that don’t contain this sequence have been found both in the brain 
and in muscle) (McDermott et a l , 1993). MEF2C is also known to bind with other 
transcription factors (including b-HLH transcription factors) to form hetero and homo­
dimers; these include myogenic factors and associated E-proteins. Interestingly, these 
interactions occur at the protein-DNA and the protein-protein level, so allowing for some 
potentially complex interactions to take place (Janson et al., 2001).
Putative MEF2 binding sites have been found in a range of neuronal genes, 
including the somatostatin receptor, the NMDA-R1 receptor (NR-1), the tau microtubule 
associated protein and brain fatty acid binding protein. Neuro D, a transcription factor 
that contains an interposed MEF2 consensus sequence at nucleotides 779-788, is a bHLH 
transcription factor responsible for differentiation of hippocampal and cerebellar granule 
cells and also causes ectopic neuronal expression in xenopus when over expressed. 
MASH1 has also been shown to interact cooperatively with MEF2 proteins and E- 
proteins in neuronal cells (Black and Olson, 1998) and with MEF2C in P I9 carcinoma 
cells (Skeijanc and Wilton, 2000) and it seems likely that MEF2C possibly acts with 
many other bHLH transcription factors as well.
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Fig. 4.23; MAS5.0 and RMA Normalised data for MeJ2c probes.
4.4.3.8 Tiam2
Tiam2 (T-cell Lymphoma Invasion and Metastasis 2), also known as Stef (SIF 
and TIAMI-like exchange factor) has previously been found in the telencephalon of 
E l3.5 mouse and also in the cerebral cortex, hippocampus and ependyma of adult mouse 
brains (Chiu et al.y 1999) . This gene is closely related to Tiaml, a transcript encoding a
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guanine exchange factor that was first identified in a screen for genes that increased the 
invasiveness of T cell lymphoma lines (Habets et al., 1994), is expressed during neuronal 
migration and neurite extension (Ehler et a l, 1997) and over expression of this gene in 
N1E-115 neuroblastoma cells induces cell migration and affects neurite outgrowth 
(Leeuwen et a l, 1997). These two closely related genes have similar embryonic 
expression patterns indicating that TIAM2 may also play an important role in 
development of post mitotic, migrating neurons within the forebrain. Unlike Tiaml, in the 
adult mouse brain Tiam2 is only expressed in high amounts in discrete areas that also 
display either synaptic plasticity (the cortex and hippocampus) or neurogenesis (the 
dentate gyrus) which may also give clues to its function in the embryonic brain (Chiu et 
a l, 1999).
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Fig. 4.24; MAS5.0 and RMA Normalised data for Tiam2jprobe.
4.4.3.9 Ndrg2
This gene is the second member of the four strong N-myc down regulated gene 
family that contains an a/(3-hydrolase domain and shares a high degree of sequence 
homology.
NDRG2 itself has four isoforms (found in rat) of which none are actually 
repressed by the N-myc promoter (Okuda and Kondoh, 1999). NDGR2 is highly related
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to N-Myc downstream-regulated protein 1, which, as well as being the best characterised 
protein in this family has putative links with a number of functions including stress 
responses, cell proliferation and differentiation as well as being reported to cause the 
genetic disorder called Hereditary Motor and Sensory Neuropathy-Lorn (HMSN-L) 
(Chandler et al., 2000; Kalaydjieva et al., 2000).
Recent studies have shown that this gene is found throughout the brain but is 
predominately expressed within neurogenic regions of the brain such as the hippocampus 
and is localised to GFAP-positive astrocytes or radial glia (Nichols, 2003). Takahashi et 
al found that when P I9 cells were treated with NGF, they began to sprout neurites. This 
neurite sprouting coincided with an increase in Ndrg2 mRNA and the resulting NDRG2 
protein was found to localise to neurite growth cones. Furthermore, over expression of 
these Ndrg2 transcripts resulted in further elongation of the neurites (Takahashi et a l, 
2005a).
The actual function of NDGR2 is, as yet, unclear but it has been implicated in a 
number of functions including promoting neurite elongation in NGF treated PC 12 cells 
(Takahashi et al., 2005a) and may have a putative involvement in neural differentiation 
and synapse formation (Nichols, 2003; Nichols et a l , 2005; Takahashi et al., 2005a).
Interestingly, Ndrg2 expression has also been shown to decrease (mRNA and 
protein) after Electro Convulsive Therapy and after treatment with Tri-cyclic 
(imipramine) and selective serotonin reuptake inhibitor (sertraline) anti depressants 
illustrating that this gene may be one of the so far unknown targets of these treatments 
(Takahashi et al., 2005b). Ndrg2 expression has also been shown to be increased in the 
pyramidal cells of the hippocampus of late-onset Alzheimer’s disease patients 
(Mitchelmore et al., 2004). After adrenalectomy it has also been shown to be under the 
positive influence of corticosteroids (Nichols et al., 2005). Its function in diseases such as 
Alzheimer’s could be as part of a regulatory process in a response to an accumulation of 
mis-folded proteins within the cells in question; perhaps to chaperone these proteins away 
from the nucleus or take part in their degradation, or the increases in expression of this 
gene may be as a result of an epigenetic deregulation as part of the disease process 
(Mitchelmore et al., 2004).
Expression of Ndrg2 has been reported to be developmentally dynamic, being 
generally lower in the early stages of development and markedly increasing during later 
stages of embryonic development (Hu et al., 2006).
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The fact that it has been implicated in neural differentiation and synapse 
formation and is up regulated at the time of maximum proliferation of striatal cells 
suggests that this gene has important functions within the striatum during this period, also 
making it a worthwhile candidate for further investigation.
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Fig. 4.25; MAS5.0 and RMA Normalised data for Ndrg2 probe.
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4.4.3.10 Cxcr4
This gene codes for The CXCR4 receptor; a seven trans-membrane domain 
chemokine receptor belonging to the G protein coupled receptor family that is also the 
co-receptor for the HIV glycoprotein gpl20 (Lin et al., 2003). It was first thought that 
this receptor was only expressed by glial cells (Banisadr et al., 2002) but it has now been 
widely accepted that they are also expressed on neurons and oligodendrocytes and their 
precursors (Ji et al., 2004; Dziembowska et al., 2005).
This receptor is conserved throughout vertebrate evolution as it has been found to 
control primordial germ and sensory cell migration in zebra fish (Doitsidou et al., 2002; 
Li et al., 2004a; Li et al., 2005). In the adult mouse this receptor is expressed in the 
cortex, hippocampus and cerebellum (Tham et al., 2001; Banisadr et al., 2002).
The only known endogenous ligand for CXCR4 is CXCL12 (formally called 
stromal cell-derived factor 1 (SDF-1). CXCL12 is a potent leukocyte chemo-attractant 
that is known to control B-cell lymphopoiesis (Nagasawa, 2002), heamatopoietic stem 
cell migration towards bone marrow (Egawa et al., 2001), intemeurons that migrate from 
the ventral regions of the forebrain to the cortex (Stumm et al., 2003a) and neural and 
oligodendrocyte precursors survival and migration within the striatum (Dziembowska et 
al., 2005).
Cxcr4 and Cxcll2 inactivation results in haemopoietic and CNS defects (Ma et 
al., 1998) resulting in perinatal death. The cerebellum of these mutants has an irregular 
external granular layer, ectopically located Purkinje cells and clumps of abnormally 
migrated granule cells within the cerebellar anlage (Ma et al., 1998). Dentate granular 
cell precursors within the hippocampus also express Cxcr4 and require, amongst other 
factors, the influence of CXCL12 in order to migrate into a proper position within the 
dentate gyrus anlage (Bagri et al., 2002; Lu et a l, 2002). It has been postulated that, as 
expression of Cxcr4 and Cxcll2 both extend into adulthood within the hippocampus and 
the hippocampus itself remains an area of adult neurogenesis, the role of CXCR4 and 
CXCL12 may also extend into adulthood (Lu et al., 2002).
The function of CXCL12 may also be modulated by other long range chemo- 
attractants so that a migrating cell could be subjected to a number of different signals, 
each containing separate pieces of information about the pathway it is migrating along 
(Lazarini et al., 2003). The response of glia and neurons to CXCL12 may also be 
different, as although some cortical neuronal precursors expressing Cxcr4 respond to the 
chemo-attractant, they do not respond to the HIV glycoprotein GP120, whereas glial cells
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responded to either signal in the same way. However, in differentiated cortical neurons a 
response was seen from both CXCL12 and GP120 to influence neuronal function 
(Lazarini et al., 2000).
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Fig. 4.26; MAS5.0 and RMA Normalised data for Cxcr4 probe.
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4.4.4 Known markers of striatal development
As discussed in Chapter One, there are a number of genes that are have already 
been shown in other studies to be expressed during striatal development. Some of these 
genes have been clearly shown to have a role on the developmental process, but some 
haven’t. Here I have looked to see if  changes in some of these genes have been picked up 
in my screen and whether the changes are consistent with what would be predicted from 
previous studies. However, these results may have either less fold change or more 
variances between samples. Some of the genes mentioned in Chapter One are also not 
contained on the Mouse 430A genechip:
4.4.4.1 Sonic Hedgehog
This gene is comparatively unchanged during the period assayed. Shh is 
represented by one probe set on the Mouse 430A genechip, and although the data has 
wide variance the trend seen is for very low expression throughout the three time points 
tested. There is little or no variation between these time points. This is to be expected, as 
Shh is an early acting gene within the striatum that induces the expression of other 
important transcription factor that induce development of the MGE and LGE (see 
Chapter One).
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Fig. 4.27; Bar charts showing MAS5.0 and RMA normalised data for Shh
4.4.4.2 BMPs
Bmp7 is found to be expressed at very low concentrations throughout the period 
of study; again there are no surprises in this as this gene is active at much earlier stages of 
development (Dale et al., 1999).
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Fig. 4.28; Bar charts showing MAS5.0 and RMA Normalised data for Bmp7
4.4.43 Dlx
Dbcl, Dlx2 and Dlx5 are all seen to increase in expression from E12, to E14, 
before decreasing again by E l6. This is interesting as these genes are all implicated in the 
development of later bom LGE GABA-ergic striatal matrix intemeurons (Eisenstat et al., 
1999; Panganiban and Rubenstein, 2002). Dlx5 is also expressed in early bom striatal 
cells (Eisenstat et al., 1999), however, Dlx6 was only found at very low levels during the 
period of E12 and E l6 in this study, suggesting that the early cells have already passed 
their peak expression of this gene.
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Fig. 4.29; Bar charts showing MAS5.0 and RMA Normalised data For Dlxl
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Fig. 4.30; Bar charts showing MAS5.0 and RMA Normalised data for Dlx2
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Fig. 4J1 ; Bar charts showing MAS5.0 and RMA Normalised data for DlxS
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Fig. 432; Bar charts showing MAS5.0 and RMA Normalised data for Dbc6
4.4.4.4 Gsh2
This gene, heavily implicated in the development of neuronal precursors in the 
MGE and the timing of production of precursors in the LGE (Casarosa et a l 1999; Kriks
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et a l 2005) is highly active earlier on between the ages of around E10.5 and E12.5, 
firstly in the MGE then spreading throughout the WGE later on (Corbin et a l 2000), but 
not in the dorsal telencephalon. It has been implicated as a precursor to Mashl (a gene 
known to be expressed in neural precursors) Therefore this data also supports previous 
published literature.
131
MAS5.0 Normalised data for Gsh2 probe
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Fig. 4J3 ; Bar charts showing MAS5.0 and RMA Normalised data for Gsh2
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4.4.4.S Foxgl
This gene is seen to be active within the ventral telencephalon at around E8.5-9 as 
a negative repressor, limiting the differentiation of progenitors that would otherwise 
cause hypoplasia (Hanashima et al., 2004; Martynoga et a l , 2005). The role of FOXG1 
between in the WGE is as a negative repressor of progenitors, causing cells to fall out of 
the proliferative cycle and differentiate. There is no change seen in the levels of 
expression over this period, and this may be expected as proliferation within this area 
slows down and differentiation o f these cells occurs.
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Fig. 4J4; Bar charts showing MAS5.0 and RMA Normalised data for Foxgl
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4.4.4.6 M eisl
This gene is first expressed in low levels in the VZ of the ventro-lateral 
telencephalon at around E l0.5 and about 24 hours later in high levels within the CGE and 
amygdala and lower levels within the MGE and LGE. Expression continues in these and 
other areas throughout development into adulthood (Toresson et a l, 2000a). Therefore it 
would be expected that this gene is found at low levels that do not change significantly 
during this assay.
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Fig. 4J5; Bar charts showing MASS.O and RMA Normalised data ior Meisl
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4.4.4.7 Retinoic Acid
This vitamin A metabolite is active within the CNS from around E7 until well 
after birth. As a result, molecules such as Crabpl and Rary will be expected to be present. 
Interestingly, a 3-5 fold increase in Crabpl was detected during the period of study while 
the expression of Rary remained more constant (with wide variance between samples).
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Fig. 436; Bar charts showing MAS5.0 and RMA Normalised data For Rar-y
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4.5 Discussion;
In this micro array experiment I have characterised the gene expression of the 
developing mouse striatum during it’s period of maximal neurogenesis (Fricker-Gates et 
al., 2004a), between the ages of E12 and E l6. The experiment provided a wealth of 
statistically significant data from which I chose a number of candidate genes that were 
worthy of follow up investigation in order to achieve the aims of this thesis.
4.5.1.1 Reliability o f the screen
In the recent past, micro array and other high throughput gene analysis techniques 
have been heralded as the answer to every molecular biologist’s dream when it came to 
elucidating gene function and expression changes within cells. Some of this has been 
proven correct, and to date there have been a number of highly rigorous studies that have 
provided many advances in our knowledge. However, the micro array technique alone 
cannot be counted on as reliable unless at least some of the results that it produces are 
validated using more traditional and well founded techniques; on its own it is no more 
than a tool that lends support to other techniques.
As described in this chapter’s introduction, the Affymetrix Mouse 430A Genechip 
contains a large number of known and unknown genes. These include some genes that are 
known to be active within the developing striatum between the ages of E12 to E16 (see 
Chapter One, introduction for a review of what is currently known about molecular 
changes at this period in development). The expression changes seen in these known 
striatal genes, lends confidence to this study, showing known genetic trends already cited 
in the literature.
4.5.1.2 Confidence in good quality o f RNA/techniques
Before undertaking an expensive procedure such as the Affymetrix technique, it
was imperative to start with high quality material that was obtained using recognised and
reproducible techniques. Therefore a lot of time went into choosing the right techniques
of dissection (training and regular checking of my dissectional accuracy by an
experienced observer), training in RNA extraction and the selection of the right micro
array platform (Affymetrix) and Genechip (Mouse430A). The quality of RNA and the
levels of quality control throughout the micro array process were therefore of a very high
standard. Only one of the Genechips (El4b) failed to achieve the high levels of quality
control (after it was found a small ‘crop circle’ irregularity had occurred on the actual
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chip during the hybridisation process which would have affected the results) so was 
repeated. As such, I have confidence in the quality and reproducibility of the results 
achieved from this experiment.
4.5.1.3 Sources o f error.
All the data was scaled and normalised (see methods section above for details) to 
correct for variations between the arrays. These variations could have arisen from two 
main sources;
• Biological (potentially interesting in this study) variation may arise from many 
sources including dissection time (minimised by limiting it to within a two hour 
window between 06:00 and 08:00 am), species variation (minimised by using 
only CD1 (ICR) mice from one supplier), variation between animals, ages of 
dams (these were all of similar/same age), sex of foetus (this was not controlled 
for due to difficulties in sexing at this age) or growth conditions (minimised here 
by housing all animals in the same conditions in adjacent cages).
• Technical (obscuring) variation (Hartemink et al., 2001) could have arisen from 
experimental variables such as reagents, handling errors and quality of targets 
hybridised.
Of course, some sources of error cut across the boundaries, for example, the 
accuracy of dissection (discussed fully in Chapter Three).
The minimisation of variation was essential and was catered for in the initial 
design of the experiment; after this, scaling and normalisation provided another means to 
remove differences and facilitate comparison analysis. However, by only taking the genes 
that were found to be significant in both normalisation methods I may have missed some 
important genes. This is an intrinsic problem of the approach employed here. Of course, 
further validation was also performed using alternative experimental strategies and this is 
elaborated in the following chapter (Chapter Five).
4.5.1.4 The decision to analyse the E l2 to E l 6 gestational window.
As with gene array experiments in general, this experiment produced a huge
amount of data. In this thesis I have been able only to follow up a very small proportion
of the information produced. Given the enormous volume of data, I selected the most
prominent genes with the largest expression changes and the smallest variances between
samples. The data that this experiment has provided is fully MIAME compliant, and as
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such will be published on the web when any literature that arises from this work is 
published for acknowledgement. The data is already serving as a resource with a number 
of the up-regulated genes being actively assessed for functionality by other researchers. 
These studies will not be discussed further here.
The up-regulated genes selected from the screen are validated using PCR and in 
situ hybridisation and are discussed further in the following chapter.
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Chanter Five
5 Validation of Micro Array using I n  S i t u  Hybridisation.
5.1 Introduction
In the previous chapter I described a series of micro array experiments in which a 
number of genes were found to be significantly up-regulated between the ages of E12 and 
E16 in the embryonic mouse striatum.
Due to the large numbers o f genes assayed in each series of experiments, there is 
a chance that ‘false positives’ can appear in the data. To make sure the chances of this 
were minimal, the Affymetrix Mouse 430A chip was chosen, as it has been proven to 
show the least false positives (below 3% at a p  value of 0.01) (Woo et al., 2004). 
However, because this gene chip has over 22,000 genes on it, this still allows for an 
estimated 660 false positives to have been made in each experiment. This is controlled for 
by running gene chip replicates, which was done. However, due to the high cost of each 
micro array experiment the numbers of these replicates were limited to three replicates.
Using Affymetrix gene chips allowed me to obtain highly reproducible results, 
however, as with any technique its efficacy can only be validated when compared to 
similar results using tried and tested methods.
In order to validate the findings of the micro array experiments described in 
Chapter Four different methods of visualising gene expression changes were required. 
Furthermore, these alternative techniques also yield additional information about the 
candidate genes in question. It was decided to use semi-quantitive PCR and in situ 
hybridisation to gauge which of the genes were worthy of further interests and analysis.
PCR was used to confirm the gene array findings and also to assess whether the 
candidate genes in question were also expressed in neighbouring areas of brain, 
specifically, the neocortex.
In situ hybridisation was then used to analyse those genes that passed this initial 
assessment, to further confirm whether they were up regulated over the period in question 
and also to provide spatial information. Specifically, whether the candidate genes were 
expressed within the ventricular zone (VZ), or the sub-ventricular zone (SVZ) or within 
the maturing striatum itself (all will be included in the dissection of the striatum). The 
location of cells expressing the candidate gene may give clues as to whether these genes
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are relevant to proliferation, migration, differentiation, maturation or normal activity seen 
within maturing cells within different parts of the developing brain (see Fig. 5.1).
vz-IGE
fvz-
LV
vz + svz— =  
: iz (nsd '
LGE
MGE
Fig. 5.1; Coronal sections around the level of the WGE at El 2 (top), E14 (middle) and E16 (bottom). These 
diagrams depict the proliferation areas (SVZ=Sub Ventricular Zone, VZ=Ventricular Zone) and directions of 
migration of cells from the LGE (black arrows) that give rise to neurons that populate the neo-striatum 
(caudate putamen-cp and globus pallidus-gp), the MGE (dark grey arrows) that give rise to GABA-ergic 
intemeurons that populate the striatum and dorsal areas such as the cortex and cortical pre-plate (CP) that 
transiently populate the neo-striatum (Hamasaki et al., 2003). Figures adapted from (Schambra et al.,
1991)
5.2 Methods
PCR methods were as described in Chapter Two. PCR was carried out using a 
pooled sample of the original WGE RNA samples and cortical samples obtained from a 
later foetal dissection to act as controls.
5.2.1.1 In situ hybridisation.
See Chapter Two: Methods for foetal dissection techniques and in situ probe 
preparation and protocol.
Due to the very small size of the tissue being studied, the whole head was used in E12 
and E14 samples, whereas just the dissected whole brain was used in E16.
These tissue samples were taken direct from dissection and placed in a plastic 
mould (made from a microfuge tube) containing OCT mounting gel and this was snap 
frozen using liquid nitrogen. Once frozen these were then stored at -80°C until cutting, 
which took place on a bright cryostat. Brains were cut into 16pm sections and placed on 
Superfrost plus slides, so that one brain was shared between several slides. Slides were 
stored at -80°C until needed.
Three replicates of both probe and controls were carried out on each candidate 
gene and the most representative slides were then photographed, cut and the picture 
mated to the nearest coronal section available from a pre-natal mouse brain atlas 
(Schambra et a l , 1991) and are shown below.
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5.3 Results
5.3.1 PCR
DMA ladder £ 1 2  E 14  £ 1 6
WGE Ctx WGE Ctx WGE Ctx
Cxcr4
F oxp l
Foxp2
G ucylb3
M ef2c
Ndrg2
Spock2
Tiam2
G3pdh
Fig. 5.2; Preliminary PCR results confirmed the micro array results, allowing progression to validation using
in situ hybridisation.
The PCR results above provided a preliminary confirmation of the micro array 
experiment results as in all candidate genes a similar pattern of expression as that shown 
in the micro array, can be seen here. Having studied these preliminary results it was 
decided to design and make RNA probes for hybridisation for all the above candidate
genes.
Expression of these candidate genes can also be viewed in the cortical samples. 
Many are expressed at lower levels in cortex, although up-regulation between E l2 and 
E16 can be seen for some genes — for example, see Mef2c.
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5.3.2 In situ hybridisations.
The following Figures show the results of the in situ hybridisation analysis carried 
out using the candidate genes selected in Chapter Four. The photographs show coronal 
sections from the caudal to rostral areas of the brains. Because of the limitations due to 
size of the tissue samples, these sections differ slightly between candidate genes. The 
areas showing the striatum are pictured below; the photographs showing the brain series, 
from caudal regions to rostral regions, for each embryonic age, are shown in full in 
Appendix C.
The first Figure in each set shows the approximate position of each coronal 
section shown.
For ease of presentation, there is some discussion specific to each gene following 
its relevant in situ and then a very brief summary at the end.
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I5.3.3 F oxpl
5.3.3.1 E12
LGE
Fig. 5.3; Coronal sections through the El2 mouse brain showing control probe (left) and experimental probe 
(right) for Foxpl (V=Ventricle, LV=Lateral Ventricle, SVZ= Sub Ventricular Zone, VZ=Ventricular Zone).
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E14
Fig. 5.4; Coronal sections from El 4 Brain showing control probe (left) and experimental probe for Foxpl. 
(SCbP=Superior cerebellar peduncle, IYF=Interventricular foramen of Munroe).
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Fig. 5.5 ; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Foxpl. (ChPL=Choroid Plexus, LV= Lateral ventricle, GE=Ganglionic Eminence, CC=Corpus Collosum, 
SVZ=Sub Ventricular Zone, VZ=Ventricular Zone).
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5.3.3.3 Foxpl
As expected, Foxpl expression was not detected in any significant amounts until 
E l4, where expression was found within the caudal SVZ of the WGE and neo-striatum. 
At E16 this expression had increased to show comparatively high amounts of expression 
throughout the neo-striatum and in the cells that are migrating from the rostral SVZ of the 
WGE, to populate the neo-striatum. This indicates that this gene is expressed in cells that 
are migrating to, and populating the whole area of the striatum. This is supported by 
previous findings by Ferland et al (Ferland et a l , 2003) who also found that Foxpl was 
not detectable at all within the VZ, and did not appear within the SVZ until E14.5, before 
being found in cells populating the developing striatum at later stages into adulthood.
This evidence backs up a suggestion that this gene has a role in migratory and 
post migratory striatal neurons, as was postulated by Ferland et al (Ferland et al., 2003), 
and perhaps in the final differentiation and then the ongoing life-long development of 
these cells (a reason why this gene remains at a high level of expression through to 
adulthood).
The sheer scale of Foxpl expression seen in this study suggests that this gene is 
also expressed in a large number of striatal cells: It seems a sensible hypothesis to suggest 
that because the murine striatum is made up of 95% MSNs, the cell type expressing this 
gene has a high likelihood of being the MSN. Future experiments that will be carried out 
in the Brain Repair Group aim to either confirm or discount this.
151
5.3.4 Foxp 2
5.3.4.1 E12
Fig. 5.6; Coronal sections from El 2 Brain showing control probe (left) and experimental probe (right) for 
Foxp2. (LV= Lateral ventricle, GE=Ganglionic Eminence, LGE=Lateral Ganglionic Eminence, 
MGE=Medial Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone).
152
53.4.2 E16
C B A
GE (VZ ♦ SVZ)
VZ ♦ SVZ. IV
\ CP
.-’i ... ;1
\ - r
______
VZ ♦ SVZ GE
Fig. 5.7; Coronal sections from El 6 Brain showing control probe (left) and experimental probe (right) for 
Foxp2. (hal=Lateral Habenula, DG=Dentate Gyrus, cp=Caudate Putamen, gp=Globus Pallidus, CC, 
G=Corpus Collosum, Genu, ChPI=Choroid Plexus, a=Nucleus Accumbens).
VZ ♦ SVZ. LV
SVZ. GE
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S.3.4.3 Foxp2
Unlike Foxpl, Foxp2 expression was not detected in any large amounts within the 
WGE/neo-striatum until E l6. This also mirrored the results seen both in the micro array 
data described in Chapter Four and in a previous study (Ferland et a l , 2003). However, 
Ferland et al did manage to detect expression of this gene within the SVZ of the WGE as 
early as E12.5, whereas the results here suggest a later up-regulation at between E14 and 
E16.
Ferland et al do, however, concur with the present data as to where the Foxp2 
expression is situated: Previous studies and this data suggest early expression is restricted 
to just the caudate putamen and to cells migrating towards this area from the SVZ. 
Ferland et al noted that expression within the mature adult mouse striatum is more 
widespread. They suggested that, as with Foxpl, this gene may have a role within 
migratory or post migratory striatal neurons (Ferland et a l , 2003). It may be that this 
candidate gene is expressed in either a different smaller subset of neurons and therefore a 
different neuronal phenotype than that of the large proportion of cells expressing Foxpl, 
or in a particular subtype of cell that may also expresses Foxpl. Evidence of the restricted 
spatial expression seen in these results supports this view.
A possible hypothesis could be that this gene is expressed within a separate 
neuronal type, possibly that of the larger aspiny neurones that also appear within the 
striatum to a lesser extent, and do not project outside the borders of the striatum; this 
hypothesis is supported by previous observations that show the majority of these GABA- 
ergic, substance P receptor positive cells make up around 13% of all GABE-ergic cells 
within the striatum and are also found predominantly in the caudate putamen (Chen et al., 
2003).
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5,3.5 Cxcr4
5.3.5.1 E12
Fig. 5.8; Coronal sections from E l2 Brain showing control probe (left) and experimental probe (right) for 
Cxcr4. (LV= Lateral ventricle, GE=Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone).
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Fig. 5.9; Coronal sections from E l4 Brain showing control probe (left) and experimental probe (right) for 
Cxcr4. (HI=Hippocampus, VZ=Ventricular Zone, CCi=Cingulate Cortex, IC=intemal capsule, LOT=Lateral
Olfactory Tract, cl=claustrum, ic= internal capsule).
156
5.3.53
C C . G
v o r
CFr
"LV
pi, CPf
C C , G
LV
G E
c p
LOT
A C , a
CC, GCCi
CFr
pi, CPf
Fig. 5.10; Coronal sections from El 6 Brain showing control probe (left) and experimental probe (right) for 
Cxcr4 (pl,C Pf=Pyram idal layer of the pyriform cortex, cp=Caudate Putamen, cl=claustrum, LOT=Lateral 
Olfactory Tract, AC»a=Anterior Commisure (Anterior part), GE=Ganglionic Eminence, LV=Lateral 
Ventricle, CC,G=Corpus Collosum (Genu), CFr=Frontal Cortex, DG Dentate Gyrus).
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5.3,5.4 Crcx4
This gene has been implicated in neuronal migration (see Chapter Four) and is 
seen to be expressed throughout the embryonic brain at all ages studied. However, this 
expression is increased through E14 and E16 within certain areas of the cortex such as the 
olfactory, or piriform cortex, cingulate cortex and corpus collosum, and the dentate gyrus 
of the hippocampus as well as in the neo-striatum. This work supports previous work 
carried out on hippocampal neuronal migration (Banisadr et al., 2002) and also 
olfactory/pyriform cortex neurons that suggests that calbindin-positive neurons of the 
claustral complex and piriform cortex originate within the sub-pallium and migrate to 
these areas by E16.5 (Legaz et a l, 2005).
These neurons may be utilizing the CXCR4/CXCL12 receptor/ligand relationship 
in order to achieve this objective as has been postulated for those cells migrating towards 
other regions of the cortex (Stumm et al., 2003b) and the hippocampus (Tham et al., 
2001; Banisadr et al., 2002).
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5.3.6 M ef2c
5.3.6.1 E12
Fig. 5.11; Coronal sections from E l2 Brain showing control probe (left) and experimental probe (right) for
Mef2c. (LV= Lateral ventricle).
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Fig. 5.12; Coronal sections from El 4 Brain showing control probe (left) and experimental probe for Mef2c 
(IIIV=3rd ventricle, CFr= frontal cortex, SP=subplate, MZ=marginal zone, CP=Cortical Plate, LV=Lateral 
ventricle, GE=Ganglionic Eminence, VZ=Ventricular Zone, IZ= Intermediate Zone).
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Fig. 5.13; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Mef2c. (CRs=Retro-spinal Cortex, Clr=Infra-limbic Cortex, GE=Ganglionic Eminence, VZ=Ventricular 
Zone, LOT=Lateral Olfactory Tract, CC,T=corpus collosum, trunk, Cln=insular/rhinal cortex).
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5.3.6.4 Mef2c
The results of the in situ experiments carried out using the Mef2c probe also 
supported previous work carried out on this gene:
It has been reported in the past that this gene is pro-neural and has been found in 
many areas of the adult human brain including the cortex, olfactory bulb, hippocampus, 
thalamus, striatum, basal forebrain, inferior colliculus and some nuclei of the 
hypothalamus (Leifer et a l , 1994; Lin et al., 1996) and within the developing brain; in 
the cortical sub-plate of the cortex and cortical plate (Lin et al., 1996). It is a downstream 
transcription factor of Ngn2 (Mattar et a l , 2004), Islet 1 (Caubit et a l , 2005) and Mashl 
(Skeijanc and Wilton, 2000) so is expressed in post mitotic neurons that are 
differentiating or have differentiated.
This study confirmed the developmental expression of Mef2c within the sub plate 
and cortical plate, from E14 through E l6. It also shows that some expression can be 
detected within the dorso-caudal and most of the rostral areas of the ganglionic eminence 
and caudate putamen of the neo-striatum by E l6. This indicated that the cells in which 
mef2c is expressed within the neo-striatum are post mitotic, and in the process of 
differentiating or have differentiated and are starting to mature.
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5.3.7 G ucylp3
5.3.7.1 E12
Fig. 5.14; Coronal sections from E12 Brain showing control probe (left) and experimental probe (right) for 
Gucyip3. (LV= Lateral ventricle GE=Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone).
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Fig. 5.15; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Gucyip3. (LV=Lateral ventricle, VZ=Ventricular Zone, SVZ=Sub-Ventricular Zone, cp=caudate putamen, 
lC=Intemal Capsule, gp=Globus Pallidus, ChPI=Choroid plexus, GE=Ganglionic Eminence)
5.3.7.3 Gucylp3
The in situ data indicated very low expression of this gene before E l6, mirroring 
the results described in Chapter Four. However, at E l6, expression of this gene was 
found to be high within the caudate putamen of the neo-striatum and some areas of the 
cortex. This gene has been implicated in many signal-transduction pathways (see Chapter 
Four: Discussion) although the most probable function of this gene at this point in
164
♦  SV Z. LV
B
ChPI.LV
development, in theses areas, is in the process of angiogenesis (Saino et aL, 2004), as the 
distances within the cortex and underlying structures of the developing brain become to 
great for diffusion to supply these increasingly metabolically active areas with enough 
nutrients. Furthermore, vasculature can be seen starting to form within these deep 
structures around the age of E l6, when viewed under a low powered dissection 
microscope (personal observations).
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5.3.8 Ndrg2
5.3.8.1 E12
Fig. 5.16; Coronal sections from E12 Brain showing control probe (left) and experimental probe (right) for 
Ndrg2. (LV= Lateral ventricle GE=Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone).
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Fig. 5.17; Coronal sections from E16 Brain showing control probe (left) and experimental probe (right) for 
Ndrg2. (CC,G=Corpus Collosum (Genu), LV=Lateral Ventricle, GE=Ganglionic Eminence, VZ=Ventricular 
Zone, SVZ=Sub Ventricular Zone, CI=Cingulum, CC,G=Corpus Collosum (Genu), cl=Claustrum,
gp=Globus Pallidus)
5.3.8J Ndrg2
The in situ experiment showed that Ndrg2 was obviously up-regulated throughout 
the whole brain during the time window of study (E l2 to E l6). This is supported by 
previous studies (Nichols, 2003; Takahashi et a l,  2005a; Takahashi et a l , 2005b) that 
suggest that this gene is expressed by radial glia and GFAP-positive astrocytes, but could
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also invoke growth cones in neurites, indicating it may be involved in neuronal migration 
away from the VZ. This is corroborated by the fact that expression density is undoubtedly 
highest within the VZ, where the radial glia reside and give rise to neurons that will 
migrate away from this area to take up position within the developing CNS.
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5.5.9 Spock2
5.3.9.1 E12
LV
VZ GE
MxPr
Fig. 5.18; Coronal sections from E l2 Brain showing control probe (left) and experimental probe (right) for 
Spock2. (LV= Lateral ventricle GE=Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone,
MxPr=Maxillary Process).
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Fig. 5.19; Coronal sections from E14 Brain showing control probe (left) and experimental probe (right) for 
Spock2. (GE=Gangl ionic Eminence, IC=Intemal Capsule, IZ= Intermediate Zone, LV=Lateral Ventrical)
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5.3.9.3 E16
Fig. 5.20; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Spock2. (LV=Lateral Ventricle, GE=Ganglionic Eminence, IC=Intemal Capsule, IZ=Intermediate Zone,
LV=Lateral Ventricle)
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S.3.9.4 Spock2
The patterns of expression of Spock2 found in this study is supported by previous 
work (Marr et a l 2000) that confirms that this gene is expressed globally within the 
developing brain, and is probably involved in cell proliferation and migration, axonal 
outgrowth and synaptogenesis (Bonnet et a l , 1996; Charbonnier et al., 2000). In the case 
of this experiment, its increase in expression with the rostral WGE and neo-striatum 
during this developmental time window (E12 to E16) indicates it is expressed highest in 
post mitotic cells of the caudate putamen, in cells that are differentiating, or have already 
done so and are in the stages of axonal outgrowth and synaptogenesis (Charbonnier etal 
2000).
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5.3,10 Tiam2
5.3.10.1 E12
LV
LGE
M G E
Fig. 5.21; Coronal sections from E12 Brain showing control probe (left) and experimental probe (right) for 
Tiam2. (LV= Lateral ventricle LGE=Lateral Ganglionic Eminence, MGE=Medial Ganglionic Eminence).
173
5.3.10.2 E14
Fig. 5.22; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for
Tiam2. (LV=Lateral ventricle).
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5.3.10.3 E16
Fig. 5.23; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Tiam2. (cp=Caudate Putamen, LV=Lateral Ventricle, CCi=Cingulate Cortex, CC,G=Corpus Collosum,
Genu).
5.3.10.4 Tiam2
Previous literature on this gene has stated that in the adult mouse this gene is only 
expressed in areas of the brain that display either synaptic plasticity (the cortex and 
hippocampus) or neurogenesis (the dentate gyrus) and it is this finding that may give a 
clue as to the function of this gene (Chiu et a l, 1999). Expression is confirmed within the
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foetal brain, with a high expression within the hippocampus, cortex and corpus collosum; 
all areas that are developing and involved in plasticity and synaptogenesis at around E16 
in the mouse. This is also true for the cells of the neo-striatum and this may be the reason 
for the small amount of expression of this gene that is evident at E14 and E16 within the 
neo-striatum However, if this is true, then the question of why it is not expressed in a 
larger proportion of cells within this comparatively young area of the brain as most of the 
cells within the neo-striatum at this point in time will be post mitotic neurons. This 
indicated that this gene’s expression is limited to a subset of striatal neurons, or, more 
likely, is expressed in neurons that project from cortical areas into the striatum, to form 
synapses with cells within the caudate putamen. This would support previous literature on 
this gene that suggests it is closely related to a guanine exchange factor that maybe 
involved in neuronal migration and neurite extension (Ehler et al., 1997). It has also been 
shown to induce cell migration and affects neurite outgrowth when it is ectopically 
expressed in in vitro models (N1E-115 neuroblastoma cells). (Leeuwen et a l, 1997).
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5.4 Discussion
The experiments described in this chapter have validated the findings of the micro 
array experiment described in Chapter Four for all the genes selected. They have also 
allowed us to visualise the spatial expression patterns of the candidate genes selected 
from the work carried out in Chapter Four, as well as confirm/validate their temporal 
expression patterns found earlier.
The spatial expression patterns of these genes is important to know as we can tell 
from the approximate position of the cells in which the particular candidate gene is 
expressed, whether it is in a cell that is proliferating, migrating, differentiating or 
developing.
A further set of in situ experiments, giving the spatial information of these 
candidate genes further through development, and perhaps after maturation of the brain 
may well have given us a wider picture of which genes are, in fact, involved in 
synaptogenesis and migration, and which are perhaps genes expressed in most areas 
anyway. This may be useful to pursue in future experiments.
Many of the genes described here have been described previously as associated 
with the developing striatum. However, they have generally not been prominent in this 
respect, for example, Foxpl and 2 which are highly up-regulated in this screen have been 
associated with striatum in a small number of studies but have not been widely associated 
with striatal development. One contribution of my study is to bring genes such as Foxpl 
and 2 to prominence.
Although, as stated in Chapter Four, one previously unknown gene was chosen to 
follow up as a candidate marker gene, due to the technical difficulties in making suitable 
primers for this cDNA clone, it had to be dropped before the in situ hybridisation 
experiment.
Although a number of the genes that have been followed up in this chapter have 
also been seen to be expressed in cortex, this does not necessarily count them out as 
markers of striatal differentiation. The fact that these genes may have different expression 
patterns than other cells, in certain genes, may well be utilised to build up a phenotype’s 
genetic signature over certain periods such as differentiation, which will set it apart from 
other cell that may express some of the same gene, just at different times, or in different 
amounts.
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5.4.1 Conclusions
This in situ data has expanded on what was found during the micro array screen 
described in Chapter Four. It has also confirmed and been supported by previous reports 
on some of the candidate genes, and has raised some very interesting hypotheses about 
some of those genes about which only small amounts was known. Only future 
experiments will give answers as to whether these hypotheses are correct, but if they hold 
true then at least two of the candidate genes highlighted during the micro array screen 
may well be good markers for different sub-types of developing striatal neurons that are 
migrating out of the S VZ and into the neo-striatum to form the mature striatum.
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Chapter Six:
6 Gene expression changes during differentiation of mouse 
primary foetal striatal cells i n  v i t r o .
6.1 Introduction
As set out in the introduction to this thesis, in order for most stem cell populations 
to be used for cell replacement on Huntington’s disease, they will need to be directed 
towards a striatal phenotype and then transplanted into the adult CNS at the appropriate 
developmental stage as it is crucial to have cells of the same phenotype as the ones lost to 
the disease process. In addition, the cells must be transplanted at the appropriate 
developmental stage; if they are taken from foetuses that are too young, then the 
phenotype will not have been specified, and if from foetuses that are too mature, then 
they will be unable to survive and integrate into the host circuitry. This knowledge has 
been obtained from studies in which rat embryos of different gestational stages were used 
to derive striatal cells for implantation into quinolinic acid-lesioned rats (a lesion model 
of HD) (Fricker et al., 1997a; Fricker et a l, 1997b). The optimum gestational window 
was assessed according to the gestational stage at which foetal striatum produced the 
optimum transplants in terms of both histological appearance and improvements on 
behavioural testing. Such transplant experiments are ultimately the only way in which 
cells can be tested fully for functionality. However, such experiments are labour- 
intensive, costly, and take a substantial period of time from transplantation of the cells to 
the read-out (typically 12-18 weeks minimum). Thus, it is not an appropriate approach for 
screening for cellular phenotype.
It is likely that screening of developing cells for their capacity to produce MSNs 
will become important when developing protocols to ‘direct’ cells towards striatal MSN 
phenotypes as this process is likely to be complex and to require multiple systematic 
manipulations of many factors. We know that development of the nervous system 
depends on the temporal and spatial gene expression changes in neural progenitor cells 
that allow them to give rise to distinctive cell types in the mature CNS (Pierani et al., 
1999; Briscoe et al., 2000). These changes could involve many combinations of 
transcription factors and morphogens, some of which have different actions depending on 
concentration (see introduction: Chapter One), Commitment to a neuronal phenotype is
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thought to be a progressive process during which time the cell will be firstly controlled by 
extrinsic signals that trigger certain events within the cells own transcription machinery 
that will lead it along its developmental pathway to its final phenotype (Edlund and 
Jessell, 1999). Thus it will be necessary to have a relatively simple screening procedure 
for a striatal-like phenotype following multiple manipulations of the culture conditions, 
as it will not be possible to take all cells right through a transplant paradigm for practical 
and economic reasons. Thus a ‘read-out’ or ‘genetic signature’ that can be used in 
developing cells that have not yet expressed mature phenotypic markers is required and 
developmentally regulated gene expression changes are an obvious tool for this.
I have already identified a number of gene changes associated with striatal 
differentiation and in this chapter I explored the extent to which these gene changes are 
associated with striatal differentiation in vitro. This was important to do, because it 
cannot be assumed that striatal cells developing in vitro, and thus separated from their 
normal cell contacts and exposure to morphogens, will behave in exactly the same way as 
they would have done in vivo. That this is the case, is suggested by a number of findings: 
For example, striatal cells that develop in vitro express much lower levels of DARPP-32 
than would be seen in normal brain tissue, suggesting that the phenotype has not 
developed fully (Nakao et al., 1994). A second reason for wishing to characterise the 
developmental gene expression patterns on this population of cells is to select cells at the 
optimum developmental stage for transplant purposes. Once protocols are available for 
directing cells towards an MSN phenotype, it will be necessary to have methods for 
recognising when cells are at the optimum developmental stage; such methods are not 
currently available. As discussed above, cells that are either too immature or too mature 
developmentally are not able to reconstruct brain circuitry in a functional way. A 
developmental ‘gene signature’ is a potential way of being able to achieve this.
A further use for ‘developmental gene signatures’ would be to analyse the 
characteristics of neural precursor cells. Although they do maintain certain aspects of 
their molecular specification even after significant expansion periods (Parmar et al., 
2002), there are time dependant changes in gene expression (Zietlow et al., 2005), In 
order to interpret changes in expression of these genes in cells allowed to differentiate in 
vitro after spending time in culture in proliferating conditions (as done in Chapter Seven), 
it is key that the gene expression patterns have been characterised during the 
differentiation of primary (non-expanded) developing striatum,
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It must also be remembered that some of the candidate marker genes in this study 
have never been studied within the context of foetal striatal development so nothing is 
known about their expression in vitro, whether it is markedly changed from that seen in 
vivo, and if it is, whether this has an effect on the cells phenotype and genotype. This 
knowledge is a necessary pre-requisite to developing methods for directing cells towards 
the phenotype we require in treating neurodegeneradve diseases such as HD and PD.
An important starting point was to assess candidate marker gene expression 
patterns when the cells are just taken out of the foetus, and differentiated straight away in 
vitro using standard tissue culture techniques. E12, E14 and E16 primary cells, dissected 
from the developing WGE were to be used, as had been done in the micro array assay, 
except in this experiment, they would be differentiated in vitro. Cells of the same 
developmental stages were dissected from the developing cortices of the same foetuses in 
order to understand the specificity of these changes.
6.1.1 Analysing the problem.
Micro array or Q-PCR would have allowed us to fully quantitate the expression of 
the candidate genes in samples of cells taken at different stages of culture. However, the 
availability and expense of these techniques precluded their use in this experiment
Instead semi-quantitive RT-PCR was used to give an indication of the levels of 
expression of certain maker genes within culture samples at different stages of expansion. 
RT-PCR was deemed to be within the project budget and the equipment needed was 
readily available to the laboratory. The primers were also available and had been 
optimised for use in the earlier in situ experiments.
To demonstrate that neuronal differentiation occurred in cultures derived from all 
ages of foetal striatum used in this study and that numbers of neurons differentiating from 
the culture did not vary widely between conditions, immuno-cytochemistry was carried 
out on differentiated cells in order to illustrate the presence of neurons within the culture 
using antibodies against GABA (the majority of neurons in this brain region would be 
expected to be GABA-ergic) and confirmed by plll-tubulin. Additional histological 
analysis was performed to visualise the products of the two most highly up-regulated 
genes. Double-staining was performed to see whether FOXP1 and FOXP2 were co­
localised in the same cells.
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6.1.2 Aims.
As discussed in Chapter Four of this thesis, a reproducible panel of candidate 
marker genes, deemed to be most interesting over the period of maximal striatal 
neurogenesis, were selected for use.
These candidate marker genes were supplemented by four other genes known to 
be involved in either enhancing or repressing pro-neural genes; these were
Groucho/TLE (Transducing-Like Enhancers of Split)/Grg (Groucho related gene). 
This gene family is known to bind to members of the Hairy Enhancer of Split (HES) 
family of transcription factors to cause inhibition of neuronal differentiation and extended 
proliferation of neuronal progenitors (Hatakeyama et al., 2004; Kageyama et a l , 2005), 
Mash-1 (a pro-neural bHLH transcription factor that causes neural progenitor 
cells to differentiate into neuronal lineages (Parras et a l , 2002)) and
Meis-2, a transcription factor expressed in both the developing and adult murine 
striatum (Cecconi et a l , 1997; Toresson et a l , 2000a).
Islet-1, a marker of striatal neurons is a LIM-homeodomain protein, and marks the 
overwhelming majority of neurons of the striatal complex (Toresson and Campbell, 2001) 
and has been implicated in neuronal differentiation which also lends support to the 
hypothesis that striatal progenitors are still present within the culture after prolonged 
expansion, although whether they are still specified to differentiate into mostly MSNs, as 
in vivo is not clear from this work.
The aims of this experiment were to test selected up-regulated candidate marker 
genes from the Affymetrix micro array study (Chapter Four) to;chart the differentiation 
of embryonic striatal cells in vitro. This would provide data on the validity of these genes 
for use as markers of MSNs in cultured cells and give an indication of how closely 
differentiation of striatal cells in vitro mirrors that in vivo.
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6.2 Methods.
Dissection of tissue, tissue culture, RNA extraction and RT-PCR were all carried 
out as per methods laid out in Chapter Two; Methods.
6.2.1 Primer Optimisation
As RT-PCR is a semi-quantitative method of measuring the mRNA signal in 
tissue it was imperative that each primer was optimised so that the cycle number used 
would produce a product that was in the linear phase of amplification.
The following primers and conditions were used in this experiment:
’rimer pairs
Forward Reverse MgCI2
Buffer
Annealing
Temp.
Optimal
Cycle
Primer
length
conditions
(°C) * (bp)
Cxcr4 AGG AAA CTG CTG GCT GAA AAG GAT GAC TCC CAA AAG GAT GAA G 1.5 55 30 383
Foxpl GCA GCA GCT CTG GAA AGA AG GCA GAC TTG GAG AGG GTG AC 1.5 55 30 481
Foxp2 AAG TTT GGG CTA TGG AGC AG GTC ACA AGT TCG TTC TCA TTC C 1.5 58 30 342
ucho/TLE/Grg TAA GGT GTG GGA CAT CAG CC TGT CAG CTC TGC CTT TAT GC 1.5 54 30 193
Gucy1B3 TGA GTG TGA GGA TGA ACT GAC TG AGG AAG GAC AGA ATA CAG CAA TG 1.5 55 32 327
IsJetl CAG CAA GAA CGA CTT CGT GA GGA CTG GCT ACC ATG CTG TT 1.0 54 30 779
Mashl AAG TCA GCG GCC AAG CAG GAT AAG CGC AGC GTC TCC ACC TTG CTC ATC T 1.5 58 30 245
Mef2c CTG TGC GAC TGT GAG ATT GC ACT GTT ATG GCT GGA CAC TGG 1.5 55 30 344
Meis2 GAC TCC GAG AGT TAT AAC TA ACT AAA GGA CAC ATG GAC GG 1.5 58 34 351
Ndrg2 CCA GGG ACA GAC TCA CTC TG GTC TCG GCG TTG TTG TAG C 1.5 55 30 649
Spock2 CCT TCT TCA ACT CCT GTG ATA CC CCT CTT CTG TCT CCT TTT CTT CC 1.5 55 28 356
Tiam2 TCG GAG GAA GTG GAA ACA ATA C CTG GTC TGG CTC TTT AGC AGT C 1.5 58 30 329
G3PDH TCC ACC ACC CTG TTG CTG TA ACC ACA GTC CAT GCC ATC AC 1.5 55 25 451
Table 6.1; PCR Primers used during this experiment, with optimised conditions
Primers were optimised with 0.5pl of control cDNA (a mixture of equal aliquots 
of E12, E14 and E16 Ctx and WGE primary cell cDNA samples). Once the primers were 
shown to have been optimised to a cycle number that was within the exponential 
amplification phase of the PCR each sample was run.
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6.2.2 Differentiation experiment.
Three biological replicates of both WGE and cortical tissue were dissected from 
three separate batches of embryos (each biological replicate sample was derived from 
tissue pooled from all the pups of a separate time-mated CD1 (ICR) dam). The tissue was 
dissected as per the methods set out in Chapter Two and put into single cell suspension 
by trypsinisation. The cell samples were counted and put in to differentiation media in 
either six well plates (seeded at 2,000,000 cells/well) or in 24 well plates (plated at
100,000 cells/well) and differentiated at 37°C in a tissue culture incubator. The following 
time points were selected for analysis:
1. Day 0 (primary cells)
2. Day 4
3. Day 7
and
4. Day 10
At the above times, samples were taken from the six well plates (containing at 
least 2,000,000 cells) or, in the case of Day 0, straight after dissociation and counting; 
these were centrifuged at 3000 x g for 3 minutes, the media taken off and replaced with 
RNA Later stabilising solution. All samples were frozen to -80°C pending RNA 
extraction. Cells plated on cover slips were fixed with 4% PFA (for those cells being 
stained for p-Tubulin), 4% PFA/Gluteraldehyde (for those cells being stained for GABA) 
or ice cold Methanol (for those cells being stained for FOXP1 and FOXP2) and then 
washed three times with PBS before being stored at +4°C in PBS azide pending immuno 
cytochemistry.
RNA samples for both experiments were processed using Qiagen Qia-shredder 
tubes and RNeasy kits with RNAse free DNAse (as per manufacturer’s instructions) 
followed by cDNA synthesis using Thermoscript RT protocol (outlined in Chapter Two; 
Methods).
6.2.2.1 Experimental Controls
This experiment compared the expression of all the candidate marker genes and 
three supplementary genes with the expression of a known housekeeping gene; 
glyceraldehyde-3-phosphate dehydrogenase (G3pdh).
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The abundance of G3pdh in eukaryotic cells is known to be relatively unaffected 
by external factors (Thellin et a l , 1999). In molecular analysis the level of G3pdh is often 
used as a reference value for comparison between different cell lysates or gel loadings in 
order to compare different samples.
cDNA samples were then equimolarised using G3pdh as a reference to make sure 
all samples being run were of approximately the same concentration. Once each of the 
cDNA samples (n=3 for each condition/area of brain and Day) had been equimolarised 
the cDNA was probed for the supplementary and candidate marker genes using PCR.
Data used for genetic expression of primary cells (Day 0) was the same for both 
this study and the expansion study described in Chapter Six.
6.2.2.2 Analysis.
The results of PCR experiments were quantified by mixing 2pl of xlO DNA 
loading buffer into the 20pl PCR reaction and then running lOpl of this mixture on a 1% 
agarose gel at 117 volts for 24 minutes before visualisation using spot densitometry 
(AlphaEase2200 imaging system and AlphaEaseFC software). Each gel was 
automatically analysed by the software for gel background and each sample was 
normalised using these figures to account for changes in light conditions and exposure 
times. This method gave a cDNA concentration figure for each of the genes probed for in 
each sample. This figure was then normalised against the corresponding sample’s G3pdh 
figure (obtained after equimolarisation) in order to account for any minor differences in 
cDNA concentration that could not be catered for during equimolarisation. Data were 
analysed using analysis of variance a (Statistica 5.0; StatSoft inc.).
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6.3 Results.
For all experiments, values were normalised against G3pdh expression. The 
average (n=3) was taken from each for the description. Results from each gene will be 
described first. The graphs show the levels of expression compared to the control gene 
(G3pdh) expression seen at the same time point. Although all the genes were analysed 
using G3pdh as a control gene in order to equimolarise between samples, the reader 
should be aware that the aim intended is to be able to compare the expression of the 
candidate marker/supplementary gene, at different time points in this cell population’s 
differentiation, compared with the expression levels of that particular gene at Day 
0/primary cells that have just been dissected out of the foetus.
The results will then be summarised at the end of this results chapter.
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Fig. 6.1; GABA staining in primary cultures after 7 days differentiation in vitro. GABA was used to label neurons (most 
striatal neurons are known to be GABA-ergic). All cultures showed a similar number o f  neurons per field (although quantification was 
not performed for technical reasons). El 6 cells showed a raised proportion o f large Hoechst (blue) stained nuclei, which, from 
previous studies indicates an increasing number o f  astrocytes. This was fully expected as by E16 the gliogenic switch has occurred 
with increased astrocytes production. P-III Tubulin (Red) also shows neuronal presence in E14 primary differentiated cultures (Scale
bar =200pm).
187
\ ‘
6.3.1 Gene changes in differentiating cells
For many of the genes, a dip in expression levels were seen at day 4 compared to 
day 0 with some recovery by day 7. This dip may have been masked in genes in which 
there was continued fall of expression levels. The reason for this decline is not presently 
known, although one explanation is that it is related to damage done during the process of 
cell extraction and preparation as a single cell suspension. During this process there may 
be cell membrane damage and cells tend to ‘round up’ and lose their processes. This may 
be associated with a fall in some levels of gene expression and recovery may have 
occurred by day 7. All gene levels are described relative to G3pdh.
6.3.2 Cxcr4
Day 0 levels can be seen to rise with increasing developmental age as 
demonstrated in Chapters Four and Five, thus confirming the micro array data and the in 
situ results. An ANOVA demonstrated levels of expression to be higher in striatal tissue 
at all gestational ages (F(i,4)=24.29,p<0.05; F(i,4)=152.72,p<0.001; F(i,4)=129.31,p<0.001 
for E l2, E l4, and E l6 respectively). Indeed, cortical levels remain low in E12 cultures 
and appear to drop off steeply in E14 and E l6 cultures, whilst striatal levels rise a little 
during the differentiation of E12 cells, remain relatively stable at a higher level in E14 
cells and fall in E l6 cells.
F ig  6 .2 ;  E x p r e s s io n  o f  Cxcr4 i n  v a r y in g  a g e s  o f  p r im a r y  F N P  c u l t u r e  a t  0 , ^  7  a n d  1 0  d a y s
d i f f e r e n t ia t io n
14(0) 14(4) 14(7) 14(10)
A g .  o f  p r im a r y  c u l tu r e  a n d  d a y s  d i f f e r e n t i a t i o n
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6.3.3 F oxpl
Day 0 levels didn’t change dramatically over the gestational window examined 
for either striatum or cortex. Levels of FoxPl were generally higher in the striatum at 
E12 (F(i)4)=92.35,p<0.001), but this effect had disappeared by E14 and E16. During the 
differentiation of E12 cells levels fell significantly in striatum over the differentiation 
period (effect of day; F(3,6)=22.58,p<0.01); there was also a fall in cortical tissue. There 
was little change in levels of both areas at E14 and levels declined overall in El 6 cultures 
(F(3,6)=29.94,p<0.001), although may have been rise by Day 10 although this was not 
significantly so.
F ig  6 .3 ;  E x p r e s s io n  o f  Foxpl i n  v a r y in g  a g e s  o f  p r im a r y  F N P  c u l t u r e  a t  0 .  4 , 7  a n d  1 0  d a y s
d i f f e r e n t ia t io n
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6.3.4 Foxp2
Primary striatal cells increased expression of Foxp2 with increased gestational age 
which agreed with the micro array data. Across all conditions striatal expression levels 
were higher than cortex (F(i54)=1 80.36, p<0.01; F(i>4)=23.44,p<0.01;
F(i,4)=814.09,p<0.001 for El 2, E14 and E16 respectively). Striatally derived cell 
expression of Foxp2 rose in E12 throughout the differentiation period
(F(3,6)=8.42,p<0.05), levels remained largely steady in E l4 cells while a significant fall in 
expression was observed in E l6 striatal cells (F(3j6)=1 1.72,p<0.01).
F i g  6 . 4 ;  E x p r e s s i o n  o f  Foxp2  i n  v a r y i n g  a g e s  o f  p r i m a r y  F N P  c u l t u r e  a t  0 ,  4 ,  7  a n d
d a y s  d i f f e r e n t i a t i o n
1.5
1
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12(0) 12(4) 12(7) 12(10) 14(0) 14(4) 14(7) 14(10) 16(0) 16(4) 16(7) 16(10)
Age of primary culture and days differentiation
Fig. 6.5; This Figure shows the expression o f  FOXPl(Red) and FOXP2 (Green) in E16 o f  primary WGE after 7 days o f  
differentiation. Arrows indicate cells single labelled for Foxp2 (no FOXP1) (Nuclei stained Blue with Hoechst) (Scale bar =200pm).
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6.3,5 G ucyip3
Primary expression levels of Gucylfi3 showed an increase between E12 and E l6 
confirming the results seen in the micro array. E l2 striatally derived cells showed little 
expression changes of this gene through differentiation, although cortically derived cells 
showed an overall increase over the period of differentiation. E l4 striatal cells also 
showed no change over the differentiation period although E16 cells showed a significant 
fall in expression (F(3,6)=169.22,p<0.001). There was no significant difference between 
striatal and cortical expression in any of the age groups.
R g  6 . 6 ;  E x p r e s s io n  o f  G  ucy1B3 i n  v a r y in g  a g e s  o f  p r im a r y  F N P  c u l t u r e  a t  0 , 4 ,  7  a n d  1 0  d a y s
differentiation
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6.3.6 M ef2c
Mef2c levels were seen to rise between E12 and E l6 in primary cells, mirroring 
the Asymetrix micro array results. E12 expression was seen to increase over the 
differentiation period (F(3,6)= 18.10,p<0.01), E14 expression was seen to rise slightly 
overall (F(3>6)=5.48,p<0.05), while E l6 levels stayed reasonably stable throughout the 
period of differentiation. There was no difference between cortical and striatal 
expression in E l2 cells, although a difference between cortical and striatal cells was 
observed in E14 F(i>4)=48.38,p<0.01) and E16 F(ij4)=59.69,p<0.01).
Fig 6.7; E xpression  of M ef2c in varying a g e s  of p reim ary  FNP culture  a t  0, 4, 7 and  10 days
d i f f e r e n t i a t i o n
2
x
0
12(0) 12(4) 1 2 (7 ) 12(10) 1 4(0) 1 4 (4 ) 14(7) 14(10 )
Ao* o# prtnary ct*u» and <fcys of dffarertiBttan
1 6(0 ) 1 6 (4 ) 16(7) 16(10)
192
6,3.7 Ndrg2
Ndrg2 primary cell expression was seen to rise between E12 and E l4, again 
mirroring the micro array and in situ results. E l2 cells showed a significant increase in 
expression of this gene over the differentiation period (F(3i6)=25.29,p<0.001). E14 cells 
also showed an increase in expression (F(3j6)=12.63,p<0.01), however, no significant 
increase was observed in E16 cells through the period of differentiation. There was no 
significant difference between striatal and cortical cells in any of the gestational stages.
F ig  6 .8 ;  E x p r e s s io n  o f  Ndrg2 in  v a r y in g  a g e s  o f  p r im a r y  F N P  c u l t u r e  a t  0 , 4 , 7  a n d  1 0  d a y s
differentiation
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6.3.8 Spock2
Levels of Spock2 were seen to rise between E12 and E l6 primary cells which 
support the results of the micro array and in situ. However, E12 Striatal cell expression 
levels decreased over the differentiation period (F(3£)=13.18,p<0.01). E14 expression 
also fell significantly through the differentiation period (F(3,6)=5.54.p<0.05, as did E l6 
(F(3,6)=22.69,p<0.01). No significant difference was observed between expression seen in 
striatal and cortical cells.
F ig  6 .9 ;  E x p r e s s io n  o f  Spock2 i n  v a r y in g  a g e s  o f  p r im a r y  F N P  c u l t u r e  a t  0 ,  4 ,  7  a n d  1 0  d a y s
d i f f e r e n t i a t i o n
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6.3.9 Tiam2
Levels of Tiam2 increased between the ages of E12 and E l6 primary cells, 
supporting the results seen in the micro array. There was no change in the low expression 
levels of Tiam2 seen during the differentiation of E12 cells, compared to the higher 
expression seen in E12 cortical cells (F(i,4)=46.45,p<0.01). E14 cells showed an increase 
in Tiam2 expression levels (F(3,6)=l 1.80,p<0.01) showing a significant difference to E l4 
cortical expression, which fell over the same period (F(ij4)=298.48,p<0.001). E16 striatal 
expression fell during differentiation, (F(3,6)=6.20,p<0.05) which was also observed to be 
different to E16 cortical cells, which had higher expression levels throughout the same 
period (F(ii4)=30.62,p<0.01).
Fig 6.10; E x p ress io n  of T ism 2  in varying a g es  of prim ary FNP cu ltu re  a tO , 4, 7 an d  10 days
differentiation
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6,3.10 Groucho/TLE/Grg
Expression levels of Groucho/TLE/Grg increase between primary E l2 and E l6 
cells, supporting the micro array results seen in Chapter Four. However, E12 and E l6 
expression levels in both striatally and cortically derived cells are reduced through the 
differentiation period (F(3,6)=112.24,p<0.001) and (F(36)=38.43,p<0.001) respectively 
(E l4 cells also show a downward trend although this was not significant). Striatal cells 
expressed higher levels of Groucho/TLE/Grg in E12 cells (F(i 4)=65.66,p<0.01), although 
there was no significant differences between E14 and E l6 striatal and cortical expression 
of Groucho/TLE/Grg.
F ig  6 .1 1 ;  E x p r e s s io n  o f  Grouch/TLE/Grg 
in  v a r y in g  a g e s  o f  p r im a r y  F N P  c u f t u r e  a t  0 , 4 , 7  a n d  1 0  d a y s  d i f f e r e n t i a t i o n
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6.3.11 Isle tl
Levels of striatal expression of Isletl increased between E l2 and E l6 primary 
cells, supporting the results seen in the micro array study described in Chapter Four. 
Expression was reduced through the differentiation period in E12 (F(36)=6.91,p<0.05), 
E14 (F(356)=97.46,p<0.001) and E16 cells (F(3,6)=33.65,p<0.001). This was significantly 
different from cortically derived cells, that showed very low levels of expression of Isletl 
throughout the study in all three gestational ages (F(i54)=228.01,p<0.001), 
(F(M)=830.88,p<0.001) and (F(M)=1 15.15,p<0.001) for E12, E14 and E16 cells 
respectively.
Fig 6.12; E xpression of is le tl  in varying ages of primary FNP culture a t 0, 4, 7 and 10 days
differentiation
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6.3.12 M ash 1
Mashl expression was seen to reduce between the gestational ages of E12 and 
E l4 in striatal cells and increase slightly in cortical cells. In all gestational ages 
expression of Mashl reduced significantly by Day 4 and remained low throughout 
differentiation ((F(3j6)=44.55,p<0.001), (F(3)6)=6.39,p<0.001) and
(F(3,6)=277.54,p<0.001) for E l2, E l4 and E16 respectively). This was significantly 
different to expression in cortical cells in all three gestational ages 
((F(M)=87.64,p<0.001), (F(i.4)=107.24,p<0.001) and (F(M)=107.70,p<0.001) for E12, 
E l4 and E l6 respectively).
F ig  6 . 1 3 ;  E x p r e s s i o n  o f  M a s / r f  i n  v a r y in g  a g e s  o f  p r im a r y  F N P  c u l t u r e  a t  0 ,  4 ,  7  a n d  1 0  d a y s
d i f f e r e n t i a t i o n
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6.3.13 Meis2
Primary levels of Meis2 were similar in all three gestational ages in both striatum 
and cortex. Expression levels of Meis2 reduced throughout the differentiation period in 
E12 striatal cells (F(3,6)=47.06,p<0.001) and E16 cells (F(3,6)=18.1 l,p<0.01) but not 
significantly so in E l4 striatal cells. Cortical cells were also seen to reduce expression. 
Striatal levels of Meis2 were generally higher than cortical levels, although this was only 
seen to be significant at E12 (F(ij4)=24.67,p<0.01).
F ig  6 .1 4 ;  E x p r e s s io n  o f  M e i s 2 i n  v a r y in g  a g e s  o f  p r im a r y  F N P  c u l t u r e  a t  0 ,  4 ,  7  a n d  1 0  d a y s
differentiation
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Table 6.2; Summary of the gene expression changes seen in this study over the differentiation period (from primary cells through to Day 10 of differentiation). The arrow
shows the general trend seen in the levels of expression of each gene. Ideally a comparison between all genes at all ages and brain regions would have been run on one PCR 
and one gel, however, due to practical reason this was not possible. However, the background on each gel was taken into account during each analysis. There were also no
major differences between age groups in cell culture (see histology).
6.4 Discussion
In this study I looked at the expression patterns of my candidate genes in primary 
murine neural striatal cells as they differentiated in vitro over a ten day period. It was 
important to characterise the gene expression patterns occurring during in vitro 
differentiation of these cells in order to be able to interpret the differentiation of cells in 
other conditions; for example the differentiation of striatal precursors that have been 
allowed to proliferate in vitro (as in Chapter Seven) and the differentiation of ES cells 
after exposure to protocols to ‘direct’ their phenotype. Although it wasn’t the primary 
aim of this study, it is also interesting to assess how closely striatal differentiation in vitro 
recapitulates that occurring in vivo.
In order to understand the changes seen in this experiment, it is important to put 
the timing of the in vitro differentiation experiments into context. The cells dissected out 
at E12 would still have carried on developing as I put them into culture so by Day 4 of 
differentiation in vitro these cells may be expected to be comparable in age to E l6 
primary cells. Likewise, Day 4 of differentiation for E14 cells may be expected to be the 
equivalent to E l8 and thus is already beyond the time point looked at in the Asymetrix 
experiment described earlier. It is important to bear this in mind when analysing the 
above results. However, although there is a wealth of experimental data demonstrating 
that striatal cells between E12 and E16 are able to differentiate in vitro into cells with 
characteristics of MSNs (Flicker et a l, 1997a; Fricker et al., 1997b), it cannot be 
assumed that the differentiation of such cells will necessarily occur precisely as it would 
in vivo, perhaps because the insult of cell preparation causes damage and perturbs certain 
cellular processes or because cells plated in a culture dish are not exposed to all the 
developmental signals that they would be exposed to in vivo.
It must also be remembered that not all cells in the developing foetal brain at E12, 
E14 or E l6 are differentiating; a proportion are still proliferating or may have 
differentiated at an earlier stage. Furthermore, although the majority of cells within the 
developing striatum during this time are neuronal, there are also other populations of cells 
within the developing striatum, including glial progenitors. Such cells may have an effect 
on the overall gene expression within the cultures, although even by E l6, the majority of 
striatal cells are neurons and neuroblasts and so this effect would be expected to be
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relatively small. However, these results still allow us to estimate what is actually 
happening to the cell populations we dissect out of the developing foetus (at varying 
ages) after they have been put into culture and differentiated in vitro. As such, it is 
relevant to take the candidate marker genes picked from the earlier micro array and try to 
work out which of these genes, if any, is a good marker of striatal differentiation.
Changes in gene expression were analysed in both developing striatum and 
cortex. As shown in previous chapters, none of the genes were found to be expressed 
exclusively in striatum, although some were expressed in much higher levels in striatum;
i.e. Foxpl, Foxp2. These genes may well be useful as striatal markers during 
differentiation. Clearly, the exclusive expression of a gene in the striatum would be 
significant as it would indicate that the gene had the potential to be used as a striatal- 
specific marker. To date, the only clearly striatal specific marker we have available is 
DARPP-32, which is found exclusively in terminally differentiated MSNs and not 
developing cells. A striatal specific developmental marker would be useful as it would 
provide the potential to be able to select and purify striatal cells for cell transplantation 
purposes. However, this was not the aim of the current project and changes that occur in 
both brain areas can still be useful for the purposes of developing a gene expression 
'signature' of developing striatal cells.
Some of the changes seen during this study may not be meaningful in terms of 
cell development, for example, in many of the genes studied, there was a fall in 
expression at Day 4 with an increase in expression by Day 7. This initial drop could be 
interpreted as the reaction to being put into culture with a substantial proportion of the 
cells being stressed in the initial stages with subsequent recovery.
There were also some technical limitations that also need to be bom in mind when 
interpreting these results:
• Due to limitations in the numbers of samples that could be run on the one PCR 
machine available and the space available on one agarose gel, it was not possible 
to run all genes and all ages on one gel. For any one gene at each of the three 
gestational ages, all differentiation time points for both striatum and cortex were 
run on the same gel and so were directly comparable. However, by comparing 
each gene's expression level with that of a housekeeping gene that remains
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constant, and by taking into account the background of all the gels while 
analysing them I have attempted to make all the data comparable
* Gene expression levels in all cases relate to a population of cells and not 
individual cells, although at the developmental ages examined, the majority of 
cells are differentiated or developing MSNs. One method of analysing this further 
would be to use antibodies for proteins that have been coded for by these 
transcripts and this was done for the Foxp genes, although at the time of writing 
antibodies were not available for the majority of the candidate genes.
* Due to RT-PCR being a semi-quantitative method of analysis it can be said that 
the results of this screen can only be used as “indications” of the true gene 
expression changes that are occurring at the different stages of culture tested. 
However, this method can be argued as being as valid for detecting quantitative 
differences in gene expression as long as the following have been adhered to: (i) 
the PCR cycle number has to be proven to be within the linear phase of 
amplification; (ii) the use of replicates and statistical analysis must prove 
significance (Halford, 1999). (In this instance the cycle number had been 
optimised) and 3 biological replicates of each condition were used. This therefore 
reduced the chances of Type 1 errors being made (where the null hypothesis is 
rejected but in fact is true; i.e. that there was no difference between expression 
levels of a gene between the start of expansion/differentiation and the end point of 
the experiment).
* Other examples of errors that could have occurred have already been discussed on 
previous chapters and include inaccuracies in gauging gestational age, dissection 
inaccuracies, cell miscounting, pipetting errors during the RNA extraction, RT- 
PCR and quantification of cDNA product
6.4.1,1 Interpreting gene changes in differentiating cells.
For many, although not all, of the genes examined, the changes in the primary 
tissue (Day 0) samples changes with gestational age in accordance with the results of the 
Affymetrix study; i.e. Cxcr4, Foxp2, etc. However, this was not the case with all the 
candidate marker genes studied; i.e.Foxpl, Spock2 and Tiam2. These differences in 
results could be due to experimental error or due to the differences in cell populations
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present between normal development and what is found in vitro, although at this stage it 
is hard to say. Further replicates would need to be carried out know for sure.
As cells differentiated over the 10 days in culture, clear and significant changes in 
expression levels could be seen for some of the genes -  i.e. those changes seen in the 
levels of Foxpl, Foxp2, Ndrg2 Spock2 and Tiam2, although in others there was more 
noise; i.e. Cxcr4, Mef2c and Gucylfl3. In order to be used as markers of striatal 
differentiation, genes would have to have clear changes that were reproducible. In order 
to see if the changes seen in this study were reproducible, more replicates would ideally 
have to be carried out.
This is, to our knowledge, the first systematic longitudinal study of gene 
expression changes carried out in striatal cells differentiated in vitro.
Some of the changes seen in this study were largely anticipated; It is known from 
previous studies (Tamura et al., 2000; Shu et a l , 2001; Tamura et a l , 2003; Ferland et 
a l , 2003; Takahashi et a/., 2004) that Foxpl and Foxp2 are both expressed in the 
developing and mature brain, so these results are in accordance with what we know. 
However, both of these genes were shown to drop in expression levels in £16 cells that 
were between 4 and 7 days into their differentiation. What is not known is whether the 
levels of these repressor genes fluctuate between these periods. These results could also 
be due to the cultures being diluted by the increasing numbers of glia that are 
differentiating at this stage of development, or by the fact that some of the cells that 
express these genes are dying off earlier on in the differentiation period due to the insult 
of being put into culture.
6.4.1.2 Specific gene changes; those that recapitulate developmental stages
The majority of genes shown in this study may well be recapitulating normal
development as was seen in both the micro array study described in Chapter Four and the
in situ study described in Chapter Five. For instance; Groucho/TLE/Grg, Mashl, Meis2,
Isletl, Mef2c and Foxp2 possibly including Foxpl, Ndrg2 and Cxcr4, all look as if they
increase after being put into culture, although some of them do have a period in the first
four to seven days when expression seems to be reduced, although this could be down to
the cells rounding up and trying to deal with the stress of trypsinisation and being put into
culture as discussed earlier. Spock2 is certainly reduced in vitro, and Tiam2 does not
increase in expression as indicated by the Aflymetrix results. Why this is, is not known at
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this point, but further studies looking into the function of these genes may well provide 
answers.
The study of additional genes also gave a lot of information as these genes did 
react as they might in vivo;
Groucho/TLE/Grg codes for a gene that inhibits neuronal differentiation so it 
could be expected for this gene to fall sharply once differentiation began. The primary 
(Day 0) levels also support previous literature that indicates that E l6 is the peak of 
neurogenesis in the striatum (Fricker-Gates et a l, 2004a).
Isletl is known to be expressed within the developing LGE, marking out a domain 
known to generate striatal projection neurons. Once these cells have been bom, this gene 
is down regulated (Skogh et a l, 2003). Another hypothesis suggests that this gene 
continues to be expressed in just a small amount of cholinergic cells that reside within the 
striatum (Wang and Liu, 2001), however, if this were the case then it might be that the 
conditions o f culture either do not favour the differentiation of these cells or the amounts 
of Isletl expressed are too small to be picked up by this technique.
Mashl is a pro neural gene that works in conjunction with other transcription 
factors to specify neuronal identity (Lo et al., 1991; Guillemot and Joyner, 1993; Joyner 
and Guillemot, 1994; Hirsch et al., 1998; Horton et al., 1999). Expression of Mashl is 
found in the VZ at around El 0.5-El 2.5, and spreads into the SVZ in cells that continue to 
divide as they migrate (Porteus et al., 1994; Casarosa et a l, 1999). As these cells 
differentiate this expression is reduced as is seen in this study.
Meis2 has been reported to be a major influencing component of striatal 
differentiation neurons bom in the LGE at around E l0.5 onwards (Toresson et a l, 1999; 
Toresson et al., 2000a). By E16.5 this gene is reported to be down regulated within the 
striatum, only to be found in a small area of the cortical plate (Toresson et al., 2000a). 
Thus, these results support the previous literature and the data suggests this gene follows 
a normal expression pattern.
In conclusion, this study has indicated that once the cells are put into culture, after 
an initial period the surviving cells adopt gene expression patterns that would loosely 
mimic what is seen in normal development, in most genes. However, as development 
continues, the amount of glia differentiating within the culture rises and this might have 
an effect on the overall gene expression seen within these populations of cells as the gene
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pool is ‘diluted’ with genes specific to the rising numbers of glial cells being bom. The 
more these patterns are reproduced, the more reliable we can assume these changes to be, 
and the more confident we can be in using some of them for markers of striatal 
differentiation.
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Chapter Seven
7 Characterisation of gene expression changes in proliferating 
foetal neural precursors (FNPs).
7.1 Introduction
In previous chapters I identified a number of genes that are shown to be up- 
regulated in the WGE over the peak period of striatal neurogenesis and have validated 
this data for a small subset of genes using other methods of analysis. In Chapter Six I 
have used some of these genes to examine whether foetal striatal tissue allowed to 
differentiate in culture recapitulates some of the gene expression changes seen in vivo In 
this chapter I used the same techniques to characterise gene expression changes in foetal 
neural precursors (FNPs), derived from the foetal striatum that have been allowed to 
proliferate in culture.
Although trials in both animal models and in the clinical setting have provided 
‘proof of principle’, future mainstream clinical use of primary tissue remains unlikely for 
reasons of supply and demand. However, FNP cell populations may provide a source of 
viable cells that may be suitable for this purpose and are also more amenable to quality 
control procedures (see discussion of FNPs in introduction: Chapter One). FNPs that have 
been derived from the developing striatum and have been allowed to proliferate for a 
relatively short period of time in vitro are able to differentiate into MSNs as indicated by 
DARPP-32 expression, but previous studies have shown that once these cells are 
expanded in vitro over a greater number of passages, their differentiated phenotype 
changes: The essential changes are that astrocytes become more abundant with increasing 
time in vitro (Quinn et dL, 1999) and although, neurons continue to develop from the 
expanded cells these neurons no longer express DARPP-32 and no longer display a 
striatal (MSN) phenotype. PCR of short-term and long-term expanded cells has 
demonstrated some gene expression changes in the late-expanded cells (Zietlow et aL, 
2005) that suggest that loss of positional information may be a factor in these changes. It 
has also been reported that the post transplant survival of grafts using long-term (20 
weeks) expanded cells is reduced when compared with shorter-term expanded cells (4 
weeks) (Zietlow et al., 2005).
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There are a number of possible reasons for these changes;
• There is positive selection for a non-striatal lineage as the period of culture 
continues, perhaps due to the culture conditions.
• The FNPs that are forced to proliferate in vitro in the presence of EGF and FGF2 
become no longer capable of responding to signals that would otherwise drive 
their differentiation towards a striatal neuronal phenotype. As cells proliferate in 
vitro, cells that had been committed to a striatal phenotype eventually die and new 
cells are bom that are not exposed to the normal sequence of developmental 
signals that would be present in the foetal brain at this time and so they are not 
properly committed to this phenotype.
Until now we have had very limited tools for exploring the mechanisms for 
change in these expanded cell populations. This work represents a potential advance as 
the future study of these issues would be greatly facilitated if markers of MSN 
differentiation were available.
In this experiment the expression of the same genes characterised for primary cell 
differentiation in Chapter Six (including the genes that were not identified as especially 
highly up-regulated in my screen, but have been identified in previous literature as being 
important for striatal development) are assessed for their expression in striatally derived 
FNPs that have been expanded in culture.
In this study PCR was used to assess gene expression patterns occurring in 
striatal-derived FNP cells during their period of in vitro expansion (Day 0, Day 2, Day 4, 
Day 7, Day 14 and Day 28). Cells allowed to proliferate for 28 days were then allowed 
to differentiate on a substrate for a further 7 days in vitro, for comparison with cells 
allowed to differentiate immediately after isolation form the foetal brain in Chapter Six.
FNPs can be derived from foetal striatum at various gestational ages and we have 
ourselves derived them from mouse and rat cells ranging from E ll to E20. At later 
times, the cultures produce mostly glia but up to E16 also produce neurons. The FNP 
cultures tend to have a greater potential to produce neurons, the younger they are in terms 
of their gestational age of derivation, however, we cannot assume that the cultures 
producing greater proportion of neurons are the ones that will most readily produce 
striatal neurons, given the right conditions. From experiments to date, all striatally
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derived FNPs lose the capacity to produce MSNs with time in culture, and so at this stage 
of the study, it was felt important to perform these studies on FNPs derived from foetal 
striatum over a range of gestational ages.
A second related reason is that in the original micro array screen, many of the 
genes seen to be up-regulated were expressed at low levels at E12 and high levels at E16, 
and thus it was possible that we might also observe differences in the response of genes 
to the proliferating conditions, depending on whether they were ‘switched on’ or not at 
the start of the proliferation period.
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7.2 Methods.
Dissection of tissue, tissue culture, RNA extraction and RT-PCR were all carried 
out as per methods laid out in Chapter Two; Methods.
All methods and materials were the same as those used in Chapter Six (apart from those 
changes mentioned below) using the same PCR primers.
7.2.1 Experimental design
7.2.2 Expansion experiment
Three biological replicates from both WGE and cortical tissue were dissected 
from murine embryos at each gestational age (E12, E14 and E16). Each biological 
replicate sample was derived from pooled tissue of pups from at least 1 separate time- 
mated dam. The tissue was then dissected as per the methods set out in Chapter Two and 
put into single cell suspension by trypsinisation. Equal amounts of cells (2,000,000/well) 
were then cultured in expansion medium (for constituents see Chapter Two; Methods) in 
six-well plates at 37°C in a tissue culture incubator. Aliquots of cells were taken out for 
analysis at the following stages;
1. Primary Tissue (Day 0)
2. Day 2
3. Day 4
4. Day 7
5. Day 14
and
6. Day28.
Each aliquot was divided into two. One sample was allowed to differentiate to 
assess the production of neurons and astrocytes and to ensure that the gene expression 
patterns were not due to artefacts of the culture conditions: for example, on occasions (for 
reasons that are poorly understood) FNP cultures may turn out to contain pure 
populations of astrocytes with an absence of neurons. Cells were plated onto a substrate 
on four cover-slips in 24-well plates (plated at 100,000 cells per cover-slip) and allowed 
to differentiate for 7 days (in differentiation media; for constituents see Chapter Two).
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The rest of the cells were then centrifuged (at 3000 x g for 3 minutes) into a 
pellet, the media removed and replaced with RNA Later stabilisation solution before 
being frozen at -80°C pending RNA extraction. Where there was a shortage of cells due 
to poor expansion of cell numbers, only the latter was carried out Cells plated on cover- 
slips were fixed with 4% PFA (for those cells being stained for piII-Tubulin), 4% 
PFA/0.2% Gluteraldehyde (for those cells being stained for GABA antibody) or ice cold 
Methanol (for those stained for the Foxpl or Foxp2 antibodies) and then washed three 
times with PBS before being stored at +4°C in PBS azide, pending immuno 
cytochemistry.
7.2.3 Differentiation o f cells after 28 Days proliferation
In addition to the above, at 28 days expansion, samples of cells differentiated for 
7 days on a substrate were also prepared for RNA extraction as above.
All RNA samples and PCRs were processed as outlined in Chapter Two and 
analysed in the same way as those in Chapter Six. However, unlike in Chapter Six, where 
there were less samples, due to number of samples in this experiment, not all were run at 
the same time, or on the same gel (i.e. although E12 Day 0 to Day 28 Foxpl samples 
were all run in the same PCR and all were run on the same gel, different ages; i.e. E12, 
E14 and E16 could not be run together due to lack of space in the PCR machine or on the 
gel). However, background was taken into account on analysis of the PCR products, 
using the AlphaEase2200 imaging system, the PCR conditions were the same and the 
gels were made and run using exactly the same ingredients and conditions. Because of 
this, caution must be taken when comparing between different age primary cells, and also 
different genes.
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R esults.
The following results show firstly the primary data (pictures of the 1% agarose 
gels taken by the AlphaEase2200 imaging system) on which the spot-denso analysis was 
carried out (note GSpdh PCR products for each sample are shown at the bottom of 
Figures 6.1a-6.1c). These are followed by a series of graphs plotting those normalised 
expression levels with SEMs and descriptions of the gene expression changes compared 
with the GSPDH expression, including results of the statistical analysis if significant.
Comparisons can be made between the results from the E l2, E14 and E l6 cultures as all 
can be related to GAPDH levels. However, some caution is required as each set of PCR 
product for each gene was run on separate gels (due to the sheer number of samples and 
space restrictions on the gels). However, it is worth noting that the primary (Day 0) 
results are the same samples as those used in Chapter Six and, as discussed in that 
chapter, are largely consistent with the micro array results described in Chapter Four.
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G3PDH
Fig. 6.1a; E12 primary tissue expanded over 28 days in vitro. The above shows three replicates for both 
Ctx and WGE at Day 0 (primary), Day 2, Day 4, Day 7, Day 14 and Day 28.
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Fig. 6.1b; El4 primary tissue expanded over 28 days in vitro. The above shows three replicates for both 
Ctx and WGE at Day 0 (primary), Day 2, Day 4, Day 7, Day 14 and Day 28.
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Fig. 6.1c; E l6 primary tissue expanded over 28 days in vitro. The above shows three replicates for both 
Ctx and WGE at Day 0 (primary), Day 2, Day 4, Day 7, Day 14 and Day 28.
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7.2.4 Cxcr4.
7.2.4.1 E12 (Fig. 6.2a)
E12 striatal cells showed a significant reduction in expression of Cxcr4 over the 
28 day expansion period (F(5jo)=3.84,p<0.05), with a decline towards Day 14 followed 
by a slight (insignificant) rise at Day 28. There was no significant difference between the 
Cxcr4 expression patterns of striatally derived cells and cortically derived cells.
7.2.4.2 E l4 (Fig. 6.2b)
E14 striatally derived cells also showed a reduction in expression of Cxcr4 
(F(5,io)=5.67,p<0.01). This overall reduction over 28 days was similar to that seen in 
cortically derived cells. These low levels o f expression at 28 days were maintained after 
differentiation for 7 days, with no significant increases in expression seen.
There was also found to be a difference in Cxcr4 expression patterns between 
striatally and cortically derived cells throughout the expansion period 
(F(i>4)=1 3.89,p<0.05).
7.2.4.3 E16 (Fig. 6.2c)
Cxcr4 expression in striatally derived cells was reduced in the 28 day expansion 
period (F(5>io)=49.52,p<0.001). There was no significant difference seen between striatal 
and cortical expression patterns of this gene.
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7.2.5 F oxp l
7.2.5.1 E12 (Fig. 7.3a)
Striatally derived cell Foxpl expression was significantly reduced as the cells 
were expanded over the 28 day period (F(5jo)=8.05,p<0.01). There was no difference 
between these cells and cortically derived cells.
1.2.5.2 E14 (Fig. 7.3b)
E14 striatal cells showed a significant decrease in Foxpl expression over the 28 
days expansion period (F(5,io)=8.59,p<0.01). After expansion, these levels of Foxpl 
expression did not change significantly on differentiation. There was also no significant 
difference in Foxpl expression between cortically derived cells and those derived from 
striatal tissue.
1.2.5.5 E16 (Fig. 7.3c)
Foxpl expression in cells derived from developing striatum reduced significantly 
over the 28 day expansion period (F(5;io)=71.79),p<0.001). There was also a significant 
difference seen in the expression level changes between striatal and cortically derived 
cells (F(it4)=12.06,p,0.05) with striatal cells expressing higher levels of Foxpl until Day 
14 when both populations expressed negligible amounts of this gene.
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7.2.6 Foxp2
7.2.6.1 E12 (Fig. 7.4a)
E12 expression of Foxp2 was significantly reduced over the 28 day period of 
expansion (F(5jo)=14.49,p<0.001). Although there was a reduction, the levels of 
expression were significantly higher than that of cortically derived cells 
(F(1>4)=9.32,p<0.05).
7.2.6.2 E14 (Fig. 7.4b)
E14 levels of expression were also found to fall over the expansion period 
(F(5,io)=15.24,p<0.001). There was also a significant difference of expression levels over 
time between brain areas (F(i,4)=52.30,p<0.05) with striatal levels being higher for the 
first 7 days. There was a continuing decrease in expression of Foxp2 after the expansion 
period of 28 days and 7 days differentiation.
7.2.6.3 E16 (Fig. 7.4c)
Expression of Foxp2 in E l6 striatally derived cells also reduced over the 
expansion period (F(5jo)=40.70,p<0.001). A significant difference between brain areas 
was also observed with striatal levels being higher until day 7 of 
expansion. (F(i,4)=3 6.61 ,p<0.05).
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Fig. 7.5; High magnification fluorescent microscopy showing FOXP1 (red), FOXP2 (green) and GABA (green) protein 
expression in E 14 cells expanded in vitro for the specified periods, and then differentiated over 7 days. A nuclear stain (Hoechst) 
has also been used (Scale bar = 200pm). Note different sized nuclei of neurons (small) and astrocytes (large).
Gucylf$3
7.2.7.1 E12 (Fig. 7.6a)
No significant changes were seen in the expression of this gene in striatally 
derived cells during the 28 day expansion period. There was also no significant difference 
between the expression of this gene between brain areas.
12.1.2 E14 (Fig. 7.6b)
E14 striatal cells showed a significant reduction in expression of Gucylft3 during 
the 28 day expansion. (F(5,io)=7.90),p<0.01). There was no difference between the 
expression levels of this gene in striatally derived and cortically derived cells. On 
differentiation after expansion, this gene continued to fall in expression levels.
12.1.3 E16 (Fig. 7.6c)
E16 striatally derived cells showed a significant reduction in expression of this 
gene over the expansion period (F(5jio)=58.62),p<0.001). However, no difference was 
observed between cortically and striatally derived cell expression.
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7.2.8 M ef2c
12.8.1 E l2 (Fig. 7.7a)
E12 striatal expression of Mef2c did not change significantly over the 28 day 
expansion period. Neither was there any significant difference between the expression 
patterns of this gene in striatally derived cells or cortically derived cells.
1.2.82 E14 (Fig. 7.7b)
E14 expression of Mef2c was seen to be complex; with an overall significant 
reduction in expression after the 28 day period of expansion, although rising initially 
between Day 2 and Day 7 (F(5,io)=6.32,p<0.01). Striatal cells that were differentiated 
after 28 days expansion showed very low levels of this gene. There was a significant 
difference between the expression of this gene in striatally derived cells and that in 
cortically derived cells; F(ij4)=102.62,p<0.001.
12.83 E16 (Fig. 7.7c)
In contrast to other embryonic ages primary E l6 striatal and cortical tissue 
expressed Mef2c in high amounts in relation to G3PDH. However, these high levels 
significantly reduced over the 28 day period (F(5,io)=20.89,p<0.001), with no significant 
difference between brain areas.
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7.2.9 Ndrg2
7.2.9.1 E12 (Fig. 7.8a)
E12 striatal expression of Ndrg2 increased significantly from low levels to high 
levels, over the 28 day expansion period (F(5j 0)=28.28,p<0.001) although there was no 
significant difference seen between the expression of this gene in striatally derived or 
cortically derived cells.
7.2.9.2 E14 (Fig. 7.8b)
E14 striatally derived cells also showed low expression level of this gene at the 
start of expansion; however this expression increased in a highly significant manner over 
the first 14 days in culture and remained high until 28 days of expansion 
(F(5.io)=92.93,p,0.001). However, once expanded, these cells were then differentiated 
over 7 days, and expression was found to fall to minimal levels in both striatally derived 
and cortically derived cells. There was no difference between brain areas.
7.2.9.3 E16 (Fig. 7.8c)
Levels of Ndrg2 also increased overall in striatally derived E16 cells 
(F(5,io)=20.75,p<0.001) after an initial reduction. There was no significant difference 
between brain areas.
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7.2.10 Spock2
7.2.10.1 E12 (Fig. 7.9a)
E12 Primary (Day 0) striatal tissue expressed this gene at very low levels 
throughout the 28 days expansion, with no significant changes to this pattern. Cortically 
derived cells were also seen to be similar in their expression levels of Spock2 throughout, 
with no significant differences in expression between brain areas.
7.2.10.2 E14 (Fig. 7.9b)
E14 primary cell expression of Spock2 did not change significantly either over the 
duration, or between individual time points, over the 28 expansion period (due to a wide 
variance between replicates). However, expression levels did reduce to negligible levels 
when these cells were differentiated over 7 days after the 28 day expansion period. There 
was no significant difference seen between the expression levels of this gene between 
striatally derived and cortically derived cells.
7.2.10.3 E l6 (Fig. 7.9c)
After initial high expression of Spock2 in E l6 primary striatal cells, these levels 
reduced significantly by Day 2 and remained low for the duration of the 28 day expansion 
period (F(s, io)= 19.40,p<0.001). This pattern was similar to that seen in cortical cells.
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7.2.11 Tiam2
1.2.11.1 E12 (Fig. 7.10a)
E12 striatally derived cell expression of Tiam2 was seen to be low in primary 
cells and did not change significantly over the 28 day expansion period. There was also 
no significant difference between the striatally derived cell expression and that of the 
cortically derived cell expression.
7.2.11.2 E14 (Fig. 7.10b)
Striatal E14 primary cell expression was also seen to be low throughout the 28 
day expansion period. This was in marked contrast to the cortical expression of this gene 
that was seen to start at high levels before reducing dramatically by Day 7 of expansion 
and remaining at these levels. There were also no significant changes in expression of 
Tiam2 in cells that had been expanded for 28 days and then differentiated over 7 days. 
There was a significant difference in expression of this gene between brain areas, with 
cortical expression being significantly higher in the first four days 
F(i,4>=292.35,p<0.001).
7.2.11.3 E16 (Fig. 7.10c)
In E16 striatal primary cells, Tiam2 was expressed at approximately half that of 
G3PDH. However, this was significantly reduced by Day 7 and remained at a low level 
for the duration of the expansion period. Cortical expression in primary cells was nearly 
double that of striatal primary E l6, however, by Day 7 the levels in both population was 
similar, however there was an effect of condition/brain area F(i?4)=58.45,p<0.01) as 
cortical levels were higher to start with.
229
Fig. 7.11a; In vitro expression of TJam2 in expanded Ctx & Sir
I-*- H anC C tT I 
I — T i tQ S tr  |
7 282 4 140
D ay s in vftro
F ig . 7 .1 0 b ; in vitro e x p r e s s  io n  o f  Tlam2 in  e x p a n d e d  E 1 4  C tx  I
0 2 4 7 14 28 28 days
-►differentiation
Days in vitro
Fig. 7.10c; In vitro expression of Tmm2 ri expanded E16 Ctx & Str
7.2.12 G roucho/TLE/G rg
7.2.12.1 E12 (Fig. 7.11a)
E12 primary cells derived from developing striatum expressed high (similar to 
G3pdh) levels of Groucho/TLE/Grg. However, these levels gradually reduced to around 
half Day 0 levels by the end of 28 days expansion. This decrease was seen to be highly 
significant (F(5jio)=21.43,p<0.001). There was no significant difference between 
expression patterns in striatally derived cells and those derived from cortical areas.
7.2.12.2 E14 (Fig. 7.11b)
E l4 Striatally derived cells did not significantly change expression levels of 
Groucho/TLE/Grg either throughout or between individual days during the 28 days of 
expansion. However, once the cells had been expanded for 28 days and then 
differentiated in vitro for a further 7 days, expression reduced sharply to negligible levels. 
This pattern was similar in E14 cortically derived cells.
7.2.12.3 E16 (Fig. 7.11c)
E16 primary striatal cells expressed very high levels of Goucho/TLE/Grg. 
However, these levels were short lived, reducing to one third of primary cell levels by 
Day 2 of expansion. Levels of expression remained at around this level for the remainder 
of the 28 day expansion period therefore a significant reduction of expression was seen 
(F(5,io)=12.16,p<0.001). There was also a significant difference between Striatally 
derived expression and cortically derived expression, with striatal expression being 
higher throughout (F (i,4)=9.44,0<0.05).
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7.2.13 Isletl
7.2.13.1 E12 (Fig. 7.12a)
E l2 primary striatal expression started at levels close to that of G3pdh. However, 
these levels reduced over the following four days to a negligible level, where they 
remained for the duration of the 28 day expansion period, therefore this gene was 
significantly down regulated over the expansion period (F(5,io)= 19.23,p<0.001). 
Cortically derived tissue showed very low levels of expression from Day 0, and as such 
there was a significant difference in expression patterns between the two brain areas, with 
striatal expression being higher.
7.2.13.2 E14 (Fig. 7.12b)
E14 striatally derived cells also showed comparatively high expression of Isletl 
which reduced over the first four days of expansion to negligible levels, thus showing a 
significant decrease in expression over the 28 day period (F(5,io)=215.46,p<0.001). 
Cortical expression started low and continued at these levels throughout the expansion 
period, giving a significant difference between brain areas (F(i 4);=248.19,p<0.05). Both 
striatal and cortically derived cells increased their expression of Isletl to high levels after 
being differentiated for 7DIV subsequent to 28 days expansion.
7.2.13.3 E16 (Fig. 7.12c)
Primary E16 striatal tissue expressed Isletl at very high levels although this was 
very much reduced by Day 2 to negligible levels, where levels stayed for the remainder 
of the 28 day expansion, thus giving a highly significant reduction in expression 
(F(5,io)=47.59),p<0.001). Cortical expression was, again, low from the start in E16 
primary cortical cells, and these levels remained so for the duration of the expansion 
period. Therefore there was also a significant difference between striatally derived and 
cortically derived cells (F(i 4)=41.29,p<0.01).
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7.2.14 Mashl
7.2.14.1 E12 (Fig. 7.13a)
Mashl expression in E12 primary striatal cells was very but reduced half of this 
by Day 2 of expansion where levels remained relatively stable for the remainder of the 
expansion period, hence a significant reduction in expression (F(s,io)=13.51,p<0.001). 
Paradoxically, cortical expression in E12 primary cells was low but increased over the 
next 2 days, remaining high for 2 days and then reduced as well. Because of this initial 
increase, a significant difference between brain areas was not apparent.
7.2.14.2 E14 (Fig. 7.13b)
E14 primary striatal cells expressed Mashl at high levels, which remained as such 
for the first 14 days of expansion before reducing at Day 28. Cells that were expanded for 
28 days and then differentiated reduced expression of Mashl even further to negligible 
levels after 7 days differentiation in vitro. Striatally derived cells expressed Mashl at 
significantly higher levels than cortically derived cells, for the overall expansion period 
(F(M)=12.04,p<0.05).
7.2.14.3 E16 (Fig. 7.13c)
Levels of Mashl in E16 primary cells were comparable to that of G3pdh. 
However, this reduced by Day 2 to just below half of this level, where expression levels 
remained for the duration of the expansion period, thus a significant decrease in 
expression was observed (F(5jo)=35.20,p<0.001). Cortical levels were lower in primary 
tissue, but levels were similar from Day 2 onwards, thus there was no significant 
difference seen between the two brain areas in expression of Mashl.
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7.2.15 M eis2
7.2.15.1 E12 (Fig. 7.14a)
E12 primary striatal expressed Meis2 at high levels, although this expression 
reduced over the following 7 days to negligible levels and remained so for the remainder 
of the expansion period, thus showing a significant reduction in expression 
(F(5,io)=12.42,p<0.001). There was no significant difference observed between striatally 
derived and cortically derived cellular expression of Meis2 over the expansion period.
7.2.15.2 E14 (Fig. 7.14b)
E14 Primary striatal tissue expressed Meis2 at moderate levels that did not change 
significantly throughout the proliferation period of 28 days. There was also no significant 
difference between the striatal and cortical expression patterns of this gene. After seven 
days differentiation the levels of this gene reduced to negligible levels.
7.2.15.3 E16 (Fig. 7.14c)
E l6 primary striatal tissue expressed high levels of Meis2 when compared with 
G3pdh. This reduced significantly (F(5,10)=117.11,pX).001) by Day 2 and remained at 
negligible levels for the remainder of the study. There was no significant difference 
between striatal and cortical Meis2 expression patterns.
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7.3 Discussion
In this study I investigated gene expression changes in murine striatal FNPs, 
expanded over time in culture, using a number of genes that had previously been found to 
be significantly up regulated during a crucial period in striatal development.
One striking finding was that, during the proliferation process, the expression of 
most genes declined irrespective of the gestational age at which the FNPs were isolated. 
In most cases this decline occurred by Day 4 or Day 7, although there were some genes in 
which this was not the case, for example Cxcr4 remained steady in E14 striatum and then 
declined sharply by Day 28, and in E14 cortex it appeared to decline and then increase at 
Day 14 before decreasing again at Day 28. However, although the variance of these 
samples was small, it would be important to perform a repeat experiment to exclude the 
possibility that these particular changes were artifactual.
The decline in the expression o f most of these genes with proliferation may be 
due to selection of FNP cells and the death of more differentiated cells once striatal tissue 
is placed into the proliferation medium. The process of deriving FNPs entails placing the 
foetal tissue into serum free medium with the mitogens FGF2 and EGF (Reynolds and 
Weiss, 1996; Tropepe et al., 1999), as described in Chapters One (Introduction) and Two 
(Methods). The precise effect of doing this on the foetal striatal cells is not well 
understood, but the generally accepted hypothesis is that serum withdrawal leads to the 
death of cells that have already gone through their last mitosis and are in the process of, 
or have completed, terminal differentiation (i.e. in our studies, this would include neurons 
that are on the way to becoming MSNs) and that the cells that are able to survive in these 
conditions are the neural stem cells and progenitors at various stages of commitment 
Cells at this earlier stage of development may be expected not to express genes associated 
with a later stage of striatal differentiation.
In addition to this it is possible that cells that haven't gone through their final 
mitosis, but which are nevertheless partially committed and starting to express some of 
the marker genes, will down-regulate them under these conditions.
In order to define more clearly what is happening over the proliferation period at a 
cellular level, it would be necessary to use methods that are not based on analysis of the 
whole cell population. One possibility would be to analyse differentiating cells using 
antibodies to the protein products of the genes assessed in this study. This was not carried
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out here, except for Foxp 1 and 2, due to specific antibodies not being available for many 
of the gene products. Antibodies are now available for a number of the proteins and 
others could be generated to produce a useful panel of histological markers.
In this study, Foxp 1 and 2 were used to stain FNP cultures that had been 
expanded between Days 0 and 28 and then allowed to differentiate in vitro for 7 days and 
this is discussed further below. However, in brief, the most striking finding was that, 
although neuronal proportion has declined by later time points, in particular 28 days, 
Foxp 1 and 2 staining is still clearly seen in cells with a neuronal phenotype at these 
times. For Foxp 7, this is in accordance with the PCR findings which demonstrate steady 
expression levels up to Day 14. For Foxp 2, however, expression levels on a population 
basis have declined substantially by Day 14 and 28, but the differentiated cultures 
demonstrate expression of Foxp 2 in the majority of neurons. This suggests that at later 
time points, the FNPs are still able to up-regulate Foxp 1 and 2 when they differentiate, 
which may suggest that they still have the capacity to become MSNs (and indeed, this is 
in agreement with the study of Zietlow et al (Zietlow et al., 2005) showing that after 14 
days of proliferation mouse MSNs are able to differentiate into DARPP-32 positive 
neurons when transplanted into the adult mouse striatum).
The immuno-fluorescence study also demonstrates the decline in the proportion of 
cells differentiating into neurons by this time point Recent data suggests that the capacity 
o f FNPs to produce neurons by 28 days remains constant, but that the capacity to produce 
astrocytes accelerates and thus the neuronal population is ‘diluted’ (C Kelly, personal 
communication). However, this data also illustrates the importance of going on to study 
this problem using antibodies to the gene products so that the changes in the neuronal 
population alone can be better understood -  in the present study the contribution of 
astrocytes to the gene expression changes cannot be assessed. This will require proper 
quantification of neuronal, astrocytic and gene markers, which was not carried out here 
due to time limitations.
As mentioned above, not all of the genes decline in expression over the 
proliferation period. In particular, this can be seen for MashJ, which is maintained in the 
striatal-derived cells and increases in the cortically-derived cells up to Day 14 in E l4- 
derived cells, and Ndrg2, which again increases with a similar pattern in E14-derived 
cells. Mashl has been shown to be associated with neuronal specification and may be
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expected to be present in neuroblasts (Parras et al., 2002), so this is consistent with the 
generation of neuronal progenitors. The decline in levels after E14 may be associated 
with the ‘dilution’ of neuroblasts with glioblasts as described above.
Groucho/TLEJGrg is also implicated in maintaining proliferative programs within 
neuronal progenitors (Hatakeyama et a l, 2004; Kageyama et a l, 2005), and the data 
from this study support this; showing that it is expressed at relatively high levels in 
striatal cells over the period of 28 days expansion in the E12 and E14 cultures with down- 
regulation in the E14 differentiated cells. However, the high levels observed in primary 
E16 with a fall in levels by day 2 are more difficult to explain.
Ndrg2 also increases with proliferation time in vitro, and this is most striking in 
the E14-derived cells. This gene is implicated in neurite extension and is particularly 
found in neurogenic regions of the brain such as the hippocampus, where it has been 
localised to radial glia and astrocytes (Nichols, 2003) and may also have a putative 
involvement in neuronal development (Nichols et al., 2005). It may be that because 
neuronal differentiation is being reduced at this point in development, in favour of glial 
cell differentiation, (as seen when cells derived from earlier embryos switch from being 
predominately neurogenic to predominately gliogenic (Sun et a l, 2003) and alluded to 
earlier, in Fig. 6.1; Chapter Six) we see an increase in expression of this gene.
An interesting, but as yet unsubstantiated finding, is that for a number of the 
genes, expression levels and/or expression patterns were subtly different in the E l4, as 
compared to the E l2 and E16 cells: Examples of this were Ndrg2, where expression 
levels increased dramatically in the E 14 cells, Groucho/TLE/Grg where levels increased a 
little in the E14 cells but fell in the E12 and E16 cells, and Mashl which followed a 
similar pattern. The precise reasons for this are not clear, however, it may be associated 
with the fact that striatal cells from E14 embryos show better graft integration when 
transplanted into the adult striatum (Fricker et a l, 1997a; Fricker et a l, 1997b; Watts et 
a l, 2000), and it may be that this is related in some way to the greater capacity of the E14 
populations to retain levels of expression o f genes important to their specification and 
identity. However, exactly what this relationship would be is not clear. It is notable that 
many of the genes that are expressed differently in the E14 FNPs are associated with 
neuroblast proliferation and thus it may be that E14 is a good age for isolation of FNPs. 
Indeed, studies of rat FNPs demonstrate that E12 and E14 are good ages for obtaining
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FNP cultures with a high neuronal potential (Kelly et a l, 2005) although this has not 
been systematically determined for mouse.
There are very few studies in the literature that attempt to analyse the 
characteristics of FNPs in this way. However, a study by Parmar et al (Parmar et a l, 
2002) in which mouse FNPs were analysed in a similar way; the medial (MGE) and 
lateral (LGE) parts of the developing striatum were assessed separately and changes were 
found to be greater in MGE derived than LGE derived cultures. However, this study also 
revealed changes over a period of expansion (6 passages) and showed that many of the 
markers for ventral cells were down regulated (i.e. Dlx genes). However, there were some 
differences between their study and this one; most notably that Parmar et al found that the 
gene Islet 1 continued to be expressed in expanded cultures, whereas it appears to be 
dramatically reduced in expression here. Cells from all three areas (MGE, LGE and 
Cortex) also showed ectopic expression of genetic markers that were known to be not 
expressed within the areas of dissection, and although the researchers rightly point out 
that this may have been due to inaccurate dissection, it may also have been due to the 
populations of cells becoming a more multi potent form of progenitor (possibly capable 
of forming both, many or all types of neurons from the three areas), or could be due to 
aberrant gene expression associated with the proliferation conditions.
7.3.1 Differentiation of FNPs after 28 days expansion
Having characterised the gene changes in FNPs expanded in culture over a period 
of 28 days and having shown that many of the genes associated with striatal 
differentiation were down-regulated in proliferating populations of cells, it was important 
to find out whether these genes could be up regulated again once the cells were allowed 
to differentiate. For practical reasons this was restricted to E14 FNPs after 28 days of 
proliferation and the cells were allowed to differentiate in vitro for 7 days. The results 
were compared to primary E14 cells that were allowed to differentiate in vitro that have 
already been described in Chapter Six. In this part of the experiment, only Isletl was seen 
to increase after the cells were allowed to differentiate. This gene is known to mark the 
majority of striatal neurons (Toresson and Campbell, 2001) and is also implicated in 
neuronal specification generally (Curtiss and Heilig, 1998). This suggests that at least a 
proportion the population of cells may still be capable of becoming striatal neurons,
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although from this work it is not known whether these progenitors would differentiate 
into MSNs, as they do in the majority of primary E14 ENPs, and the fact that most of the 
other striatal associated genes remain expressed at low levels would suggest that this is 
not the case. However, as discussed above, it needs to be emphasized that the expression 
levels are on a population basis and that it will be necessary to follow up these findings 
with studies to look at the presence of the gene product using antibodies.
7.4 Conclusion
From this study it can be concluded that the expansion of FNPs in the presence of 
FGF2 and EGF does cause changes in the expression of genes found in previous chapters 
to be associated with striatal differentiation, and that most of these genes are not up- 
regulated with subsequent differentiation. The extent to which this is an indication that 
the cells have lost the capacity to express these gene after proliferation and the extent to 
which the down regulation is an artefact due to ‘dilution’ of neuronal precursors by 
astrocytic precursors has yet to be determined.
This work has taken forward our understanding of the changes that are occurring 
during FNP proliferation, but it is clear that, for the future of these cells as a potential 
alternative cell source for neural transplantation, further work is required to fully 
understand the effect that proliferation has on these cells.
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Chapter Eight
8 Final Discussion.
Neural transplantation augers to be an effective strategy for treating 
neurodegenerative disorders such as HD by replacing the MSNs that are the predominant 
cells lost in this condition; however, its clinical application is limited by the absence of a 
suitable renewable donor source of cells capable of differentiating into MSNs. With this 
in mind, this thesis has attempted to find gene expression changes associated with MSN 
differentiation in order to;
• (i) identify potential markers of MSN differentiation to facilitate studies aimed at
producing donor cells for HD transplantation (by increasing our understanding of 
striatal FNPs; allowing sorting of FNPs in order to purify a progenitor cell 
population for expansion and/or transplantation and contributing to work to direct 
precursors towards this phenotype), and
* (ii) to identify genes that are potentially part of the machinery of striatal 
differentiation.
Towards this aim, I have completed a screen of gene expression during the period 
of peak neurogenesis in the developing mouse striatum and I have validated these results 
for a small proportion of these genes. I have then used these results to characterise the in 
vitro differentiation of developing striatal cells and interrogate foetal striatally derived 
precursors when expanded in vitro.
8.1.1 The gene expression screen.
8.1.1.1 Would it have been beneficial to study gene expression at earlier/later embryonic 
ages?
The original micro array study was successful in so far as it produced highly 
significant results for a number of gene expression changes seen during the period 
studied. The screen looked at gene expression changes between the embryonic ages of 
E12 and E16, as previous studies have found that this period is when peak neurogenesis 
occurs in the mouse (Shimazaki et al., 1999). However, peak neurogenesis defines the 
period during which most MSNs were bom, but it is still possible that progenitor cells
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undergoing differentiation to MSNs are specified to do so in the preceding hours or days 
before this time (i.e. before E l2). Thus there may be important gene expression changes 
that occurred before E12 that may be important for understanding the pathways that 
regulate MSN differentiation and so it may be advantageous to look at striatal gene 
expression at an earlier time point; for example E l0 or Ell .  This is technically difficult 
because the size of the developing murine brain at these stages in development is so 
small. In order to ensure accuracy, another method of dissection, for example laser 
capture micro dissection (LCMD), would most likely have to be employed. To do this 
would mean that the later time points would also have to be dissected using the new 
method (in order to ensure continuity in methods and to control for differences that may 
occur due to different techniques being used).
8.1.1.2 Was the right technique used?
LCMD has been developed to allow accurate dissection of very small areas of 
tissue and this may have provided a suitable technique. However, because LCMD is 
designed to dissect such a small area, it presented two problems for the work carried out 
in this thesis:
(i) As this was the first systematic screen of its kind for striatal development, 
it was necessary to obtain, as far as possible, the whole developing 
striatum as there may be intra-striatal regional differences in development 
and dissection of a subset of the developing neurons may have lead to 
bias: the developing ganglionic eminence contains many different cells 
types which later migrate into many different areas of the brain as well as 
the adult striatum. If  LCMD had been used, some of these cell populations 
may have been missed while others may have been over represented;
(ii) The small size of the tissue pieces would have introduced the need for 
RNA amplification, which at the time the project was commenced, was 
not thought to be reliable due to the possibility of non-linear amplification. 
Having said this, non-linear amplification has turned out to be much less 
of a problem than was originally anticipated and does not appear to have 
inhibited other researchers from using this technique (see (Pietrzyk et al., 
2004; Fink and Bohle, 2005; Mizuarai et al., 2005)).
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8.1.1.3 Was the appropriate area dissected?
In this study, population gene expression within the WGE was observed. It was 
valid to look at gene expression within the WGE initially for two reasons:
• Firstly, it is not fully understood how the LGE and MGE interact to produce the 
normal medium spiny neurons that populate the adult striatum.
• Secondly, although there may be no interaction between these areas it may be that
the developing cells within the MGE play a crucial role in guiding the
differentiation of MSNs.
Previous studies have shown that WGE, when transplanted into the striatum, 
produces functional striatal-like tissue, and although transplanted LGE would also 
produce striatal-like tissue, the functionality of that tissue has not yet been determined 
experimentally (although see (Parmar et a l , 2002) for a molecular approach to this).
This is, however, an important issue and future experiments that compare the
LGE and MGE using micro array and more refined dissection techniques would be very 
useful in determining the functionality of these areas.
8.1.1.4 Did the criteria for selection o f the candidate marker genes achieve the turns set 
out?
From the original data set produced from this micro array I selected a number of 
candidate marker genes to follow up, and the expression changes seen in these genes 
using the micro array were successfully validated primarily using PCR and then by using 
in situ hybridisation.
The candidate marker genes that I chose for further investigation were all 
significantly up-regulated between E12 and E16, thus making them easier to study than 
other genes that were shown to be significantly down-regulated during the same period.
However, it cannot be stressed enough that down regulated genes may also be 
very important in directing the differentiation and development of the cell population 
within the whole ganglionic eminence at this point in development This point is 
illustrated further when we see that two of the most significantly changed candidate 
markers chosen are both transcription factors that repress the expression of other genes, 
thus causing down regulation in other genes. The question still remains as to which genes
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are being down-regulated because of these gene’s influences and what would happen if 
this repression was reduced or enhanced.
Another point to remember is that although I selected genes that were highly up 
regulated between E12 and E l6, this method of selection automatically dismisses those 
genes that were only up, or down regulated by a small amount, and it cannot be assumed 
that subtle changes in gene expression are unimportant. However, the use of micro array, 
the validation methods used and using in situ hybridisation meant that my methods would 
not have been sensitive enough to highlight these genes without also increasing the rate 
of false positives.
The way the micro array data was analysed was very conservative, in order to 
reduce the amount of false positives that could arise from the analysis. I chose the two 
most robust and commonly used normalisation methods (MAS 5.0 and RMA) and then 
merged the results, effectively discounting any genes that did not pass both 
normalisations at the required p-value level. I did this to discount any arguments that, at 
the time of doing these experiments, were being highlighted in the literature, about the 
efficacy of some normalisation techniques. However, in doing this I also discounted 
many genes that would otherwise have been highlighted as being significant and 
worthwhile candidate marker genes.
The above points highlight an area of caution which must be borne in mind when 
analysing datasets as big as those produced by micro array and other high throughput 
assays: That is, that because the researcher has so much data at hand from such an 
experiment, he/she also is at liberty to ‘cherry pick’ the most significantly changed, or 
easily validated results; but in doing so, they are also at risk of missing vital data that may 
be overlooked as being insignificant when in fact, biologically these small, or downward 
changes in gene regulation may be very important
8.1.1.5 Were the selection criteria right?
The primary aim, once the results had been analysed from the micro array
experiment, was to focus on those changes that were deemed to be ‘interesting’, and to
leave to one side genes known to be involved in other functions apart from the
differentiation and maturation of the striatum (such as so called ‘house-keeping’ genes). I
especially wanted to look at transcription factors (i.e. the controlling genes) that may
have been implicated in specifying certain changes to do with differentiation and
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maturation within the cells that populate the developing striatum at the times chosen. 
Foxpl, Foxp2 (Tamura et al., 2000; Shu et a l, 2001; Tamura et al., 2003; Ferland et a l, 
2003; Wang et a l, 2003a) and M eflC  (Leifer et a l, 1993; Leifer et a l, 1994; Leifer et 
a l, 1997; Janson et a l, 2001) all proved to be interesting genes that are seen to be up 
regulated during this period of peak neurogenesis.
I also wanted to select genes implicated in axonal path finding and migration, as 
these may well be expressed in the developing MSNs as they move to, and take up 
residence within the neo-striatum. Spock2 (Cuschieri and Bannister, 1975; Charbonnier et 
a l, 2000), Cxcr4 (Doitsidou et a l, 2002; Stumm et a l, 2003b; Dziembowska et a l, 
2005) and Ndrg2 (Nichols, 2003; Nichols et a l, 2005; Takahashi et al., 2005a; Takahashi 
et a l, 2005b) were all genes that fulfill these criteria and as such proved very interesting 
to study.
Thirdly, signaling receptors or proteins that may be implicated in progenitor 
differentiation were also interesting and Gucylp3 and the putative Brain Specific Binding 
Protein (2310037P21Rik) (about which very little was known at the start of this study) 
were both worthy candidates for study.
Novel genes found to be significantly changed in expression over the period 
studied were also of interest. One novel gene putatively named Brain Specific Binding 
Protein (2310037P21Rik) and now known to be homologue of the human gene Ras 
Induced Senescence 1 (RIS1), was found to be highly up-regulated during the period of 
study. However, at the time of the experiment, the corresponding Affymetrix probe had 
been designed around a gene fragment that proved too small to design working primers 
for in order to carry this gene through to validation. Due to these difficulties, this gene 
had to be dropped from further investigation.
8. L 1.6 Have we found markers fo r striatal differentiation ?
The genes studied here have proven worthwhile candidates for providing a cell
gene expression signature that appears to be associated with striatal differentiation. We
may have also highlighted gene markers that are largely striatal specific in Foxpl and
Foxp2, although they occur in other regions during neural development. Indeed, it
appears from our studies, and those o f others, that many of the genes up-regulated during
striatal differentiation are also up-regulated during cortical differentiation, and some are
also known to be important for differentiation of other tissues (eg Mef2C, which is a key
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gene involved in muscle differentiation). This does not distract from their value as 
markers of striatal differentiation in the context in which they are used here as the aim is 
to have a ‘signature’ of gene expression changes rather than to rely on one or two gene 
changes specific to the striatum.
However, it may be that some of the markers eventually turn out to be useful for 
the identification of striatal tissue. For example, Foxpl and Foxp2 are expressed within 
the developing striatum and continue to be expressed in the adult striatum, and may be 
useful specific markers used in conjunction with DARRP-32 to mark cells grown in vitro 
in culture and grafting experiments. However, although there is a clear association of the 
expression of Foxpl and 2 with striatal development, no link or function has been proven 
as yet.
As such we now have a panel o f genes that provide a gene expression signature of 
the population of progenitor cells that give rise to the mature striatum. Once fully 
validated this panel of genes can be used in future as a reference to how a cell population 
dissected from the WGE should behave (with respect to gene expression) over the period 
of peak neurogenesis.
8.1.1.7 Further Work
The micro array described in this thesis has now been validated and will be 
published on the World Wide Web so that other groups may also make use of the 
information it provides. The information has already become the subject of follow up 
studies within the laboratory to find the role of Foxpl and 2 within the developing 
striatum. A Foxpl deletion is known to be embryonically lethal due to its activity in 
development of other areas such as the lungs. Foxp2 mutations have been implicated in a 
familial speech disorder. Further work will provide a more detailed history of these genes 
functions.
As well as the follow-up work to understand the functional roles of the genes 
from this screen in striatal development, it will also be important to further quantify the 
gene expression patterns of the developing WGE, using a wider set of embryonic ages. 
This may give clues as to which genes are being repressed by the Foxp genes, as well as 
giving more genetic information about the population as a whole. It will also be important 
to investigate the down-regulated genes as described above.
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Further in vitro work should also be carried out to further validate the 
differentiation results seen after 28 days expansion, with differentiation at earlier time 
points such as Day 2, Day 4, Day 7 and Day 14, that may give clues as to when these cell 
populations become incapable of differentiating into striatal-like cells.
8.1.2 In conclusion
This thesis has studied the gene expression of the population of cells that make up 
the whole ganglionic eminence during its period of peak neurogenesis using Affymetrix 
micro array. It has then validated the results of a subset of genes found to be significantly 
up-regulated during this period using in situ hybridisation and then used these genes to 
characterise either primary cells that were differentiated, or cells that have been 
proliferated and then differentiated in vitro.
The genes highlighted from the micro array provide not only a gene expression 
signature of a developing population of striatal precursors, enabling future experiments to 
compare and contrast expression patterns seen in different in vitro studies, but it has also 
highlighted Foxpl and Foxp2 that have been shown to have a high degree of association 
with this period of development. This has encouraged future work in this laboratory in 
which the developmental functions of these genes in relation to MSN differentiation and 
development will be studied.
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Appendices
9 Appendix A
9.1 Affymetrix array
The following protocol was carried out by technicians at the Department of 
Pathology, University o f Wales College of Medicine (UWCM).
9.1.1.1 Synthesis o f double stranded cDNA from  total RNA
(NOTE: T7-(dT)24 primer -  Must be HPLC purified).
Starting material: lOpg of high quality, total RNA (see above).
First strand synthesis was carried out by adding the following to an RNase-free tube; 
dFfeO (variable)
RNA(lOpg)
T7-(dt) 24 primer
lp l (lOOpmol/pl)
This was incubated at 70 °C for 10 minutes, then briefly centrifuged and placed on
ice.
Once on ice the following was added (in order);
4pl 5x First Strand Buffer
0.1M DTT (mixed well to resuspend 
2 pi any precipitate) 
ljil 1 OmM dNTP mix
This was incubated at 42°C for 2 minutes. After incubation, 2pl of Superscript II 
Reverse Transcriptase was added and the total volume made up to 20pl before incubating 
at 42°C for 1 hour.
Second strand synthesis was carried out by placing the first strand reaction on ice, 
then centrifuging briefly to bring down the condensation on sides of tube. The following 
reagents were then added;
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91 pi DEPC treated water I
30pl 5x Second Strand Reaction Buffer 
3 pi 10 mM dATP; dCTP; dGTP; dTTP 1 
lp l 10 U/pl DNA Ligase 
4pl 10 X_J/|j.l DNA Polymerase I 
1 (ill 2 U/pl RNase H 
This gave a final volume of 150|nl.
The contents of the tube were mixed and then briefly centrifuged before being 
incubated at 16°C for 2 hours in a water bath. After this 2pl of T4 DNA Polymerase 
(lOUnits) was added and the reaction was incubated for 5 min at 16°C, after which, 10|xl 
0.5M EDTA was added.
9.1.1.2 Clean-up o f double stranded cDNA
NOTE: Use ‘Heavy’ 0.5 ml or 1.5 ml Phase Lock Gel tubes (PLG).
Immediately prior to use, PLG tubes were centrifuged at max speed for 20-30 
seconds then 162pl o f the above sample was added to the pre-spun PLG tube. An equal 
amount of phenol:chloroform:isoamyl alcohol (25:24:1) was then added and thoroughly
mixed (do not vortex). This was centrifuged at maximum speed for 5 minutes (to separate
the phases).
Note: after centrifuging some PLG may remain at the bottom of the tube. If a 
second extraction is necessary and maximum tube volume is not exceeded, more organic 
solvent can be added to the tube, mixed and re-centrifuged.
Once centrifuged, the upper aqueous phase was removed and pipetted into a fresh 
tube, where the following was then added:
0.5 volumes of 7.5 M NH4Ac
2.5 volumes of absolute EToH 
(-20oC)
1 pi Glycogen (5mg/ml)
This was left to precipitate for at least 1 hour, or overnight.
This was mixed briefly then centrifuged at 12,000xg for 20 min at 4°C. The 
supernatant was removed and the pellet washed with 0.5ml of 80% ethanol (previously 
stored at -20°C). This was again centrifuged at 12,000xg for 5 min at 4°C and the
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supernatant removed. This ethanol wash was repeated before air drying the pellet (taking 
care not to “over-dry” the pellet as this stops it from going back into suspension, but 
bearing in mind that any residue ethanol may interfere with the IVT reaction).
The dried pellet was resuspended in 12pl of DEPC-treated water, heated to 65°C 
for 5 minutes and then left on ice for between 30 minutes and 1 hour to rehydrate; lp l of 
this sample was kept for Agilent® chip analysis.
The cDNA sample concentration was then analysed using a system that could 
differentiate between RNA, ssDNA and dsDNA (the Picogreen® system was used by the 
UCWM Affymetrix Micro array facility). The sample was then stored at -80°C until 
required.
9.1.1.3 In vitro transcription (IVT)
Synthesis of Biotin Labelled cRNA kit required the use of an Enzo Bio-Array 
High Yield RNA Transcript Labelling Kit (available from Affymetrix). Reactions were 
done in a thermo cycling PCR machine (requiring the reactions to be set up in PCR 
tubes).
The following reaction components were added to an RNase-free 1.5ml microfuge 
tube in the order indicated:
lOjLll
Template cDNA (from the above reaction- this equated 
to 1 pg of cDNA)
4pl lOx HY Reaction Buffer
4pl lOx Biotin Labelled Ribo-nucleotides
4pl 10X DTT (mixed well to remove any precipitate)
4pl RNAse Inhibitor mix
4pl 20X T7 RNA polymerase
12 j l i 1 DEPC-Treated Water to a final volume of 40pl
Contents were carefully mixed then briefly centrifuged (a pulse for 5 seconds) 
then incubated immediately in a 37°C water bath, for 6 hours. The contents were gently 
mixed every 30-45 minutes during this incubation. This reaction must not be left 
overnight.
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9.1.1.4 IV T  cleanup
Kit required: RNeasy mini kit (Qiagen).
Note: Buffer RLT should NOT contain p-mercaptoethanol as this contributes to 
fluorescence of the Affymetrix GeneChip arrays and leads to high background.
Sample volume was adjusted to lOOpl with 60pl of RNase-ffee water and 350pl 
Buffer RLT added and mixed by pipetting. 250pl of absolute ethanol was then added and 
mixed by pipetting. The sample (700pl) was then loaded onto an RNeasy mini column 
which was then placed into a 2ml collection tube. This was centrifuged at 8000xg for 15 
seconds; the sample was then passed through the column again and centrifuged before 
discarding the flow-through and collection tube. The column was then transferred to a 
new 2ml tube and 500pl Buffer RPE added. This was centrifuged at 8000xg for 15 
seconds, the flow through discarded and the column replaced in the 2ml collection tube. 
Another 500pl Buffer RPE was added to the column which was then centrifuged at 
8000xg for 2 minutes (to dry the membrane) before discarding the flow-through and 
collection tube. The column was placed into a fresh 1.5ml collection tube and centrifuged 
at 8000xg for 1 minute before discarding tube and flow-through. The column was then 
placed into a new 1.5ml tube and 30pl o f RNase-ffee water pipetted directly onto the 
RNeasy silica-gel membrane. This was allowed to stand for 1 minute before centrifuging 
at 8000xg for 1 minute (to elute the DNA). A further 30pl of RNA-free water was then 
pipetted onto the membrane, the column and tube turned 180° then allowed to stand for 1 
minute and centrifuged for a further minute at 8000xg.
9.L1.5 Ethanol Precipitation o f cRNA
0.5 volumes of RNAse-free 7.5 M NH4 Acetate, 2.5 volumes of RNAse-free 
100% ETOH and lp l of glycogen were added to the sample and mixed well. This was 
then left to precipitate overnight at -20°C before being centrifuged at 12,000xg at 4°C for 
30 minutes. The pellet was then washed with 80% ETOH, centrifuged at 12,000xg at 4°C. 
This was repeated before air drying the pellet briefly and resuspending in 34pl o f RNAse- 
free water. The sample was then heated to 65°C for 5 minutes then left on ice for between 
30 minutes and 1 hour to rehydrate.
A 1 pi aliquot of this purified unfragmented cRNA was taken for Agilent® analysis.
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9.1.1.6 cRNA Quantification and Fragmentation
The adjusted cRNA yield was then worked out:
Adjusted yield = (Amount of cRNA measured after IVT, in pg) -  (Amount of total 
RNA used in the cDNA synthesis reaction) (Fraction of cDNA synthesis reaction used in 
IVT)
UWCM Affymetrix micro array facility generally did not proceed to the cRNA 
fragmentation unless they had around 15pg of adjusted cRNA.
The fragmentation reaction was performed in microfuge tubes; these were then used to 
make the Hybridisation Cocktail.
The following reaction was made up;
1-
32pl cRNA to make 15pg
8 pi 5x Fragmentation Buffer
RNAse-free water to a final 
volume of 40pl
This reaction was incubated at 94°C for 35 minutes; then placed on ice. A lp l aliquot 
was then taken for later Agilent chip analysis. The remaining sample was stored at -20oC 
until the hybridization.
9.1.1.7 Agilent Analysis
Agilent Lab-on-a-chip chips were used to examine cDNA, cRNA and fragmented RNA.
9.1.1.8 Test3 hybridisation
The Affymetrix GeneChip Test3 Array provides a convenient and accurate
method to determine the quality o f a labelled target prior to its analysis on the GeneChip
expression arrays. It contains probe sets representing a subset of characterized genes from
various organisms, including mammals, plants, and bacteria. Additionally, the GeneChip
Test3 Array contains a subset of human and mouse housekeeping genes (shown to be
expressed early in fetal development and throughout adulthood).
The above samples were routinely hybridised to Test3 chips. The protocol was ran
in such a way so when making a hybridization cocktail for a full chip, there would
automatically be enough to run on a Test3 chip without the need to process more sample.
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2x and lx  hybridisation buffers were made up. The 20x Genechip Eukaryotic 
control and B2 Oligo tubes were heated to 60°C for 5 minutes to ensure that the cRNA 
was fully resuspended.
The chips were taken out of the bags and left to fully equilibrate at room 
temperature. The hybridisation rotisserie oven was switched on to warm up.
The hybridisation cocktail was made up using the following;
15ng
Fragmented cRNA (usually 40pl fragmentation 
reaction)
5(5 Control Oligo B2
15(il 20x Eukaryotic Hybridisation Controls
3(5 Herring Sperm DNA (lOmg/ml)
3(5 Acetylated BSA (50mg/ml)
150(il 2x Hybridisation Buffer
RNAse-free water to a final volume of 300pl 
(usually 84pl)
This hybridization cocktail was heated to 99°C for 5 minutes, followed by 45°C 
for 5 minutes in a PCR machine.
While the hybridisation cocktail is denaturing the Test3 chip was filled with lOOpl 
of lx Hybridisation Buffer. They were then pre-hybridised in the rotisserie oven for 10 
minutes at 45°C, rotating at 60 rpm.
The hybridisation cocktail was then centrifuged at maximum speed for 5 minutes 
in order to remove any insoluble material from the hybridisation mixture. After 
centrifuging and when the chips have finished pre-hybridising, the chips were taken out 
of the oven and the hybridisation solution removed from the Test3 chips and replaced 
with 80pl of hybridisation cocktail.
The chips were then hybridised in the rotisserie oven for at least 16 hours at 45°C, 
rotating at 60 rpm.
9.1.1.9 Washing, Staining and Scanning Test3 chips
All solutions used were filter sterilized before use and the fluidics station was 
primed with buffers A and B by running the Prime protocol.
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The Test3 chips were removed from the rotisserie hybridisation oven and the 
hybridisation cocktail was removed and stored at -20°C. The chip was filled with lOOpl 
of wash buffer and placed in the fluidics station.
1200pl of Stain Solution was made up in an eppendorf;
600pl 2x Stain Buffer
540pl RNAse-free water
48pl Acetylated BSA (50mg/ml)
12pl SAPE (1 mg/ml)
This was then split in to two 600pl aliquots in separate eppendorfs. 
600pl of Antibody solution was then made up in an eppendorf using;
300pl 2x Stain Buffer
266.4pl RNAse-free water
24pl Acetylated BSA (50mg/ml)
6pl
Normal Goat IgG 
(lOmg/ml)
3.6pl
Biotinylated Antibody 
(0.5mg/ml)
The washing and staining protocol was then run adding the staining tubes and 
antibody tubes when required. At the end of the protocol each chip was checked for 
bubbles (if found, replace the chip in the fluidics station and refill with Wash Buffer A). 
If no bubbles were found the chip was scanned in the scanner.
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The following quality controls were then checked before the sample could 
proceed onto being hybridised onto a full chip;
The chip was seen to be well aligned (no more than 2 pixel rows out).
No scratches or fluff obliterated the chip features.
The scale factor was below around 0.75, and similar for all chips.
The raw Q was around 1.
All Bio spiked controls were called as present with the exception of BioB.
The Bio and Cre spiked controls were called as present and increasing in intensities.
The relevant housekeeping genes were all present and at reasonable levels.
None of the relevant housekeeping genes had a 375’ ratio of above 3.
9.1.1.10 Full Chip hybridisation
Full chips were unpackaged and left to equilibrate to room temperature while 
rotisserie oven was allowed to warm up.
The frozen hybridisation medium that was previously withdrawn from the Test3 
chip was allowed to thaw and then heated to 99°C for 5 minutes followed by 45°C for 5 
minutes in PCR machine.
While the hybridisation medium was denaturing the full chip (GeneChip Mouse430A 
array) was filled with 250(il of lxHybridisation buffer. The full chips were then pre­
hybridised in the rotisserie oven for 10 minutes at 45°C, rotating at 60rpm.
After denaturing, the Hybridisation cocktail was centrifuged at maximum speed for 5 
minutes in order to remove any insoluble material. When both the hybridisation cocktail 
and the chips are ready the chips were taken from the rotisserie oven, the pre- 
hybridisation medium removed and replaced with 200pl of hybridisation cocktail.
The chip was allowed to hybridise in the rotisserie oven for 16 hours or more at 45°C, 
rotating at 60 rpm, with the chips secured in the oven racks.
9.1.1.11 Washing, Staining and Scanning fu ll chips
All solutions such as Buffer A and Buffer B were filter sterilized before use. 
Antifoam was then added to Buffer A after filtration. The Fluidics station was primed and 
the chips removed from the rotisserie oven. The Hybridisation Cocktail was then 
removed from the chip and stored at -20°C and the chip filled with 250pl of 
Hybridisation buffer A and placed in the fluidics station.
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1200pl o f Stain Solution was made up in an eppendorf;
600pl 2x Stain Buffer
540pl RNAse-free water
48pl Acetylated BSA (50mg/ml)
12pl SAPE (1 mg/ml)
This was then split in to two 600pl aliquots in separate eppendorfs. 
600pl of Antibody solution was then made up in an eppendorf using;
300pl 2x Stain Buffer
266.4pl RNAse-free water
24pl Acetylated BSA (50mg/ml)
6pl
Normal Goat IgG 
(lOmg/ml)
3.6pl
Biotinylated Antibody 
(0.5mg/ml)
The stain protocol (EukGE-WS2) was run on each chip adding the Stain Solution 
when required.
When the fluidics station requested the antibody solution (after the second wash 
with Buffer A), the chip was instead taken out of the fluidics station and scanned under a 
different filename. This was in order to give a pre-amplification back up of the data, just 
in case the chip had reached saturation. Once this was done, the chip was replaced in the 
fluidics station and the antibody solution and SAPE added in turn.
Once the protocol had finished (approximately 2 hours) the chip was checked for 
bubbles and if free from bubbles, placed in the scanner.
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10 Appendix B
10.1 MIAME (Minimal Information about A Micro array Experiment):
10.1.1 Experiment Design/Type of Experiment:
This experiment was designed as a time course experiment to measure the gene 
expression changes within the Whole Ganglionic Eminence (WGE) at the embryonic 
ages of E12, E14 and E16.
10.1.1.1 Experimentalfactors:
The only Experimental parameters tested in this experiment were the gene expression 
changes seen between the three embryonic ages of E12, E14 and E16.
Each experimental array was hybridised once.
Three replicates for each age group were tested. Each RNA sample replicate was 
extracted from a pooled sample of WGE tissue dissected from the embryos of three dams.
10.1.1.2 Quality control steps taken:
Dissectional accuracy was checked using semi-quantitive RT-PCR of WGE RNA to 
probe for the dorsally expressed Pax-6 gene.
RNA was quality was checked using both UV spectrometry and the Agilent 2100 
Bioanalyser.
TEST3 chips were run before hybridising to the Affymetrix Mouse430a Genechips.
10.1.2 Samples used, extract preparation and labelling:
10.1.2.1 The origin o f the biological sample
Samples were taken from the CD 1 (ICR) strain o f Mas musculus; time mated dams were 
supplied by Harlan UK Ltd (Bicester). These were housed in 12:12 conditions and fed on 
an expanded supplementary diet (due to pregnancy).
Dams were food deprived for 12 hours prior to sacrifice (taking account of genetic 
changes due to short term effects caused by eating and insulin release).
Dams were sacrificed and the tissue dissected within 2 hours of lights on (between 06:00 
and 08:00) to take account of genetic changes due to circadian rhythms.
287
Tissue was flash frozen in liquid nitrogen immediately after dissection and kept at -80°C 
until RNA extraction (as described in Chapter Two; Methods).
All samples were processed using the same methods (outlined in Chapter Two; Methods). 
All samples were treated under blind conditions after RNA extraction.
All samples were labelled using the same techniques, in the same laboratory, by the same 
technician (outlined in Chapter Two; Methods).
All Mouse430a Genechips were from the same print batch and each contained 64 “spiked 
in” control genes.
10.1.3 Hybridization procedures and parameters:
10.1.3.1 The protocol and conditions used during hybridization, blocking and washing: 
These are described in full in Chapter Two; Methods.
10.1.4 Measurement data and specifications:
10.1.4.1 Type o f scanning hardware and software used:
An Agilent GeneArray Scanner was used to scan the GeneChip. This information was 
then saved in a data (*.dat) file.
10.1.5 Type of image analysis software used:
MAS (Microarray Suite) version 5.0.0.032 (2001 ;Affymetrix) was then used to generate a 
cell intensity file (*.cel) from the image data file (*.dat). The cell analysis algorithm 
analyzes the *.dat and computes a single intensity value for each probe cell on an array 
convert the (*.dat) files into cell intensity (*.cel) files.
10.1.5.1 A description o f the measurements produced by the image-analysis software:
MAS 5.0 computed the signal intensities of all 22,690 probes; These figures were saved 
as a data (*.dat) file. MAS 5.0 was used the Expression Analysis algorithm to compute 
the cell intensities (which were stored in a cell (*.cel) file). These arbitrary figures ranged 
from 0 to 7671.2 and described the amount of biotin fluorescence picked up during the 
image analysis from each probe on the Genechip. These figures were used by RMA and 
MAS 5.0 to normalise the data by two different methods before looking at the data in 
GeneSpring and the NIH online Micro Array Analysis ANOVA tool.
288
10.1.5.2 The complete output o f the image analysis before data selection and 
transformation (spot quantitation matrices).
The complete data set, before any normalisation (the (*cel) file for each chip) can be 
viewed on the Compact Disk in Appendix D.
10.1.5.3 Data selection and transformation procedures.
As described in Chapter Four; Methods
10.1.5.4 Final gene expression data table(s) used by the authors to make their conclusions 
after data selection and transformation (gene expression data matrices).
The complete expression data used to make conclusion on temporal expression changes 
of selected genes can be viewed in the results section of this chapter.
10.1.5.5 Array Design:
All samples were hybridised to Mouse430a Aflymetrix GeneChips (from the same print 
batch). All technical specifications and probe locations/details can be found on the 
Affymetrix website at http://www.affVmetrix.com/index.affx.
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11 Appendix C
11.1 In  situ  h y b rid isa tio n s
11.1.1 F o x p l
11.1.1.1 E12
vz-
LGE
MGE
Fig. C.l; Coronal sections through the E12 mouse brain showing control probe (left) and experimental probe 
(right) for Foxpl (V=Ventricle, LV=Lateral Ventricle, SVZ= Sub Ventricular Zone, VZ=Ventricular Zone).
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Fig. C.l(cont); Coronal sections through the E l2 mouse brain showing control probe (left) and experimental 
probe (right) for Foxpl (V=Ventricle, LV=Lateral Ventricle, SVZ= Sub Ventricular Zone, VZ=Ventricular
Zone).
11.1.1.2 E14
LV
LGE
MGE
v B
r 1
\i l u
A \
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- v ^ tP p \ * 
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Fig. CJ2; Coronal sections from El4 Brain showing control probe (left) and experimental probe for Foxpl. 
(SCbP=Superior cerebellar peduncle, IVF=Interventricular foramen of Munroe).
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Fig. C.2(cont); Coronal sections from E l4 Brain showing control probe (left) and experimental probe for 
Foxpl. (SCbP=Superior cerebellar peduncle, IVF=Interventricular foramen of Munroe).
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IL L  1,3 E16
Fig. C.3; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Foxpl. (ChPL=Choroid Plexus, LV= Lateral ventricle, GE=Ganglionic Eminence, CC=Corpus Collosum,
SVZ=Sub Ventricular Zone, VZ=Ventricular Zone).
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Fig. C«3(cont); Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) 
for Foxpl. (ChPL=Choroid Plexus, LV= Lateral ventricle, GE=Ganglionic Eminence, CC=Corpus 
Collosum, SVZ=Sub Ventricular Zone, VZ=Ventricular Zone).
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11.1.2 Foxp 2
11.1.2.1 E12
vz-LGE
Cvz-
““ W
K V
Fig. C.4; Coronal sections from El 2 Brain showing control probe (left) and experimental probe (right) for 
Foxp2. (LV= Lateral ventricle, GE=Ganglionic Eminence, LGE=Lateral Ganglionic Eminence, 
MGE=Medial Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone).
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Fig. C.4(cont); Coronal sections from E l2 Brain showing control probe (left) and experimental probe (right) 
for Foxp2. (LV= Lateral ventricle, GE=Ganglionic Eminence, LGE=Lateral Ganglionic Eminence, 
MGE=Medial Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone).
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11.1.2.2 E14
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MLF
Fig. C.5; Coronal sections from E l4 Brain showing control probe (left) and experimental probe for Foxp2. 
(SCbP=Superior cerebellar peduncle, IVF=Interventricular foramen of Munroe).
298
GE
DT
E
\ \ \\ \ \\ \\
1 7  \
m  IfL
5 1 \  /
-V- V  _ _ _ _ _ L _ _
Fig. C.5(cont); Coronal sections from E l4 Brain showing control probe (left) and experimental probe for 
Foxp2. (SCbP=Superior cerebellar peduncle, IVF=Interventricular foramen of Munroe).
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11.1.2.3 E16
Fig. C.6 ; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Foxp2. (hal=Lateral Habenula, DG^Dentate Gyrus, cp=Caudate Putamen, gp=Globus Pallidus, CC, 
G=Corpus Collosum, Genu, ChPNChoroid Plexus, a=Nucleus Accumbens).
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FR
DG
CC.G
GE(VZ + SV2)
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Fig. C.6(cont); Coronal sections from El 6 Brain showing control probe (left) and experimental probe (right) 
for Foxp2. (hal=Lateral Habenula, DG=Dentate Gyrus, cp=Caudate Putamen, gp=Globus Pallidus, CC,
G^Corpus Collosum, Genu, ChPI=Choroid Plexus, a=Nucleus Accumbens).
VZ + SVZ, LV
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11.1.3 Cxcr4
11.1.3.1 E12
Fig. C.7; Coronal sections from E l2 Brain showing control probe (left) and experimental probe (right) for 
Cxcr4. (LV= Lateral ventricle, GE=Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone).
V
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Fig. C.7(cont); Coronal sections from E12 Brain showing control probe (left) and experimental probe (right) 
for Cxcr4. (LV= Lateral ventricle, GE=Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone).
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11.1.3.2 E14
W G E VZ + SVZ- 
W G E  IZ (N S T )
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9P
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Fig. C.8; Coronal sections from E l4 Brain showing control probe (left) and experimental probe (right) for 
Cxcr4. (HI=Hippocampus, VZ= Ventricular Zone, CCi=Cingulate Cortex, IC=intemal capsule, LOT= Lateral
Olfactory Tract, cl=claustrum, ic=intemal capsule).
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Fig. C.8(cont); Coronal sections from E l4 Brain showing control probe (left) and experimental probe (right) 
for Cxcr4. (HI=Hippocampus, VZ=Ventricular Zone, CCi=Cingulate Cortex, IC=intemal capsule, 
LOT=Lateral Olfactory Tract, cNclaustrum, ic=intemal capsule).
HI (VZ)
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11.1.3.3 E16
(VZtSVZ)
Fig. C.9; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Cxcr4 (pl,CPf=Pyramidal layer o f the pyriform cortex, cp=Caudate Putamen, cl=claustrum, LOT=Lateral 
Olfactory Tract, AC,a=Anterior Commisure (Anterior part), GE=GangIionic Eminence, LV=Lateral 
Ventricle, CC,G Corpus Collosum (Genu), CFr=Frontal Cortex, DG=Dentate Gyrus).
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Fig. C.9 Coronal sections from El 6 Brain showing control probe (left) and experimental probe (right) for 
Cxcr4 (pl,CPf=Pyramidal layer of the pyriform cortex, cp=Caudate Putamen, cl=claustrum, LOT=Lateral 
Olfactory Tract, AC,a=Anterior Commisure (Anterior part), GE=Ganglionic Eminence, LV=Lateral 
Ventricle, CC,G=Corpus Collosum (Genu), CFr=Frontal Cortex, DG^Dentate Gyrus).
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11.1.4 M ef2c
11.1.4.1 E12
vz-
LGE
Fig. C.10; Coronal sections from E l2 Brain showing control probe (left) and experimental probe (right) for
Mef2c. (LV= Lateral ventricle).
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Fig. C.lO(cont); Coronal sections from E12 Brain showing control probe (left) and experimental probe
(right) for Mef2c. (LV= Lateral ventricle).
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11.1.4.2 E14
WGE VZtSV2' IZ(NST)
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Fig. C.11; Coronal sections from E l4 Brain showing control probe (left) and experimental probe for Mef2c 
(IIIV=3rd ventricle, CFr= frontal cortex, SP=subplate, MZ=marginal zone, CP=Cortical Plate, LV=Lateral 
ventricle, GE=Ganglionic Eminence, VZ=Ventricular Zone, IZ= Intermediate Zone).
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Fig. C.ll(cont); Coronal sections from E14 Brain showing control probe (left) and experimental probe for 
Mef2c (IIIV=3rd ventricle, CFr= frontal cortex, SP=subplate, MZ=marginal zone, CP=Cortical Plate, 
LV=Lateral ventricle, GE=Ganglionic Eminence, VZ=Ventricular Zone, IZ= Intermediate Zone).
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11.1.4.3 E16
(VZ ♦ SVZ)
Fig. C.12; Coronal sections from El 6 Brain showing control probe (left) and experimental probe (right) for 
Mef2c. (CRs=Retro-spinal Cortex, CIr=Infra-limbic Cortex, GE=Ganglionic Eminence, VZ=Ventricular 
Zone, LOT=Lateral Olfactory Tract, CC,T=corpus collosum, trunk, Cln=insular/rhinal cortex).
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Fig. C.12(cont); Coronal sections from E l6 Brain showing control probe (left) and experimental probe 
(right) for Mef2c. (CRs=Retro-spinal Cortex, Clr=Infra-limbic Cortex, GE=Ganglionic Eminence, 
VZ=Ventricular Zone, LOT=Lateral Olfactory Tract, CC,T=corpus collosum, trunk, Cln=insular/rhinal
cortex).
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Fig. 12(cont); Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) 
for Mef2c. (CRs=Retro-spinal Cortex, Clr=Infra-limbic Cortex, GE=Ganglionic Eminence, VZ=Ventricular 
Zone, LOT Lateral Olfactory Tract, CC,T—corpus collosum, trunk, Cln=insular/rhinal cortex).
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11.1.5 G ucylpS
1L 1.5.1 E l 2
vz-LGE
MGE SVZ
Fig. C.13; Coronal sections from E12 Brain showing control probe (left) and experimental probe (right) for 
Gucylfi3. (LV= Lateral ventricle GE=Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone).
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* 1
Fig. C.13(cont); Coronal sections from E l2 Brain showing control probe (left) and experimental probe 
(right) for Gucylfi3. (LV= Lateral ventricle GE=Ganglionic Eminence, IZ=Intermediate Zone,
VZ=Ventricular Zone).
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Fig. C.14; Coronal sections from E l4 Brain showing control probe (left) and experimental probe for 
Gucylp3 (IIIV=3rd ventricle, CFr= frontal cortex, SP=subplate, MZ=marginal zone, CP=Cortical Plate, 
LV=Lateral ventricle, GE=Ganglionic Eminence, VZ=Ventricular Zone, IZ= Intermediate Zone).
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--------------
Fig. C.14(cont); Coronal sections from E14 Brain showing control probe (left) and experimental probe for
Gucyl|33 (IIIV=3rd ventricle, CFr= frontal cortex, SP=subplate, MZ=marginal zone, CP=Cortical Plate,
LV^ Lateral ventricle, GE=Ganglionic Eminence, VZ=Ventricular Zone, IZ= Intermediate Zone).
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Fig. C.14(cont); Coronal sections from E l4 Brain showing control probe (left) and experimental probe for 
Gucyl|33 (IIIV=3rd ventricle, CFr= frontal cortex, SP=subplate, MZ=marginal zone, CP=Cortical Plate, 
LV=Lateral ventricle, GE=Ganglionic Eminence, VZ=Ventricular Zone, IZ= Intermediate Zone).
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11,1.5.3 E16
Fig. C.15; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Gucyip3. (LV=Lateral ventricle, VZ=Ventricular Zone, SVZ=Sub-Ventricular Zone, cp=caudate putamen, 
IC=Intemal Capsule, gp=Globus Pallidus, ChPI=Choroid plexus, GE=Ganglionic Eminence)
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Fig. C.15(cont); Coronal sections from E16 Brain showing control probe (left) and experimental probe
(right) for GucylfB. (LV=Lateral ventricle, VZ=Ventricular Zone, SVZ=Sub-Ventricular Zone, cp=caudate
putamen, IC=Intemal Capsule, gp=Globus Pallidus, ChPl=Choroid plexus, GE=Ganglionic Eminence)
321
11.1.6 Ndrg2
11.1.6.1 E12
Fig. C.16; Coronal sections from E l2 Brain showing control probe (left) and experimental probe (right) for 
Ndrg2. (LV= Lateral ventricle GE=Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone).
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Fig. C.16(cont); Coronal sections from E l2 Brain showing control probe (left) and experimental probe 
(right) for Ndrg2. (LV= Lateral ventricle GE=Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular
Zone).
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11.1.6.2 E14
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Fig. C.17; Coronal sections from El 4 Brain showing control probe (left) and experimental probe for Ndrg2 
(IIIV=3rd ventricle, CFr= frontal cortex, SP=subplate, MZ=marginal zone, CP=Cortical Plate, LV=Lateral 
ventricle, GE=Ganglionic Eminence, VZ=Ventricular Zone, IZ= Intermediate Zone).
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Fig. C.17(cont); Coronal sections from E14 Brain showing control probe (left) and experimental probe for
Ndrg2 (IIIV^S"1 ventricle, CFr= frontal cortex, SP=subplate, MZ=marginal zone, CP=Cortical Plate,
LV=Lateral ventricle, GE=Ganglionic Eminence, VZ=Ventricular Zone, IZ= Intermediate Zone).
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11.1.6.3 E16
(vz*svz)
Fig. C.18; Coronal sections from El 6 Brain showing control probe (left) and experimental probe (right) for 
Ndrg2. (CC,G=Corpus Collosum (Genu), LV=Lateral Ventricle, GE=Ganglionic Eminence, VZ=Ventricular 
Zone, SVZ=Sub Ventricular Zone, CNCingulum, CC,G=Corpus Collosum (Genu), cl=Claustrum,
gp=Globus Pallidus).
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Fig. C.18; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Ndrg2. (CC,G=Corpus Collosum (Genu), LV=Lateral Ventricle, GE=Ganglionic Eminence, VZ=Ventricular 
Zone, SVZ=Sub Ventricular Zone, Cl=Cingulum, CC,G=Corpus Collosum (Genu), cl=Claustrum,
gp=Globus Pallidus).
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11.1.7 Spock2
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Fig. C.19; Coronal sections from E l2 Brain showing control probe (left) and experimental probe (right) for 
Spock2. (LV= Lateral ventricle GE=Ganglionic Eminence, IZ=Intermediate Zone, VZ=Ventricular Zone,
MxPr=Maxillary Process).
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Fig. C.19(cont); Coronal sections from E l2 Brain showing control probe (left) and experimental probe 
(right) for Spock2. (LV= Lateral ventricle GE=Ganglionic Eminence, IZ=Intermediate Zone,
VZ=Ventricular Zone, MxPr=Maxillary Process).
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11.1.7.2 E14
Fig. C.20; Coronal sections from E l4 Brain showing control probe (left) and experimental probe (right) for 
Spock2. (GE=Ganglionic Eminence, IC=Intemal Capsule, IZ= Intermediate Zone, LV=Lateral Ventrical).
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Fig. C.20(cont); Coronal sections from E14 Brain showing control probe (left) and experimental probe
(right) for Spock2. (GE=Ganglionic Eminence, IC=Intemal Capsule, IZ= Intermediate Zone, LV=Lateral
Ventrical).
331
11.1.7.3 E16
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Fig. C.21; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for 
Spock2. (LV=Lateral Ventricle, GE=Ganglionic Eminence, KMntemal Capsule, IZ=Intermediate Zone,
LV"= Lateral Ventricle).
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Fig. C.21(cont); Coronal sections from E l6 Brain showing control probe (left) and experimental probe
(right) for Spock2. (LV=Lateral Ventricle, GE=Ganglionic Eminence, KM ntemal Capsule, IZ=Intermediate
Zone, LV=Lateral Ventricle).
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11.1.8 Tiam2
11.1.8.1 E12
vz-LGE
Fig. C.22; Coronal sections from E l2 Brain showing control probe (left) and experimental probe (right) for 
Tiam2. (LV= Lateral ventricle LGE=Lateral Ganglionic Eminence, MGE=Medial Ganglionic Eminence).
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Fig. C.22(cont); Coronal sections from E l2 Brain showing control probe (left) and experimental probe 
(right) for Tiam2. (LV= Lateral ventricle LGE^Lateral Ganglionic Eminence, MGE=Medial Ganglionic
eminence).
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11.1.8.2 E14
Fig. C.23; Coronal sections from E l6 Brain showing control probe (left) and experimental probe (right) for
Tiam2. (LV=Lateral ventricle).
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Fig. C.23(cont); Coronal sections f r o m  E l6 Brain showing c o n t r o l  probe (left) and experimental probe
(right) for Tiam2. (LV=Lateral ventricle).
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11.1.8.3 E16
Fig. C.24; Coronal sections from El 6 Brain showing control probe (left) and experimental probe (right) for 
Tiam2. (cp=Caudate Putamen, LV=Lateral Ventricle, CCi=Cingulate Cortex, CC,G=Corpus Collosum,
Genu).
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Fig. C.24(cont); Coronal sections from E l6 Brain showing control probe (left) and experimental probe 
(right) for Tiam2. (cp=Caudate Putamen, LV=Lateral Ventricle, CCi=Cingulate Cortex, CC,G=Corpus
Collosum, Genu).
